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From Cancer to Sexually Transmitted Infection: Explorations of Social Stigma
Among Cervical Cancer Survivors
Karen E. Dyer
ABSTRACT

This research project aims to examine the idea of stigma attached to cervical
cancer in light of its association with HPV, a sexually transmitted infection (STI). The
public recognition of this relationship appears to be increasing due to the current media
attention surrounding HPV’s causative role in the development of cervical cancer, and
the newly-released HPV vaccine. Thus, this study explores the experiences and
perceptions of cervical cancer patients and survivors living with this type of cancer at a
moment in time when it is becoming a very visible manifestation of a sexually
transmitted infection, versus one identified historically as a life-threatening cancer.
Disease-related stigma has vast individual, community, and societal
repercussions: in the context of both cancer and sexually transmitted infections, it is
broadly associated in the literature with decreased levels of screening, reluctance to seek
treatment, decreased access to social support, economic discrimination, and major
difficulties in implementing large-scale prevention efforts, such as contact tracing or
name-based reporting. This study is premised on the belief that including the voices of
patients and survivors themselves will provide a more holistic and complete
understanding of the dimensions of cervical cancer-related stigma, which in turn will help
v

to inform future educational and prevention messages tailored to reduce its impact.
Additionally, it will illuminate the complexities and dynamics of how patients/survivors
are able or unable to access social support—a first step in designing more effective and
relevant support programs.

vi

Chapter One:
Introduction
Much has been written on the subject of stigma and illness in recent decades.
Contributions by sociologists and psychologists abound, spanning vastly different
afflictions ranging from mental illness, to tuberculosis, HIV/AIDS, sex work, hepatitis C,
and smoking (Collins, von Unger, and Armbrister 2008; Genberg 2008; Grow and
Christopher 2008; Hallgrimsdottir, Phillips, Benoit, and Walby 2008; Macq, Solis, and
Martinez 2006; Stuber, Galea, and Link 2008). Anthropologists in particular have
offered meaningful and holistic documentations of the lives of those suffering with
stigmatized conditions. Additionally, they have critiqued and expanded the stigma
paradigm itself, arguing for the importance of the sociocultural, political, and economic
context in which it is always and necessarily situated (Castro and Farmer 2005; Coreil
2008; Parker and Aggleton 2003).
It is from this anthropological lens that I examine the concept, presence, and
effects of stigma in one particular case: cervical cancer. The public recognition of the
relationship between cervical cancer and the human papillomavirus (HPV)—a sexually
transmitted infection (STI)—appears to be increasing. This is due in large part to the
current media attention surrounding HPV’s causative role in the development of cervical
cancer, and the newly-released HPV vaccine. Thus, this study explores the experiences
and perceptions of cervical cancer patients and survivors living with this type of cancer at
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a moment in history when it is becoming a very visible manifestation of a sexually
transmitted infection, versus one constructed historically as a life-threatening cancer.
This period in time, in which cervical cancer is being repositioned in and by educational
and media messages, offers an opportunity to examine the rapid re-definition of a
stigmatized condition as it occurs, and its subsequent impact on individuals previously
diagnosed with cervical cancer. This study is premised on the belief that including the
voices of those affected will provide a more balanced, holistic, and complete
understanding of the dimensions of cervical cancer-related stigma and the potential ways
that it can be alleviated.
CERVICAL CANCER AND SCREENING IN THE UNITED STATES
Cervical cancer is a major medical and public health concern around the world.
The disease accounts for 3,870 deaths among over 11,000 cases diagnosed each year in
the United States (ACS 2008). Mortality from cervical cancer is concentrated heavily in
developing countries: indeed, it is the number two cause of cancer-related death in
women globally (WHO 2008), affecting 510,000 and causing over 288,000 deaths each
year (Ferlay, Bray, Pisani, and Parkin 2004).
Although once ranking among the most common causes of death among
American women, the United States has witnessed a vast reduction in the rate of cervical
cancer over the course of the last 50 years (ACS 2008). Indeed, the American Cancer
Society reports that between 1955 and 1992, cervical cancer mortality rates declined by
over 74 percent (ACS 2008). These improvements have been directly attributed to the
increased utilization of the Papanicolaou (Pap) screening test, which is able to detect cell
changes and abnormalities in the cervix before they advance to cancer (ACS 2008; Akers,
2

Newmann, and Smith 2007; Casper and Clarke 1998; Solomon, Breen, and McNeel
2007).
Developed by George Papanicolaou, a German medical doctor and zoologist, the
Pap test was introduced as a screening tool in the mid-1940s (Casper and Clarke 1998).
Sixty years later, it has become the most successful, widely used and “entrenched cancerscreening technology in the world” (Casper and Clarke 1998:255; Stoler 2005). Regular
Pap screening is now firmly integrated into women’s preventive healthcare schedules—in
one survey, nearly 85 percent of women born after 1930 had reported receiving a Pap test
in the prior three years (Solomon et al. 2007). It is estimated that by the year 2010, 75
million tests will be performed annually (Solomon et al. 2007). Consistent and
widespread use of the Pap test is extremely effective but also expensive, such that “a
program of annual conventional Pap tests costs $2,457 over the lifetime of a woman and
reduces cervical cancer by 89%” (Goldie, Kim, and Wright 2004). Yearly, the economic
burden of routine cervical cancer screening in the United States (direct medical costs)
totals an estimated $2.3 billion (Insinga, Dasbach, and Elbasha 2005).
HPV AND THE VACCINE
Over the last several years, two major scientific developments relating to cervical
cancer have occurred: the discovery that HPV is a necessary factor in cervical cancer, and
the development of the HPV vaccine. First, it has been recognized for some time that
there is an association between cervical cancer and sexual activity, due mainly to studies
demonstrating higher rates among sex workers and almost non-existent rates among nuns
(Braun and Gavey, 1999a). However, scientists were recently able to isolate the agent
that is the necessary factor in the development of 99 percent of all cervical cancers—the
3

human papillomavirus (HPV), a sexually transmitted infection (Parkin 2006). Two
strains, 16 and 18, are direct factors in nearly 70 percent of all cervical cancers in the
U.S. (CDC 2006). HPV can be transmitted by contact alone and does not require the
exchange of bodily fluids. It is the most common sexually transmitted infection in the
United States: epidemiological studies have documented infection rates in sexually active
adults of 70 to 80 percent over the course of their lifetime (Burk et al. 1996; Koutsky
1997; Lorincz 1996).
Accompanied by stirring debate, controversy, fanfare, and sky-high expectations,
the second vaccine to prevent a sexually transmitted infection was approved by the
Federal Drug Administration (FDA) in June 20061. Released to the public by Merck
Pharmaceuticals under the name Gardasil for females aged 9 to 26, the vaccine was
advertised to prevent the four strains of the human papillomavirus (HPV) that together
are responsible for 70 percent of cervical cancers and 90 percent of genital warts in the
United States (CDC 2006; Merck Pharmaceuticals 2007a). Because of HPV’s high
prevalence rates (CDC 2008), the vaccine has the potential for widespread impact.
The ensuing years have been marked by as much controversy as they have by
excitement. For the first time, a vaccine seemed poised to finally make a difference in
the exceedingly high rates of cervical cancer mortality, especially in developing countries
(Dailard 2006). It has been increasingly recognized among biomedical and public health
professionals that cervical cancer is a “disease of disparity,” with steep gradations in
socioeconomic status linked to greatly increased incidence and mortality rates stemming
largely from constrained access to screening and treatment services (Akers, Newmann,
1

Routine use of the first vaccine released to prevent an STI—Hepatitis B—began in 1991 among U.S.
children (CDC 2007b).
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and Smith 2007; Newmann and Garner 2005). Among women in the United States
diagnosed with cervical cancer, the inequalities are clear: the greatest burden of cervical
cancer falls on minority women, immigrants, older women, the uninsured, and those in
lower income and educational brackets (Akers et al. 2007). Health disparity literature has
extensively covered the barriers to screening and treatment that these same groups
encounter; thus, for some, the vaccine’s release represented a rare opportunity to
challenge these inequalities in a cost-effective way by preventing cervical cancer’s very
occurrence (Saslow et al. 2007). In the U.S., steps were quickly taken in many states to
consider potential vaccine mandates for school-age girls (Colgrove 2006).
Yet, just as quickly, another perspective arose and gained national recognition.
The view that HPV is a result of lifestyle choices, and entirely preventable by responsible
sexual behavior, led many to question the utility and ethics of the vaccine and in
particular of mandatory vaccinations (Monk and Wiley 2006). A central argument in the
mandatory vaccination debate was the prospect that vaccination against HPV would
implicitly sanction improper pre-marital sexual conduct by adolescent girls (Dailard
2006; Monk and Wiley 2006). More specifically, it was theorized that vaccination would
lead to their sexual “disinhibition,” now that the vaccine would eliminate the threat of
bodily harm that comes with an STI (Haber, Malow, and Zimet 2007). Thus, the vaccine
was thrust into the spotlight in a national debate on morality, sexuality, and parental
autonomy.
Meanwhile, Merck Pharmaceuticals had taken on the task of advertising with a
vengeance, culminating in multiple awards at the 2008 Pharmaceutical Advertising and
Marketing Excellence awards (Rosenthal 2008). Numerous television ad campaigns
5

were released that were intended to create a public awareness of HPV, and in particular,
its significant role in the causation of cervical cancer. On November 13, 2006, Merck
announced the launching of its now well-known campaign, One Less. In its press release,
the company stated that this multi-media print, web and television campaign is designed
to encourage Gardasil vaccination among eligible girls and women in addition to the
maintenance of their regular screening routine (Merck 2006:1). Its most notable aspect is
the “strong and positive message designed to empower them to want to become (or help
their daughters want to become) ‘one less’ person who will battle cervical cancer”
(Merck 2006:2)—specifically by learning about the connection between HPV and
cervical cancer and getting vaccinated.
However, One Less was not the first advertising campaign initiated by Merck. A
year prior to the approval of Gardasil and the subsequent launch of the One Less
campaign, the company had already embarked on multi-lingual educational programs.
Television advertisements entitled Tell Someone encouraged women to inform others
about the link between cervical cancer and HPV, while Make the Connection (later Make
the Commitment) emerged as a Merck-funded consumer-oriented campaign run by two
non-profit organizations (Zimm and Blum 2006). Because Merck is prohibited legally
from advertising its drug directly before FDA approval, the campaigns were designed
instead to raise Americans’ awareness about the link between cervical cancer and HPV
(Merck 2006)—a critical point given the company’s assertion that as of early 2005, only
20 percent of women in the U.S. were aware of HPV’s role in cervical cancer (Zimm and
Blum 2006). However, critics contend that this was just a preliminary step in the roll-out
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of the vaccine, a “priming of the market,” intended to create demand for the vaccine
rather than reflecting a genuine concern for public health.
Merck’s intentions aside, this increasing publicity creates a predicament for
women who have already been diagnosed with cervical cancer. For the first time, ad
campaigns were demonstrating to the public the causal association between a sexually
transmitted infection and their own cancer diagnosis—something that they may not yet
have even known themselves. And, given our society’s historically complex and
oftentimes stigmatizing views of women and sexually transmitted infections (Brandt
1987), it is indeed possible that this phenomenon will have unanticipated consequences
on their quality of life.
RESEARCH PROJECT OVERVIEW
Thus, it is within this complicated context of national vaccine awareness
campaigns, morality, stigmatization, disparities, and our cultural values regarding cancer
patients and sexually transmitted infections that this research project is situated.
Specifically, it is intended to examine the experiences of women who are survivors of
cervical cancer, with a focus on possible stigmatization relating to the release of the HPV
vaccine and the increasing publicity of cervical cancer’s connection with an STI. In
short, it will document how these women view their own disease within this emerging
public health framework of prevention and how—if at all—it has impacted their lives.
The following chapter, Chapter Two, will present a thorough overview of the
current research on cancer, sexually transmitted infections and stigma. First and
foremost, it will examine the ways that these diseases have been perceived historically in
the United States, and the impact of stigma individually and from a societal perspective.
7

It will conclude by discussing cervical cancer’s position at the intersection of chronic and
sexually transmitted disease. This review will serve to situate the current project in both
anthropological and public health research, while simultaneously drawing on important
sources from other disciplines when necessary to illuminate the current state of the
literature.
Chapter Three discusses the specific objectives of the research project, overall
research design, and the methods employed to answer the primary research questions.
Data were collected through four sources: key informant interviews, a website content
analysis, semi-structured interviews, and an online survey. Accordingly, data collection
and the participant selection procedures, recruitment strategies, and the data analysis plan
are detailed for each method. The chapter will also address informed consent,
confidentiality and compensation issues; and challenges encountered during the research
process.
Chapter Four will systemically present all of the findings from the data analysis.
The results are broken down first by methodology—key informant interviews, website
content analysis, in-depth interviews, and online surveys. Then, within each of these
sections, I detail the demographics of the participants and discuss major themes arising
from the data. Both the key informant interviews as well as the content analysis were
intended to provide a background picture of the issue as well as preliminary data that
would structure the design of the interview guide. Because the overall focus of this
research was to investigate the dynamics and subtleties of women’s experiences with
cervical cancer and stigma attached to the disease, the analysis puts its primary emphasis
on qualitative methods, that is, the interviews. The major, interdependent themes
8

emerging from the analysis of the interview data were then tested through the use of the
online survey.
Finally, Chapter Five will present a detailed synthesis and discussion of the key
informant interview, content analysis, in-depth interview, and survey results, focusing on
concrete areas for action and potential contributions to applied anthropology and public
health. Here I will tie my findings both to previous literature as well as to my own
research questions, outline current gaps in our understanding, and pose important future
questions and avenues for anthropological and public health research. This chapter will
conclude by outlining study limitations and offering recommendations gleaned from the
insights of both the participants as well as myself, the researcher.
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Chapter Two:
Literature Review
Much research has investigated the claim that both cancer and sexually
transmitted infections carry significant societal stigma. The underlying premise upon
which this research project is based is that cervical cancer’s public perception as both a
cancer and as a manifestation of a sexually transmitted infection impacts survivors’
experience through the cumulative stigma borne from these conditions. This chapter first
offers a brief background on the recent stigma literature, outlining critiques and
contributions by anthropologists. It then examines the ways in which cancer and sexually
transmitted infections have been perceived historically in the United States, and the
impact of associated stigma both on individuals’ lives and on prevention and treatment
efforts. The chapter concludes by discussing cervical cancer’s position at the intersection
of cancer and sexually transmitted disease. When available, I have drawn from
anthropological and public health sources in these areas; however, as will be discussed
below, there are notable gaps in the literature addressing certain topics. In these
instances, sources from other disciplines have been used in order to illuminate the current
situation and thinking.
BACKGROUND ON STIGMA
The vast majority of literature reviewed that addresses stigma draws from the
definition inspired by sociologist Erving Goffman and his seminal work Stigma: Notes on
10

the management of spoiled identity (1963). Briefly, Goffman defines stigma as the
perception of what a person is not, but should be, based on societal standards—in other
words, the stigmatization of an individual results when he or she possesses a trait or
condition that is viewed negatively by society, and is thus rejected, ostracized, and
discriminated against on the basis of possessing this trait. Especially salient for our
discussion here is Goffman’s posited connection between stigma and personal
responsibility: stigmatized conditions are often perceived by wider society as
punishments for some moral (often sexual) misdeed, a point that is repeatedly returned to
in later research studies (Das 2001; Gilmore and Somerville 1994; Newton and McCabe
2005). According to Lichtenstein, Hook, and Sharma (2005), most authors differentiate
between enacted and felt stigma – “enacted stigma is when people who are considered to
be morally, socially, racially, or physically tainted are actively discriminated against by
so-called ‘normals’: felt stigma is the fear or experience of this type of discrimination”
(2005:44).
The literature notes a plethora of negative social, psychological and physical
consequences resulting from stigma. Importantly, a number of authors contend that
stigma increases vulnerability to dangerous conditions or diseases because it mediates
exposure and prevention opportunities, such as quarantine (Gilmore and Somerville
1994), while some “have gone so far as to suggest that stigma causes illness because ‘it
generates and regenerates mechanisms that link it to disease’” (Link and Phelan
2001a:10, as quoted in Lichtenstein et al. 2005:44). The possibility that stigma can
actually cause and perpetuate both the disease itself and resultant disparities among the
afflicted makes the topic an exceedingly critical area for health research.
11

Thus, this volume of stigma research has expanded considerably in recent years,
fueled primarily by researchers within the fields of sociology and social psychology
along with some notable contributions by anthropologists. Stigma and its effects have
been investigated in a huge variety of conditions across diverse populations around the
world. Though plentiful, the cohesiveness of this body of work, according to some, has
suffered from a vague definition and conceptualization of what exactly stigma is and
what it encompasses (Castro and Farmer 2005; Link and Phelan 2001a). In 2001,
sociologists Link and Phelan (2001a and 2001b) reviewed much of the multidisciplinary
work on stigma and subsequently offered a useful conceptualization of stigma and its
components in order to clarify the construct for future research:
In our conceptualization, stigma exists when the following interrelated
components converge. In the first component, people distinguish and label
human differences. In the second, dominant cultural beliefs link labeled persons
to undesirable characteristics—to negative stereotypes. In the third, labeled
persons are placed in distinct categories so as to accomplish some degree of
separation of “us” and “them.” In the fourth, labeled persons experience status
loss and discrimination that lead to unequal outcomes. Finally, stigma is entirely
contingent on access to social, economic, and political power that allows the
identification of differentness, the construction of stereotypes, and separation of
labeled persons into distinct categories, and the full execution of disapproval,
rejection, exclusion and discrimination (367).
According to the authors, much of the existing literature offered in psychology
and sociology has offered a definition that does not necessarily take into account the
convergence of all of these components, using one individual component interchangeably
with stigma. For example, a study might assume that the existence of discrimination is
the same as the existence of stigma. Over time, this has resulted in a body of literature
that reflects the effects of stigma in many different populations without clearly
articulating exactly what stigma constitutes in the first place. Thus, the authors call for
12

future research on stigma that takes into account the interplay of these components within
an existing power structure that allows these processes to unfold.
Anthropological Contributions and Critiques
Anthropology in particular has offered numerous contributions to the existing
literature on stigma. Much important work has centered on the design of culturallyappropriate interventions and care that mitigates stigmatization. For example, Coreil,
Lauzardo, and Hertelou (2001) conducted a cultural feasibility study to inform the design
of a tuberculosis healthcare program offered to Haitians in South Florida. The
identification of social stigma and confidentiality breaches as major concerns among the
participants led to a program design structured around minimizing and mediating the
effects of stigma on this population. Additionally, numerous ethnographies have been
conducted on the meaning and effect of disease-related stigma on specific populations
(for examples on stigma and tuberculosis in Haitian populations, see: Coreil, Mayard,
Lauzardo, Simpson and Hamilton 2005; Coreil, Lauzardo, Mayard, Hamilton and
Simpson 2007).
Still other work has challenged and extended the theoretical foundations of
Goffman’s work. For example, in their writing on AIDS-related stigma, Castro and
Farmer (2005) have expanded on Link and Phelan’s (2001a) discussion of the necessity
of power in stigmatization. According to them, the issues of power, dominance, and
oppression have been virtually ignored by many stigma scholars, who choose instead to
focus on individual and micro-level traits and interactions—this has subsequently led to
findings that are “decontextualized from larger social processes…[and] the social
inequalities in which stigma is invariably rooted” (Castro and Farmer 2005:53-54). They
13

call instead for a return to analyzing Goffman’s original focus on the interplay of
relationships, social change, and stigma. Accordingly, these authors offer structural
violence as a conceptual framework for understanding the concept of stigma, arguing that
“every society is shaped by large-scale social forces that together define structural
violence. These forces include racism, sexism, political power, poverty, and other social
inequalities that are rooted in historical and economic processes that sculpt the
distribution and outcome of HIV/AIDS” (Castro and Farmer 2005:54-55). In turn, these
forces also determine who suffers from stigma and discrimination (McMulllin in press).
For example, in many studies the consequences of stigma appear to be gendered and it is
women who suffer disproportionately—for instance, “it may limit their marital prospects;
constrain their participation in community, household and family roles; and diminish
their quality of life” (Jones, Weil, Coreil, and Shoush 2004).
Other anthropologists have offered similar critiques of the highly individualistic
nature of research on stigma. For example, Parker and Aggleton (2003), in their analysis
of the stigma concept in HIV/AIDS, argue that a reading of Goffman himself might
suggest that “as a formal concept, stigmatization devalues relationships rather than being
a fixed attribute” (Parker and Aggleton 2003:14) that is mapped onto an individual.
However, subsequent researchers’ tendency to approach stigma as if it were a static
individual attribute or interaction rather than a “constantly changing (and often resisted)
social process has seriously limited the ways in which stigmatization and discrimination
have been approached” (Parker and Aggleton 2003:14). Rather, these authors believe
that “it is vitally important to recognize that stigma arises and stigmatization takes shape
in specific contexts of culture and power” (Parker and Aggleton 2003:17), and that,
14

drawing from a combined analysis of Goffman and the work of Michael Foucault, its
strategic deployment serves to establish social control and maintain the social order.
Similarly, Das (2001) argues that Goffman’s focus on the individual as the only
bearer of stigma’s burden leads to the neglect of the community- and society-wide
production and consequence of stigma. She also challenges Goffman’s conceptualization
of “resistance” to stigma as appearing only in the form of individual action against wider
society and its values. This dichotomous view necessarily precludes both a recognition
of how cultural values are embodied and negotiated within an individual, and a
discussion of the mechanics of collective action and resistance to stigmatization.
A contribution emerging from both anthropology and sociology concerns voice
and perspective (Castro and Farmer 2005; Kleinman, Wang, Cheng, Dai, Li, and
Kleinman 1995; Link and Phelan 2001a, 2001b; Parker and Aggleton 2003; Whittaker
1992). Many have challenged scholars who write about stigma without being informed
by the lived experiences of those who are most affected by it. According to Schneider
(1998), a majority of researchers give priority “to their scientific theories and research
techniques rather than to the words and perceptions of the people they study” (Link and
Phelan 2001a:365), resulting in theorizations about stigma that are divorced from the
realities of its occurrence in individuals’ lives. Instead, the main focus of research on
stigma has been on the attitudes and beliefs of stigmatizers—or those that produce
stigma—rather than the perceptions of those stigmatized. This has resulted in a plethora
of knowledge, attitude, and belief surveys that aim to generate some kind of assessment
on the level of stigma that exists for a given condition in the general population instead of
exploring the personal impact on afflicted individuals’ lives (Parker and Aggleton 2003).
15

One concept that is critical to our discussion on stigma is cervical cancer’s
identification as a “disease of disparity.” Much public health and biomedical literature
has called attention to the fact that cervical cancer incidence reflects underlying
socioeconomic disparities and inequalities, such that it strikes primarily women of lower
income levels whose class status restricts their access to healthcare (see, for example,
Akers, Newmann, and Smith 2007; Newmann and Garner 2005). From an
epidemiological perspective, cervical cancer incidence is indeed much lower among
middle- and upper-class women who presumably have much easier and affordable access
to the United States’ vast screening system, allowing for early detection before cell
abnormalities progress to invasive cervical cancer. Yet, as some anthropologists and
stigma scholars have argued, labeling a certain condition as a disease of poverty—
whether it be tuberculosis, HIV/AIDS, or cervical cancer—has dramatic implications for
its stigmatization (Baral, Karki, and Newell 2007; Castro and Farmer 2005; Macq et al.
2006; Noyes and Popay 2007). Because poverty in itself “already represent[s] an almost
universal stigma” (Castro and Farmer 2005:55), the association between it and a certain
affliction can exacerbate the disease-related stigma already present. One study on stigma
and tuberculosis in Nepal found that a root cause of discrimination against those suffering
from the disease was the “perceived link between TB and other sources of discrimination,
particularly poverty and low caste” (Baral, Karki, and Newell 2007:211). In other words,
the threat of being labeled “poor” in addition to “TB patient” added another layer of
perceived negative experience.
In summary, this particular research project is situated well within the
anthropological literature on stigma. First, it is designed to be thoroughly informed by
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the voices of those who have experienced cervical cancer. Second, its focus is applied
and thus has been positioned from the start to offer concrete recommendations. Third,
cervical cancer is aptly suited for analysis within the structural violence/inequality
framework because of its designation in public health and biomedical literature as a
“disease of disparity.” And finally, a succession of researchers, including
anthropologists, has argued that many conditions become stigmatized because they are
perceived to have been caused by a violation of a sexual taboo. Thus, those conditions
that biomedicine has demonstrated to relate directly to sexual behavior “bring questions
of guilt and shame much more to the surface” (Das 2001:8)—an assertion that is highly
salient for a discussion on cervical cancer.
CANCERPHOBIA AND THE MORAL ORDER
Having explored the general background literature on stigma and anthropology’s
contributions to this volume of work, we now turn our attention to briefly analyzing two
health conditions within this stigma framework: cancer and sexually transmitted
infections.
According to one author, the phenomenon of “cancerphobia” has marked the
history of the disease in the United States (Patterson 1987). One hundred years ago, a
physician described cancer as “a loathsome beast, which seized upon the breast, drove its
long claws into the surrounding tissues, derived its sustenance by sucking out the juices
of its victims, and never even relaxed its hold in death” (Patterson 1987:vii). According
to Patterson (1987), the explicit nature of cancerphobia has relaxed a bit throughout the
course of the twentieth century, alleviated by several factors: the search for biomedicine’s
“magic bullets,” the dramatic hope in new experimental treatments, and the recognition
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that oncology has made inroads with increasing survival rates, especially among children.
However, even in contemporary times, it remains a feared and dreaded disease (Ablon
2002). The lingering perceptions of cancer as the “leprosy of modern times” (Weiss
1997:458) are most likely due in large part to cancer’s still notoriously high mortality
rate, the life-threatening, disfiguring and aggressive therapies required to treat it, and the
difficulty biomedicine has had in preventing it or even explaining away with certainty its
ultimate cause (Gregg and Curry 1994; Weiss 1997).
Hunt (1998) argues that “science strives to translate observed phenomena into a
value-free framework, removing it from the elements of ordinary existence” (1998:309);
thus, in the absence of biomedicine’s explanations of cancer’s ultimate cause, individuals
must create meaning about why they themselves became sick—meanings that often
reflect personal experiences and how these may or may not have contributed to the
development of their own cancer. As she goes on to note, “biomedical concepts are silent
on this moral plane” (Hunt 1998:309). Several anthropological studies conducted both in
the U.S. and other countries highlight the moral overtones inherent to cultural meanings
of cancer, especially those cancers of the reproductive organs (Chavez, Hubbell,
McMullin, Martinez, and Mishra 1995; Hunt 1998; Martinez, Chavez, and Hubbell
1997). For example, Hunt’s (1998) study in southern Mexico among women diagnosed
with reproductive cancers (breast, cervical, uterine) found that the cause of these cancers
was usually explained through “concepts of breaches in the social order, and of proper
and improper behaviors … [and in particular] interpersonal aggression and improper
reproductive behaviors” (1998:303) in that individual woman’s life. Chavez and
colleagues (1995) revealed similar findings in their U.S.-based study on the perceptions
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of breast and cervical cancer risk factors among Latinas, Anglo women, and physicians.
Although there were marked differences in the cultural models of cervical cancer
espoused by each group, a recurrent theme was that of sexual behavior that did not
conform to social norms. This conceptualization of cancer as a consequence of deviation
from accepted cultural standards and the moral order is reflected in other writings by
Brandt (1987), Erwin (2007), Gregg (2003), McMullin (2007 and in press), McMullin,
Chavez, and Hubbard (1996), Patterson (1987), and Sontag (1978), among others.
Interestingly, it seems that moralistic beliefs surrounding cervical cancer have
been documented to a much greater extent among Latinas than among other specific
populations; this might be accounted for by the increasing number of studies addressing
Latina beliefs about cancer (Chavez et al. 1995; Erwin 2007; Hunt 1998; Martinez et al.
1997; Chavez, McMullin, Mishra, and Hubbell 2001; McMullin, de Alba, Chavez, and
Hubbell 2005). One of the few studies that focused on explanatory models in Caucasian
women was the above article conducted by Chavez and colleagues (1995). As noted
previously, the authors investigated the cultural models of breast and cervical cancer
among Chicana, Mexican, and Salvadoran women living in the United States, using
Caucasian women and physician as comparative groups. They found that Caucasian
women most frequently viewed family history as the predominant risk factor for cervical
cancer, and overall their views paralleled physicians’ most closely than the other groups.
Although the women did list several lifestyle risks for cervical cancer such as multiple
sexual partners and STIs, they did so “less often than the Latina immigrants, for whom
perceived non-normative or morally tinged behaviors were associated with cancer,
especially cervical cancer”—for example, rough sex, sex during menstruation, or
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abortion (Chavez et al. 1995:54). Among the Latina groups, the risk that irregular sexual
practices presented for cervical cancer related more to the moral component of that
particular behavior rather than the possible exposure to a sexually transmitted infection,
which was more the case for the Caucasian women.
Conceptions of Cancer Patients and Stigmatization
In many respects, as illness itself can be seen as socially constructed, any illness
represents a deviation from the norm. However, Fife and Wright (2001) argue that some
illnesses, such as cancer or HIV/AIDS, are “imbued with cultural meanings that result in
a ‘spoiled identity’ and the stigmatization of afflicted individuals” (2001:52). These
associations of cancer with death, disorder, extreme suffering, and moral deviation are
critical elements in the stigmatization of cancer. For example, participants in one study,
when asked to draw their conceptualization of a cancer patient, invariably created
illustrations of patients that were “embodiments of chaos… Images of them were
fragmented and distorted. The outlines of their bodies were drawn with gaps; their
internal organs were often hanging out. They were represented as without hair, without
gender, and without any surrounding context. In short, respondents’ depictions
of…cancer patients evoked a sense of entropy and of bodily fragmentation and
dissolution” (Weiss 1997:470). Ablon (2002) contends that cancer, along with
homosexuality and mental illness, constitutes what might be termed a “master stigma,” an
affliction that can seemingly “be used to define a person, discounting his or her other
more relevant-to-the-context characteristics” (Ablon 2002:S4).
A number of authors note that moral theories surrounding causation, as well as the
persistent association of cancer with death and disorder, have had negative impacts on the
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lives of cancer patients (Braun and Gavey 1999a; Chapple, Ziebland, and McPherson
2004; Gregg and Curry 1994; Patterson 1987). Indeed, illness-related stigma can result
in reluctance to seek treatment or fear of treatment itself (Katz, Wewers, Single, and
Paskett 2007), as exemplified by Gregg and Curry’s (1994) study on explanatory models
for cancer among African American women undergoing screening for breast and cervical
cancer at community health clinics. In another study on the stigma and shame
experienced by lung cancer patients, it was found that many were concerned that
“diagnosis, access to care, and research into lung cancer might be adversely affected by
the stigma attached to the disease and those who smoke” (Chapple, Ziebland, and
McPherson 2004). Furthermore, psychosocial and advocacy literature has paid much
attention to the economic discrimination that survivors face in the United States:
difficulties accessing health insurance, job discrimination, and the impossibility of
securing life insurance are just a few consequences of the “financial risk” that many
employers assume survivors pose (Hoffman 2004). These economic repercussions can
seem insurmountable when added to the vast debts often incurred by the treatment alone.
SEXUALLY TRANSMITTED INFECTIONS AND THEIR VECTORS
Few anthropologists have focused their writings and research on sexually
transmitted infections in a broad sense and almost none on stigma attached to them, apart
from those exclusively addressing HIV/AIDS. Given this gap in the literature, this
section draws from complementary work in a variety of disciplines in addition to
anthropology, specifically feminism, public health, and history.
Notable in all the literature reviewed for this section is the pervasive association
of sexually transmitted infections with dirt, filth, uncleanliness, and immorality (Ablon
21

2002; Brandt 1987; Ehrenreich and English 1973; Inhorn 1986; Lichenstein et al. 2005;
Pliskin 1997; Wailoo 2001). Similar to the causal explanations of reproductive cancers
as rooted in a deviation from moral norms, STIs in American society have come to be
seen as “an affliction of those who willfully violated the moral code, a punishment for
sexual irresponsibility” (Brandt 1987:5), and since the late 19th century have “been used
as a symbol for a society characterized by a corrupt sexuality” (Brandt 1987:5). This
association between sexually transmitted infections, uncleanliness and immorality is just
as strong as the complicated relationship between STIs and women in the popular
imagination. Although this belief has ebbed and flowed over the course of the last
century, women traditionally have been characterized as the vectors of disease, or
‘natural reservoirs’ (Lichtenstein et al. 2005), as one author puts it (Brandt 1987;
Ehrenreich and English 1973). Additionally, a moral division between “good” (pure and
chaste) and “bad” (dirty, dangerous and sexualized) women has been noted extensively in
the feminist literature exploring sexuality in the American Victorian era (mid-19th
century) through to the present (Amaro, Raj, and Reed 2001; Braun and Gavey 1999a;
Leonardo and Chrisler 1992; Nack 2002; Wahab 2002). This moral dichotomization of
women according to sexual behavior and perceived promiscuity serves to identify a
woman with a sexually transmitted infection as “bad”, and thus contagious and
responsible for her own condition.
Also important to note is the persistence of the association between STIs, poverty,
and ethnicity in the United States. A number of authors argue that STIs are associated in
the popular discourse with urban poor minorities (Brandt 1987; Ehrenreich and English
1973; Pliskin 1997; Wailoo 2001). Brandt (1987) notes that, traditionally, “venereal
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disease has engaged a number of social fears about class, race, ethnicity, and in
particular, sexuality and the family. Venereal disease—in its social constructions—has
been used during the last century to express these anxieties” (Brandt 1987:6).
Historically, immigrant classes were often singled out for this moral label: according to
Ehrenreich and English (1973) in their classic feminist analysis of the relationship
between biomedicine and women, “the working class woman might not faint, or get
‘uterine disease’ [as the upper class woman did], but she undoubtedly harbored germs of
typhoid, cholera or venereal disease” (1973:14). Furthermore, Pliskin (1997) goes on to
argue that contemporary STI prevention programs often further this stereotype by
targeting minorities, prostitutes, and adolescents in their quest to identify and isolate
high-risk sexual behaviors.
STIs and Stigma
As conditions that spring from perceived immoral sexual behavior, Brandt (1987)
points out that “individuals [with STIs] often have suffered a double jeopardy: the
physiological consequences of the disease itself, as well as the deep psychological
stigma” (1987:5) attached to it. This stigma in itself has consequences that are outlined
by several authors (Brandt 1987; Fortenberry et al. 2002; Lichtenstein et al. 2005;
Newton and McCabe 2005; Perrin, Daley, Naoom, Packing-Ebuen, Rayko, McFarlane,
and McDermott 2006; Pliskin 1997; Woods et al. 1999). For example, embarrassment or
shame might inhibit individuals from seeking or continuing treatment and accessing
necessary social support; furthermore, diagnosis with an STI often creates major conflicts
in intimate relationships. Importantly, stigma attached to STIs has impeded the success
of large-scale public health prevention efforts, most notably contact tracing and name23

based reporting (Fortenberry et al. 2002; Woods et al. 1999). Lichtenstein and colleagues
(2005) note that “as a contributor to STI control, partner notification has had little success
in the USA, perhaps because stigma has complicated every aspect of control and
elimination” (2005:44).
Newton and McCabe (2005) contend that a discussion of the effects of stigma is
particularly relevant for HPV, given that it “can be physically evidenced on the body,
may often result in physical pain, and [is] transmitted to others through sexual contact”
(Newton and McCabe 2005:63). When discussing implications for screening related to
HPV and cervical cancer, Braun and Gavey (1999a) argue that the good girl/bad girl
discourse can effectively prevent the success of screening efforts, in that women need to
first identify themselves as “promiscuous” (in accordance with the “bad girl” label) and
then based on this must recognize that they are at risk for cervical cancer and in need of
screening.
CERVICAL CANCER: INTERSECTIONS OF CANCER AND STIs
The preceding two sections have examined the perceptions of cancer and sexually
transmitted infections separately. However, as will be discussed below, the current
media attention surrounding the HPV vaccine has made explicit the causal link between
sexual behavior and cervical cancer. My contention in this research is to position
cervical cancer at the intersection between both conditions, as it is now at once perceived
as both a cancer and as a sexually transmitted infection. I argue that this position
heightens the stigmatization of patients and survivors in two ways: first, as theories of
causation for both cancer and STIs are characterized by moral overtones, patients and
survivors deal with the cumulative stigma borne from both; and second, with the advent
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of the HPV vaccine, cervical cancer is now identified as a preventable disease, which
positions it under the public health paradigm of personal responsibility and
accountability.
It has long been recognized that there is a murky association between cervical
cancer and sexual activity, principally heterosexual activity (Braun and Gavey 1999a;
Wailoo 2001). As Braun and Gavey (1999a) note, “much attention has been given to
differences in cervical cancer incidence between nuns (very low) and prostitutes (very
high)” (1999a:203). However, the explicit relationship between sexual behavior and
cervical cancer has remained unclear until the last several years, when it was discovered
that strains 16 and 18 of the human papillomavirus (HPV) directly cause nearly 70
percent of cervical cancer cases in the United States, while strains 6 and 11 cause 90
percent of genital warts (CDC 2006; Calloway, Jorgensen, Saraiya, and Tsui 2006;
Merck Pharmaceuticals 2007a). HPV is a necessary factor in the development of 99
percent of cervical cancers, 90 percent of anal cancers, and 40 percent of vulva, vaginal,
and penile cancers, as well as certain oropharyngeal and oral cancers (Parkin 2006).
Currently, there are 100 strains that are known to researchers, but their role in cancer and
genital warts remain unclear; thus, it appears as if the majority of HPV infections are
cleared from the body of the individual without known consequences, and most often,
without symptoms (CDC 2006; Calloway et al. 2006). HPV is, importantly, the most
common sexually transmitted infection in the United States: it is reported that up to 70 to
80 percent of sexually active adults will contract at least one of the strains at some point
in their lifetime (Burk et al. 1996; Koutsky 1997; Lorincz 1996). In a recent point
prevalence study, the National Institutes of Health discovered that 26.8 percent of
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sexually active females between the ages of 14 and 59 tested positive for one or more
strains of HPV at any given time (National Institutes of Health 2008a).
This causative role of HPV in cervical cancer has taken on new significance in the
last two years with Merck Pharmaceuticals’ release of the first vaccine to prevent its
transmission, in June 2006. The vaccine has shown in clinical trials to have a 100 percent
efficacy rate in preventing the four strains of HPV that cause cervical cancer and genital
warts. Currently, it is approved only for young girls and women aged 9 to 26 and no
clinical trials have been completed in men, even though it is estimated that at least 50
percent of sexually active men and women have been infected with HPV at some point in
their lives, and the virus is known to cause anal cancer, penile cancer and oral cancer in
men (CDC 2008). Many states have pending legislation to mandate the vaccine for girls
in 5th and 6th grades; the rationale behind this age is based on the fact that the vaccine will
be most effective if given to girls who have not yet been exposed to the virus (CDC
2006)—thus, in girls who are not yet sexually active. This is an example of legislation
that is based upon sexual behavior, and in turn, it makes the discourse about the vaccine
sexual.
Interestingly, although this recognition of the association of cervical cancer and
sexual activity has existed for quite some time, some authors have noted that suppressing
this information in the past has served useful purposes. Lovell, Kearns, and Friesen
(2007) have noted that the tendency of public health discourse on cervical cancer
screening has been to avoid disclosing this information because it “eliminates any
association in the public eye between sexual practices and cervical cancer” (Lovell et al.
2007:4). Braun and Gavey (1999b) contend that the lack of attention on behavioral risk
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factors for cervical cancer, such as multiple partners, first intercourse at a young age, and
unprotected sex, has been due to three reasons. First, HPV is extremely prevalent within
sexually active populations. Second, it can be transmitted through skin-to-skin contact
(not just intercourse), rendering barrier contraceptive methods such as condoms less
effective than for other sexually transmitted infections. Third, and perhaps most
importantly for this research project, practitioners have feared that “highlighting this
association with sexuality may be in direct conflict with the promotion of cervical
screening, and that it may deter some women, particularly older women, from having
smears” (Braun and Gavey 1999b:1464). It seems that only with the release of the
vaccine, and the implementation of the pharmaceutical companies’ marketing campaigns,
have these risk factors and the link to sexual activity become more explicit than in the
past.
The educational and media blitz surrounding the release of the HPV vaccine, and
the controversies about access, female adolescent promiscuity, school mandates, and
vaccine ‘acceptability,’ have heightened exposure to dramatic levels (Calloway et al.
2006). In turn, this has served to solidify the relationship between cervical cancer and
sexual behavior in the public consciousness. Pliskin (1997) contends that “only recently,
mainly since the beginning of the AIDS epidemic, has the subject of STIs been pursued
consistently by the media. For years the subject was avoided” (1997:102), although there
is a precedent to HPV’s current attention in the media. In her ethnographic study on
genital herpes in American society, Inhorn (1986) contends that the media played a
pivotal role in the public awareness of herpes, and the extreme fear and stigma
subsequently attached to it: “the reason for [genital herpes’] notoriety is believed to be
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due to the media—and a process of stigmatization that took place almost overnight”
(1986:61), with herpes quickly becoming the “new scarlet letter.”
I argue that this recent attention to the HPV vaccine with regards to cervical
cancer emerges within the framework of the good girl/bad girl discourse, and engages the
historical construction of women as the traditional vectors of sexually transmitted
infections. By focusing primarily on the consequences of HPV in the woman—cervical
cancer—and the fact that adolescent girls are the only targets for the vaccine, the
educational and media message enforce traditional notions of (1) women as the reservoirs
of infection, (2) cervical cancer as punishment for ‘immoral’ or improper behavior, and
(3) women as responsible for protecting both themselves and thus the rest of the
population—i.e., men—from the ravages of this virus by getting themselves vaccinated.
As previously discussed, sexually transmitted infections share with cancer
decidedly moral overtones regarding causation: in the public consciousness, both
conditions are associated in some way with deviation from the moral order and the sexual
expectations attached to women in society. Thus, the woman with cervical cancer finds
herself in a peculiar position, bearing the brunt of two stigmatized conditions. In the
category of a cancer, cervical cancer is associated with death, suffering, disorder, and
improper behavior. Simultaneously, as associated with a sexually transmitted infection,
cervical cancer is imbued with meanings about the proper sexual behavior of women in
contemporary American society, and the consequences associated with deviation from
these standards (Martinez et al. 1997). “Product of a metaphorical double whammy,
cervical cancer, as a cancer, [is] considered deadly, horrifying and possibly contagious;
as an STI, it [is] shameful and indicative of sexual misconduct” (Gregg 2003:130).
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Furthermore, racialized stereotypes about women with cervical cancer exist,
having apparently bled over from the negative assumptions that have become so much a
part of contemporary American discourse about STIs. As noted earlier in this chapter,
historically STI’s have been associated most closely in the popular discourse with
women, minorities, immigrants and the urban poor, which has ultimately served to shape
approaches to STI prevention with the increased targeting of “high-risk” groups (Pliskin
1997). This pattern is highly relevant for a discussion on cervical cancer, as educational
and awareness messages aggressively broadcast the association with HPV in an
increasingly public way. McMullin’s (in press) study on the diagnosis experiences of
Latina cervical cancer patients provides an instructive parallel between racial stereotypes
of STI carriers and, now, increasingly racial stereotypes of cervical cancer patients.
Latinas bear the burden of cervical cancer incidence and mortality rates that are twice the
national average (Canto and Chu 2000, as cited in McMullin in press). Yet, despite the
structural, political-economic inequalities and racism that are at the heart of these
disparities, the social construction of Latinas as promiscuous and irresponsible is used
instead throughout popular and biomedical discourse as an explanation (McMullin in
press).
One final thought deserves mention. The HPV vaccine has now served to
position cervical cancer as a preventable disease. Lupton (1993), in her article on the
discourses of risk in the public health paradigm, discusses the increasing emphasis on
lifestyle risks—those risks created by an individual’s life choices regarding sex, nutrition,
exercise, reproduction, or any number of things. These are the risks to which society can
assign blame should an individual develop obesity, or be diagnosed with lung cancer, a
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sexually transmitted infection, or HIV/AIDS. Responsibility is assigned to the individual
to both avoid and to minimize (Ablon 2002). I see this paradigm as one that engages
moral theories about the causation of disease by focusing on the lifestyle component as a
principal means of disease development, one that effectively divides “those who don’t
take care of themselves and become sick” from “those who take proper care of
themselves, and thus stay well.”
This is an important concept that plays into a new understanding about cervical
cancer in two ways. First, because cervical cancer is now definitively attached to sexual
behavior in the scientific literature, a woman is expected to be sexually responsible to
avoid contracting HPV and thus developing cancer. Second, she will be expected to get
the vaccine to avoid being infected at all. The woman who does develop cervical cancer
failed in those two ways, because cervical cancer is now positioned as entirely
preventable both by responsible sexual behavior and by the new vaccine. Thus, cervical
cancer remains a punishment for immoral or improper behavior, despite the change in
rhetoric to ‘lifestyle risks’. As Newton and McCabe (2005) note, much research has
suggested that “when a person is perceived to have been responsible for the acquisition of
their stigmatizing condition, they are more likely to be treated negatively than someone
who is not perceived as being responsible for the stigmatizing condition” (Newton and
McCabe 2005:66). Thus, I do not argue about the necessity of prevention in the case of
cervical cancer; however, it can be a double-edged sword, and the discourses on
preventability, individual responsibility and blame, can serve to stigmatize women who
have already been diagnosed with it and those who will in the future.
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SUMMARY
This chapter has outlined the ways in which our historical perceptions of cancer
and sexually transmitted infections are associated with moral transgressions, sexual
misbehavior, and deviation from the social order, which has resulted in the stigmatization
of both conditions. With cervical cancer’s increasingly recognized association with
HPV, a sexually transmitted infection, the disease is now situated in the intersection of
these two conditions. Thus, survivors experience stigma borne from cancer and STIs.
This can have dramatic implications for their quality-of-life and access to treatment.
Indeed, this chapter has demonstrated the vast individual, community, and societal
repercussions of disease-related stigma: in the context of both cancer and sexually
transmitted infections, stigma is broadly associated with decreased levels of screening,
reluctance to seek treatment, decreased access to social support, economic discrimination,
major difficulties in implementing large-scale prevention efforts, and in extreme
instances, denial of basic human rights. A fuller and more holistic understanding of the
dimensions of patients’ and survivors’ experiences with cervical cancer and diseaserelated stigma will help to inform future educational and prevention messages tailored to
reduce its impact. Thus, the remaining chapters will detail methods and findings of this
research project, and offer a concluding discussion and set of recommendations.
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Chapter Three:
Methods
In order to get as complete a picture as possible about the effect of the HPV
vaccine on the lives of women who have experienced cervical cancer, it was necessary to
employ a variety of anthropological methods in this study. This chapter will discuss the
specific aims of the research as well as the methods used to answer four primary research
questions. The chapter is sub-divided into four sections: the first addresses the overall
research design and the four methods utilized—key informant interviews, website content
analysis, in-depth interviews, and an online survey. Data collection and the participant
selection procedures, recruitment strategies, and the data analysis plan are detailed in turn
for each method. The second section, Ethical Conduct, discusses informed consent,
confidentiality and compensation issues. The third section focuses on challenges
encountered during the research process; specifically, recruitment issues and elements of
the researchers’ personal experience that required attention during the initial stages of the
project. Study limitations are briefly outlined in the final section.
RESEARCH DESIGN AND METHODS
This was an exploratory study utilizing both qualitative and quantitative methods,
including key informant interviews, content analysis, semi-structured interviews, and an
online survey. These methods were employed to address research questions formulated
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from a review of the anthropological and public health literature on cervical cancer as
well as input from key informants, faculty advisors, and colleagues:
1.

How do women diagnosed with cervical cancer experience the media attention
surrounding the HPV vaccine and cervical cancer’s link to sexual behavior, and
how has this affected their perceptions of their own diagnosis and survivorship
status?

2.

How do cervical cancer patients/survivors perceive and experience stigma, if
any, attached to this piece of their identity? What is the nature and origin of this
stigmatization?

3.

According to patients and survivors, what are the important aspects involved in
minimizing stigmatization? How can educational and prevention messages be
designed to reduce it?

4.

How do cervical cancer advocacy groups, pharmaceutical companies, and
commercial websites providing information on cervical cancer represent the link
between HPV and cervical cancer, and what are their educational messages on
this topic?

Key Informant Interviews
Interviews were conducted with three key informants prior to the initiation of
research. Two of these informants were prior work contacts, one of whom is a cervical
cancer survivor herself and heavily involved in advocacy efforts for this population. This
woman was instrumental in the initial conceptualization of the project prior to the
proposal, and offered continuing assistance throughout the course of the study by
reviewing draft instruments and helping with recruitment for the online survey. The third
informant was a woman previously diagnosed with cervical cancer who was an
acquaintance of one of my committee members, and expressed interest in the direction of
the study. These conversations were not tape-recorded although thorough notes were
taken during and afterwards, which I referred back to during the development of each
instrument.
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Website Content Analysis
In order to address research question #4, I conducted a content analysis of the
websites of selected cervical cancer advocacy organizations, commercial groups,
government agencies, and pharmaceutical companies from June through August 2007 to
generate preliminary data. The aim of this phase was three-fold: first, to assess how these
entities present information to the public related to HPV and cervical cancer’s connection
to a sexually transmitted infection, and the degree to which this link to sexual behavior
may or may not be made apparent in their educational messages. Also of interest was the
organizations’ treatment of the current controversy surrounding the vaccine’s availability
and administration to adolescent girls. Most importantly, findings from this exercise
were used to guide the development and revision of the in-depth interview guide.
Sampling
A total of seven websites were sampled: three advocacy organizations, one
commercial group, one government agency, and two pharmaceutical companies. The
inclusion of not-for-profit, non-governmental organizations in this analysis was based
upon the assumption that these organizations represent, more or less, public extensions of
patients and survivors. As these organizations’ messages are targeted both at this
population and the wider public, it was assumed that analyzing their approach to this
topic would shed additional light on how patients and survivors experience their own
disease in the context of public education and advocacy messages. Three organizations
were included in this phase: the National Cervical Cancer Coalition (NCCC), Tamika &
Friends, and the American Cancer Society (ACS). The first two organizations were
selected because they are the most visible players in the cancer community that target
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only cervical cancer, while the ACS is one of the largest non-profit cancer advocacy
organizations in the country and very widely known.
The websites of one commercial company (WebMD), one government agency
(Centers for Disease Control and Prevention), and the two pharmaceutical companies
currently marketing the HPV vaccine (Merck Pharmaceuticals and GlaxoSmithKline)
were included to contrast the content and presentational style of the information.
WebMD was selected due to its prominence as a commercial health information
company. The CDC was chosen because it is the primary public health arm of the federal
government, and thus is most responsible for providing consumer health information.
Finally, Merck Pharmaceuticals and GlaxoSmithKline (GSK) were natural candidates for
inclusion because they are the two companies that currently manufacture the HPV
vaccine and that are responsible for the current media campaigns on the topic. At the
time of data collection, GSK’s vaccine, Cervarix, had not yet been released to the public,
although information on it was available through their website. Data collection took
place from June through August, 2007.
Data Analysis
All content pages on each website were printed and included in the analysis; this
also included pages addressing the mission and structure of each organization. Sections
that detailed organizational contact information, links, and additional resources were left
out of the analysis. Following Bernard (2006), who described content analyses as
deductive procedures, I developed a set of hypotheses to apply to the data based on a
thorough review of the literature and informal conversations with key informants.
Specific questions were formulated within each hypothesis in order to measure the
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number of times a certain piece of information occurred, and then, in combination with a
qualitative review of website text, these were used to extract key themes emerging from
the data. Findings were then used to develop the preliminary interview guide and to
provide overall background information on the issue.

Specific questions that were developed to guide the website review included:
o How many times does the website state that HPV causes cervical cancer?
o Does the website state that HPV is transmitted sexually? If so, how many times
do they mention this?
o What is the ratio of mentions of “HPV causes cervical cancer” to “HPV is
sexually transmitted”?
o How many times is HPV mentioned as the causative factor, and how many times
is it mentioned alongside other factors?
o Does the website discuss prevention strategies that involve modifying sexual
behavior? If so, what kinds of strategies are mentioned?
o How often does the website state HPV incidence/prevalence rates in conjunction
with their explanations of cervical cancer’s causes and/or HPV’s causes?
o Does the website have a section for men and HPV?
o Do these groups provide information on the HPV vaccine?
o Do they offer a position on the vaccine or vaccine mandates?
The size of the websites varied considerably, ranging from a minimum of five
pages of relevant content addressing cervical cancer and/or HPV (in the case of
GlaxoSmithKline) to 105 pages for the National Cervical Cancer Coalition’s website.
Five of the sites recorded the last date that each page was modified or reviewed. The
ACS last modified all of their pages between July 2006 and March 2007; the CDC
between June and July 2007; GSK in March 2007; and Merck in November 2006.
WebMD had last modified most of their pages in December 2004, with one related to the
vaccine updated in September 2006. The NCCC recorded the most recent revision
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date—between September 2005 and March 2006—on approximately half of its pages,
while Tamika & Friends website did not record a date on any of their pages.
Semi-Structured Interviews
A total of 19 in-depth interviews were conducted using a semi-structured, openended interview guide. Each interview lasted between 45 and 90 minutes, with most
interviews concluding after one hour. Ten interviews were conducted face-to-face in a
location of the participant’s choice: most commonly, participants selected a public space
for their interview, such as a coffee shop or a park picnic table. Due to recruitment
challenges (discussed later in this chapter), it was necessary to include nine non-local
participants and these interviews were conducted over the telephone. All interviews were
tape-recorded for later transcription and analysis. Data collection took place over a
course of six months from October 2007 to March 2008.
As noted above, the open-ended interview guide (see Appendix A) was developed
using data gathered from the key informant interviews and content analysis. The study
began by using a draft guide and items were refined through pre-testing and expert
review by thesis committee members and key informants. The final guide consisted of
23 items in addition to several demographic questions.
Broadly, the interviews addressed how cervical cancer survivors perceive their
own experience in the context of public educational and media messages that emphasize
the link between sexual behavior and cervical cancer; whether or not they experience
stigma and how this has impacted their own sense of their diagnosis and survivorship
status; and what they believe are the important steps involved in minimizing this
stigmatization in relation to educational, prevention, and outreach efforts.
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Participant Selection and Recruitment
Interview participants must have fulfilled all of the following inclusion criteria.
They must have: (1) experienced a diagnosis of cervical cancer at some point in their
lives; (2) been between the ages of 18 and 75; (3) been fluent in English; and (4) have
given their consent to participate in the study.
Participants were recruited locally in Tampa Bay and surrounding counties using
four strategies: (a) through the offices of gynecologic oncologists in Hillsborough
County; (b) through local non-profit organization addressing cervical cancer; (c) via
flyers sent out electronically through organizational listservs, and (d) by snowball
sampling through personal contacts. Personal contacts include those made through the
researcher’s thesis committee members and faculty advisor, previous work experiences in
cancer advocacy organizations, and word of mouth. Difficulties in recruiting local
participants necessitated a change of approach midway through the interview process,
and several non-local survivors were included through the use of telephone interviews
(for a more detailed discussion, see Section III: Challenges).
In strategy (a), gynecologic oncologists in Tampa and surrounding cities were
mailed a letter of introduction, describing the study and providing sample recruitment
materials (specifically, a study flyer). This letter of introduction described the study and
asked for the oncologists’ assistance in passing along flyers to their patients, or to display
them in clinic waiting rooms. Contact with the potential participant was made in one of
two ways: the participant either contacted the researcher directly after receiving the
information, or, the provider retained the names of participants who stated that they were
interested in being contacted about participation. The researcher then followed up with
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the potential participant directly using the contact information that they provided. During
that initial contact, the researcher would confirm that the woman met the inclusion
criteria described in the project proposal and IRB application. Although this was both the
most time-consuming and least successful recruitment method in terms of actual
participants enrolled—only two—a total of seven gynecologic oncologists representing
four different local practices agreed to collaborate and assist in recruitment.
Strategy (b) relied on the assistance of two local non-profit organizations
addressing cervical cancer in some capacity. Faces of Courage is a Tampa-based
organization providing support and resources to individuals diagnosed with any type of
cancer. The founder, Peggie Sherry, was a tremendous help in sending out flyers through
her listserv and otherwise getting the word out to members of her organization that had
been diagnosed at some point with cervical cancer. Four participants were recruited in
this fashion. The other organization, the Sarasota-based Wellness Community, was
initially very supportive because of their weekly Gynecologic Cancer Support Group but
turned out not to have any women with cervical cancer enrolled at that time.
Relatively speaking, strategies (c) and (d) were very fruitful in terms of the
number of participants recruited—a total of 13. Study flyers were sent out electronically
through the USF Health listserv, the USF Anthropology Department listserv, the
University of Florida Anthropology Department listserv, and the University of Central
Florida Women’s Studies Department listserv. Additionally, an announcement was sent
to the membership of Fertile Hope, a national non-profit organization providing
infertility resources to cancer patients and survivors with whom I was employed for
several years prior to graduate school.
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Data Analysis
All interviews were tape-recorded so that I was able to focus more closely on the
actual interview and conversation; immediately afterwards they were transcribed
verbatim and interview notes were recorded. After all of the interviews were completed,
the transcripts were reviewed and a set of codes based on the interview topics was
developed and used to partition the interviews. Then, coded transcripts were analyzed for
frequently expressed themes.
Online Surveys
In order to reach a wider range of participants, a final method utilized in this
research project was a short online survey administered to 70 non-local cervical cancer
patients and survivors between March and May 2008. In an attempt to streamline the
administration process and include participants residing nationwide, the survey was
offered electronically through Survey Monkey, a free web survey software program.
The preliminary online questionnaire was developed after most interviews had
been completed, and thus, key themes emerging from the interviews structured the design
of many questions. In addition, a survey in an ongoing study by Coreil (2008) on
tuberculosis and stigma was used as a general guide, and several items were inspired by
an HIV-stigma scale developed by Berger, Ferrans, and Lashley (2001). The items were
refined through pre-testing and review by thesis committee members and a key
informant, and the final survey (see Appendix B) included a combination of 38 closeended and open-ended items. All close-ended questions included an optional text box for
additional comments, which were later analyzed in the same manner as the open-ended
items.
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Participant Selection and Recruitment
As in the interview phase, all survey participants must have fulfilled all of the
following inclusion criteria. They must have: (1) experienced a diagnosis of cervical
cancer at some point in their lives; (2) been between the ages of 18 and 75; (3) been
fluent in English; and (4) have given their consent to participate in the study.
Participants were primarily recruited via listserv and website advertisement
through four sources: the National Cervical Cancer Coalition, Tamika & Friends,
Women in Government, and the National Council of Women’s Organizations. Located in
Los Angeles, the National Cervical Cancer Coalition is the largest national non-profit
organization addressing cervical cancer. A link to the survey was posted on their patient
and survivor message board. Tamika & Friends is a national Washington, DC-based
non-profit advocacy group representing cervical cancer patients and survivors, and the
Executive Director of this organization sent the survey link to their member listserv.
Women in Government is a national organization also headquartered in DC that
represents women state legislators; the survey link was posted on the homepage of their
national “Challenge to Eliminate Cervical Cancer” program website. The National
Council of Women’s Organizations, also in DC, is an umbrella organization uniting nonprofit groups that address issues of concern to women in the United States. An email
containing the survey link was sent to their member listserv after one of their staff
members received the email from Tamika & Friends.
Data Analysis
Results from the survey were handled in two ways. First, quantitative items were
entered into SPSS in order to obtain descriptive statistics. Second, qualitative items
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(including both open-ended questions and the optional comment boxes for the closeended questions) were analyzed using the same coding scheme developed for the in-depth
interviews.
ETHICAL CONDUCT
This research study was approved by the University of South Florida Institutional
Review Board on June 20, 2007 (Protocol 105855). Subsequent modification
applications addressing recruitment sites, recruitment procedures, and revisions of study
instruments were approved on July 27, 2007; September 19, 2007; October 25, 2007;
November 21, 2007; and March 26, 2008. A continuance was issued on June 3, 2008.
Informed Consent
All study participants gave their consent via several IRB-approved methods.
Interviews were conducted either in-person or over the phone; as such, consent
procedures differed slightly between the two. For in-person interviews, a written
informed consent form was read and given to participants prior to the beginning of every
interview, allowing time for questions and the option of refusing to participate in the
project. Willing participants were then asked to sign the consent form. For telephone
interviews, a consent script approved by the IRB through a Waiver of Informed Consent
Process was read to the participants over the phone. The participants were allowed time
for questions and the option of refusing to participate in the interview, and then were
asked explicitly if they gave their consent to proceed. In both cases, participants were
clearly notified of their right to stop the interview at any time without any adverse
consequences.
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Participants completing the online survey read the posted IRB-approved informed
consent prior to the start of the survey and indicated their consent by checking a box. All
interviewees and online survey participants received the same consent information and
the option to refuse or discontinue participation.
Confidentiality
The last name of the participant and other personal identifying information was
not recorded on study notes, in the tape-recorded sessions, or on surveys. Participants
were assigned numerical codes, and the only instance in which their last name was
recorded was on the consent form and in an enrollment codebook. Only the researcher
and Faculty Advisor had access to these data, and no copies were made of the consent
forms. All participants were assured that any publications resulting from the collected
data would be presented in aggregate form and would thus be anonymous. Pseudonyms
have been used throughout this paper.
Compensation
No compensation was offered to participants. However, no cost to participants
was incurred because of their participation in the study. All interviews were conducted at
a location of the participant’s choice, such as home, office, or public space. In this case,
the researcher traveled to the site, and in the case of telephone interviews, the call was
made at the expense of the researcher. All questionnaires were completed online through
a web survey software program that was free to participants.

43

CHALLENGES
Recruitment Issues
Recruitment for the interview phase was a significant challenge, and necessitated
changes in strategy several times. An entire chapter could likely be written on
recruitment strategies alone; thus, for considerations of space I will not detail every
attempt or change of course but rather will discuss the underlying factors that I believe
played a role in it. Suffice it to say that it was necessary to conduct many interviews over
the telephone because participants did not live locally, and these women were recruited
through previous work contacts in New York. Rather than label these “study
limitations,” as some may consider them to be, I believe that this challenge does shed a
brighter light on the predicaments facing women with cervical cancer and it is fruitful to
consider these limitations within the overall context of the study objectives and findings.
First, from an epidemiological perspective, cervical cancer incidence in this
country is now relatively low. With the increasingly widespread use of the Pap smear
between 1955 and 1992 in the United States, overall cervical cancer incidence rates
declined by 74 percent (National Cancer Institute 2008a). While this represents an
excellent success story in preventive medicine, it also means that it is more difficult to
locate study participants.
However, this fact alone does not mean it is inherently difficult to recruit
participants. Just as importantly, the Tampa Bay area—and, as far as I can tell, the entire
state of Florida—has no organized community of cervical cancer patients and/or
survivors. Many cancer type-specific support groups do exist in Hillsborough County
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and surrounding counties, such as breast cancer, prostate cancer, lung cancer, leukemia,
and childhood cancers. However, no such group exists solely for women with cervical
cancer despite the presence of multiple community organizations whose primary mission
it is to provide support to cancer patients and survivors. Yet even in general cancer
support groups, there is very rarely even one member who has had cervical cancer. This
discovery is important to the study in two very significant ways. First, it challenges our
traditional concepts of ethnographic research that have typically relied on the
identification of a bounded community to study, such as a school or neighborhood.
Second, it has overall significance for the ways in which the participants have
conceptualized their cancer experience as frequently alone and isolated within the general
“cancer community,” overlooked even more by funding and research initiatives that tend
to glorify “favored” types of cancers (see Chapter Four: Results and Chapter Five:
Discussion and Recommendations for a lengthier discussion on this finding).
It seems that the only instance in which a critical mass of women with cervical
cancer gathered at any one time was in the offices of gynecologic oncologists. This
presented its own challenges not unique to research with clinical populations: health
privacy laws intended to protect the confidentiality of the patient. As a graduate student
with limited amounts of time and funding (read: a low priority researcher), it was
virtually impossible to navigate successfully through all the requirements of various
institutional ethics boards and compliance committees in order to have a personal
presence in the clinic.
Further, being granted permission to advertise in some of these doctors’ offices
raised additional considerations from both the provider and participant perspectives.
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Providers had to “agree” with my study; some did not see the relevance, and others did
not want me to discuss HPV because they had consciously shielded their patients from
information about the link between HPV and cervical cancer in an attempt to avoid
stigmatizing them. On the participant side, the participant and I would have made contact
within a clinical context where the focus is on a biomedical model of disease causation,
whereas a major purpose of my study was to find out about their own ideas about
causation and how these interact with both biomedical reasoning and their own bodily
experience and knowledge. I did not want them to feel as if I was quizzing them on their
medical knowledge, and this might be confusing given the fact that I appeared to be
working with their doctor. In addition, contacting participants through their own
healthcare providers always runs the risk of inadvertently making them feel obligated to
participate because their doctors seemed to be asking them to do so.
And finally, as the title of this thesis suggests, cervical cancer can frequently be a
stigmatizing condition for those who have been diagnosed with it. Because of this, one
might assume that those with the condition might be more reluctant to be in the public
eye or to take the necessary steps in reaching out to speak with a researcher about it.
Accordingly, in summary, my challenges with recruitment largely reflect how difficult it
can be to research a sensitive, stigmatized topic such as this in a location where there is
no organized, identified community. There exists no easy opportunity to establish
rapport with women in an ongoing, consistent fashion, and because of health privacy
laws it was often necessary to rely on a third party (healthcare providers) to make the
initial contact for me.
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Subjective Experience
Another significant challenge for me throughout the course of the study, but
particularly in the beginning, was my own personal history as an adolescent cancer
survivor and as someone who has been involved with several cancer advocacy
organizations. There were two dimensions to this. First, many aspects of my own
identity are intertwined with my cancer experience, and I found that some of my
unproblematically-held assumptions about “cancer survivorship” were constantly
challenged. For example, I have always identified myself as a cancer “survivor,” and
had, for the most part, taken this label for granted when referencing myself and others I
knew that had cancer. All of my friends who have had cancer do the same. Thus, it came
as a surprise to me that within the first couple of interviews this label was resisted and
critiqued by some participants. In some instances, a seeming hierarchy of cancer
experiences appeared, with those people who had gone through the most difficult
treatments resting comfortably at the top of the ladder. They were—at least in some
people’s minds—the “real” survivors and the ones most deserving of that designation.
Additionally, the “taking-on” of that label for many women was a very deliberate
decision made at a particular time, and it spoke volumes about the meaning that that
experience held for them. This realization led me to ask a separate question in both the
interviews and the survey in order to shed light on the use of this label and what it meant
for those affected. Although these types of realizations were surprising to me at times, in
a personal sense they allowed me to reflect more deeply, critically, and positively on my
own beliefs and experiences, and—equally as important—to try to apply these
considerations back to my own research and interactions with the participants.
47

Second, I had to devote much thought and attention to whether or not I should
disclose this piece of information about myself to participants—and if so, how I should
go about doing it. In the end, I opted for disclosing it in the beginning of the interview
before the informed consent, while emphasizing the motivation behind these interviews:
that my own experience had made me interested in hearing other people’s stories. For the
most part, this mutual sharing was a very positive experience and I believe that it helped
put the women (and myself) at ease, especially during those interviews conducted over
the phone. Rarely did it have one of the effects that I had been concerned about—
specifically, having the interview turned around on me. Overall, I believe that both this
sharing and questioning of my own experience strengthened my research project, by
increasing its reflexivity, and—I hope—by allowing women to feel more comfortable
sharing an exceedingly private and often painful experience with a total stranger.
SUMMARY
Data were collected in this project through four primary sources: key informant
interviews, a website content analysis, semi-structured interviews, and an online survey.
The key informant interviews as well as the content analysis were intended to provide
both a background picture of the situation as well as preliminary data that would structure
the design of the interview guide. Seven websites were ultimately included in this phase.
Nineteen semi-structured interviews were then conducted with women who had been
diagnosed at some point in their lives with cervical cancer, both in person in the Tampa
Bay area as well as over the telephone. Findings from the interviews were then used in
the design of a 38-item survey, which was administered online to an additional 70 women
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residing nationwide. Data collection for all three phases took place from June 2007
through May 2008, while analysis of the data was ongoing throughout the project.
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Chapter Four:
Results
As addressed in detail in Chapter Three, a variety of methods were employed in
this project to create a holistic picture of the views of cervical cancer survivors on their
illness and its association with HPV. This chapter will present in detail the findings from
the data analysis. It is sub-divided into four sections. First, findings from key informant
interviews and the website content analysis will be briefly outlined. Next, the semistructured interviews will be discussed in-depth, including the demographics of the
participants as well as major themes that emerged from the data. Many of these themes
were incorporated into the survey questions, and findings from these data will be
addressed in the fourth section.
KEY INFORMANT INTERVIEWS
Interviews were conducted with three key informants at the very beginning stages
of the project, and were influential in the initial conceptualization of the research topic.
Two of the informants resided in Tampa and the other in Washington, DC. These three
women had very different experiences with cervical cancer and so shed light on a diverse
set of issues related to the disease. Two had experienced diagnoses: one with invasive
cancer and the other with pre-cancer. Two were also heavily involved in providing
cancer support services through non-profit organizations and thus were very
knowledgeable about specific resources available for cervical cancer patients and
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survivors, both locally and nationwide. One of these interviews was conducted in-person
in Tampa; the others took place over the telephone. Two of the women were Caucasian
and one was African American; and all women were under the age of 50.
Because these informants had either been previously diagnosed with cervical
cancer themselves or were involved in advocacy efforts for this community, the objective
of these initial interviews was to learn more about the major issues confronting women
with cervical cancer. Several important ideas arose through these conversations, one of
which became the principal focus of this study, while the other two subsequently
appeared repeatedly throughout the in-depth interviews.
First, two of the initial interviews took place in the months following the release
of the Gardasil HPV vaccine (June 2006). At that time, the story—and subsequent
controversy over school mandates—was appearing frequently in the news, and the
advertisements for the vaccine had just commenced. Therefore, it seemed to these
women that HPV was more clearly in the public eye than ever before, and they were in
the midst of negotiating a situation where they felt “exposed” by the media attention on
HPV’s link to cervical cancer. They spoke about feeling acutely ashamed whenever
these commercials came on television, wondering if everyone thought they were now
“dirty” or promiscuous, or had contributed to the creation of their own disease. The idea
of moral labels being attached to cervical cancer had been an initial research idea, and the
strength of this theme emerging in the key informant interviews served to sharpen and
focus it more towards the ways in which women negotiated these labels in the face of
ever-increasing media attention and awareness of HPV.
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These interviews were also where a challenge to the concept of “cancer survivor”
first arose, something that I had not considered before in my initial conceptualization of
the project (discussed in-depth in Section III, this chapter). One of the informants
questioned the relevance and application of this term to herself, given that she had not
experienced debilitating treatments like other, more seemingly legitimate, cancer
survivors. She had only undergone “a procedure,” and thus would never classify herself
as a true survivor. She was concerned that if I used this phrase in my study, I would lose
many potential participants who would never have considered themselves eligible in the
first place. Her concern merited serious consideration, and following this I modified
many of my recruitment materials so that they advertised for “women who have
experienced cervical cancer” rather than using the more contested phrase.
Another idea that came up very strongly was that of infertility. Given the
physical location of cervical cancer, fertility is inherently a concern for this group of
women, especially considering its demographics—peaking in a woman’s reproductive
years. Although this was not a principal focus of this study, this issue was consistently a
particularly painful and poignant one throughout the course of the study (please see
Section III this chapter for a more detailed discussion). The combination of a lifethreatening illness with the ending—in some cases—of a dream or expectation that had
been held since childhood created a huge amount of distress and this is certainly an issue
that merits further study consideration.
WEBSITE CONTENT ANALYSIS
Next, a website content analysis was conducted to provide preliminary data
between June and August of 2007. As detailed in Chapter Three (Methods), the goals of
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this analysis were three-fold: first, to assess how these groups present information to the
public related to HPV and cervical cancer’s connection to a sexually transmitted
infection, and the degree to which this link to sexual behavior may or may not be made
apparent in their educational messages; second, to determine the organizations’ position
on the HPV vaccine; and finally, to guide the development of the in-depth interview
guide.
Four groups of websites were included: non-profit advocacy groups, commercial
groups, governmental agencies, and pharmaceutical companies. Three non-profit groups
were sampled: the American Cancer Society, National Cervical Cancer Coalition, and
Tamika & Friends. WebMD was selected to represent a commercial health information
company, while the CDC was chosen because it is the public health agency of the federal
government. Merck Pharmaceuticals and GlaxoSmithKline Pharmaceuticals were both
selected because they are the two companies currently producing a vaccine for HPV.
Bernard (2006) describes content analyses as deductive methods, and following
this I developed a set of hypotheses from which to examine the data. Close-ended
questions were generated in order to measure the number of instances a certain piece of
information occurred; a combination of these and a qualitative review of website text
were useful in extracting key themes. As size and the amount of content naturally varies
from website to website, it is important to note that the conclusions reached are
preliminary—they are intended to provide both a background picture of the issue as well
as to guide the direction of future questions meant to be answered by the interview and
survey portion of the study.
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Major Themes
Causation
All websites stated that HPV causes cervical cancer, occurring most often within
the advocacy and pharmaceutical websites. Further, to varying degrees, all stated that
HPV is sexually transmitted (American Cancer Society 2007; CDC 2007a;
GlaxoSmithKline Pharmaceuticals 2007; Merck Pharmaceuticals 2007b; National
Cervical Cancer Coalition 2007; Tamika & Friends 2007; WebMD 2007). However,
certain types of websites—specifically governmental and commercial ones—seemed to
place more emphasis on HPV’s sexual transmission. For example, they described both
what HPV is, and that it is transmitted sexually (CDC 2007a; WebMD 2007). For
example:
“The virus that causes cervical cancer is spread through sexual contact. The best
way to avoid getting a sexually transmitted disease is not to have sex” (WebMD
2007:Topic Overview).
“Genital human papillomavirus (HPV) is the most common sexually transmitted
infection in the United States” (CDC 2007a:Reducing Risk).
Conversely, advocacy groups and pharmaceutical websites placed a good deal
more emphasis on HPV’s causative role in cervical cancer—for example, they often
stated that cervical cancer is caused by HPV, but did not as frequently discuss what HPV
is or how one gets it (Merck 2007b; NCCC 2007; Tamika & Friends 2007). In doing
this, organizations avoid mentioning cervical cancer in conjunction with loaded terms
such as “STI” and “sexual behavior.” For example:
“Cervical cancer is caused by certain types of HPV. When a female becomes
infected with certain types of HPV and the virus doesn’t go away on its own,
abnormal cells can develop in the lining of the cervix. If not discovered early and
54

treated, these abnormal cells can become cervical precancers and then cancer”
(Merck Pharmaceuticals 2007b:FAQs).
“Unlike most types of cancer, the cause of cervical cancer is known. Almost all
cases of cervical cancer are caused by high-risk types of the human
papillomavirus (HPV)” (Tamika & Friends 2007:Myths and Facts).
De-Stigmatization
The above comment plays into this next theme of de-stigmatization. By not
pairing the concepts of HPV and sexual transmission, the emphasis on sexual behavior is
lessened, and thus—if we are assuming that the stigma of cervical cancer is related to
this—stigmatization might be minimized. Advocacy and pharmaceutical websites most
often utilized what might be interpreted as attempts at de-stigmatization: these websites
do not as frequently discuss prevention strategies that involve modifying sexual behavior
(GSK 2007; Merck 2007b; NCCC 2007; Tamika & Friends 2007); tend to mention HPV
as only one potential factor among several (ACS 2007); and state HPV’s high prevalence
rates in relation to cervical cancer (ACS 2007; GSK 2007; Merck 2007b; NCCC 2007;
Tamika & Friends 2007), in addition to the more infrequent pairing of HPV and its sexual
transmission (Merck 2007b; GSK 2007; NCCC 2007; Tamika & Friends 2007). For
example:
“Even though HPV is an important risk factor for cervical cancer, most women
with this infection do not get cervical cancer. Doctors believe that other factors
must come into play for this cancer to develop. Some of these factors are listed
below: smoking, HIV infection, Chlamydia, diet, birth control pills, having many
pregnancies, low income, DES, and family history” (ACS 2007:What Causes
Cancer of the Cervix?)
“Cervical cancer is caused by the human papillomavirus (HPV). Only some
high-risk types of HPV cause cervical cancer. Most adults will have high-risk
HPV at some point in their lives and are able to clear the virus through their
body’s normal immune response. Most women will clear an HPV infection within
9-15 months” (Tamika & Friends 2007:The Facts).
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Focus on Women
With the exception of two websites (ACS 2007; NCCC 2007), there is an
exclusive informational focus on women. While this may seem obvious given that many
of these websites specifically target a woman’s cancer, most of these websites do not
even mention the fact that HPV has health consequences for men, or that they can even
carry it. For example, on the WebMD (2007) website, a good deal of discussion is
devoted to risk reduction for women by modification of specific sexual behaviors and
choices: “the virus that causes cervical cancer is spread through sexual contact. The
best way to avoid getting a sexually transmitted disease is not to have sex. If you do have
sex, practice safer sex, such as using condoms and limiting the number of sex partners
you have” (WebMD 2007:Topic Overview). However, there is no discussion of HPV’s
potential adverse effects on men (such as genital warts, anal cancer or penile cancer),
their ability to carry or infect others, or the need for men to practice safer sex to protect
themselves against the health consequences of HPV.
This is perhaps a little dangerous—as cervical cancer has become a gendered
disease, by not mentioning men, these websites represent HPV as a woman’s disease too
when it is clearly not. Thus, women become both the target of the disease and the source
from which it springs, running the risk of furthering stereotypes of female sexual dirtiness
and disease.
Presentation of the HPV Vaccine
The underlying motivation behind this objective was to get an overall picture of
the ways in which these groups presented information on the vaccine, and whether or not
they had adopted a pro-vaccination stance. With the exception of the two pharmaceutical
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websites (GSK 2007; Merck 2007b), it appeared that all other websites attempted to offer
unbiased information about the HPV vaccine (ACS 2007; CDC 2007a; NCCC 2007;
Tamika & Friends 2007; WebMD 2007). The FDA guidelines were cited often, and
somewhat surprisingly, none openly advocated a position either pro- or anti- mandatory
vaccination.
“A new vaccine called Gardasil protects against four types of HPV, which
together cause most cases of cervical cancer and genital warts…The vaccine is
recommended for girls 11 to 12 years old. It is also recommended for females 13
to 26 years old who did not get the vaccine when they were younger” (WebMD
2007:2-3).
None acknowledged the mandatory vaccination “controversy,” then ongoing in
the news. On the other hand, the pharmaceutical websites, not surprisingly, were
essentially long advertisements for the vaccine.
“Gardasil is the only vaccine that may help guard against diseases caused by
HPV Types 16 and 18, which cause 70% of cervical cancer cases, and HPV Types
6 and 11, which cause 90% of genital warts cases” (Merck 2007b:Know the
Link—Cervical Cancer and HPV).
SEMI-STRUCTURED INTERVIEWS
Participant Demographics
A total of 19 women participated in the interview phase of this study. Ten of
these interviews were conducted in-person with women who resided in the Tampa Bay
area; the remaining nine were conducted over with phone with participants living outside
of Florida (specifically, in California, Georgia, Michigan, New York, Pennsylvania, and
Texas). Participants were recruited through a variety of sources: two women were
recruited through doctors’ offices, four women through a local Tampa-based cancer
support organization, and 13 through various organizational email listservs. The median
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age was 39, although women ranged in age from 24 to 65. Nine of the participants were
married, four were unmarried but in long-term monogamous relationships, four were
single, and the relationship status of the remaining two participants is unknown. An
equal number of the women had children as did not (eight each), while one woman was
currently in the process of adopting and another was expecting a baby through a
surrogate.
Women were asked to self-identify by ethnicity: the greatest proportion (12)
identified as Caucasian, three as Latina with different countries-of-origin, two as African
American, and one each as Polish and Asian. Occupations were diverse: five worked in
administrative positions while four were healthcare professionals; three worked in media
(television and magazine), one was involved in community services/outreach, one in the
travel industry, and one worked as an animal trainer. Four were students, either part-time
or full-time, and many were involved to some degree in advocacy for the cancer
community—three working full-time for non-profit organizations while others on a more
informal level. One woman did not report an occupation.
Relatively speaking, the women who participated in the interview had been
diagnosed recently: the median time since diagnosis was two years. However, there were
large differences in the time-since-diagnosis among the women, ranging from 33 years to
2 months prior to the interview. Cervical cancer had been discovered during the course
of regular Pap screening in eight of the women, and in three others it was discovered in
the middle of lengthy fertility treatments. Seven others had been experiencing either
worrisome or life-threatening symptoms, and in one participant the reason for discovery
was unknown. The women’s stage of disease at diagnosis ranged from very early (Stage
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0 or I) to advanced (Stage IV), although in the greatest proportion of cases the cancer was
caught at Stage I.2 Types of treatment were varied and included some type of surgical
procedure (i.e., hysterectomy or trachelectomy) in 11 of the cases, internal radiation (4),
external radiation (10), and/or chemotherapy (10).
Major Themes
Causation
“Causation” is a complex category reflecting various, and at times conflicting,
ideas about the root causes of both cervical cancer and HPV. Incorporated in the
responses within this theme are first, biomedical theories of disease development—
presented by participants as objective and scientific notions—and second, personal
explanations about why participants themselves became sick, which were behavioral in
nature and often tinged with moral judgment. As discussed earlier in Chapter Two, Hunt
(1998) argues in her work that “science strives to translate observed phenomena into a
value-free framework, removing it from the elements of ordinary existence” (1998:309).
In the absence of biomedicine’s explanations of cancer’s fundamental cause, individuals
must create meaning behind their own illness, and indeed, these ideas seem to be
reflected within the stories of these interviews. Within these broad strokes lie differing
explanations about the cause of, first, HPV, and second, cervical cancer—in general and
then within themselves. Simply put, these responses answer the questions, “What do you

2

In Stage I cervical cancer, the cancer has not spread outside the cervix. Stage II indicates that the cancer
has spread beyond the cervix but not yet to the pelvic wall or bottom third of the vagina. In Stage III, the
cancer has spread either to the pelvic wall or to the lower third of the vagina, while Stage IV cancer is the
most advanced stage in which the cancer has spread to a close organ, such as the bladder or rectum, or a
distant part of the body, such as the lungs, liver or brain. Stage 0 indicates carcinoma-in-situ—a “precancer” that has not yet become invasive (National Cancer Institute, 2008b)
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think causes HPV? Cervical cancer?” and then, “How do you think that you developed
HPV? Cervical cancer?”
HPV: Theories of Causation
Overall, participants’ explanations for the cause of HPV in general tended to
reflect the current biomedical discourse surrounding HPV as a sexually transmitted
infection. The majority spoke of HPV as sexually transmitted, and specific behaviors
that might lead to catching it. For example, when discussing who was more at risk for
getting HPV, one participant noted that, “They say that certain women, like younger
women if you're first sexual experience is below a certain age and if you smoke, and if
you've had a lot of sexual partners” (Kate, 25 years old). Other women spoke about the
seemingly high-risk nature of HPV, and how even one act is enough to contract the virus:
“We know that you can have sex one time and be exposed to the virus” (Amanda, 45
years old).
Explanations for how people in general contract HPV were remarkably similar to
the explanations participants shared for how they themselves contracted HPV—both
reflected current biomedical theories surrounding the virus. For example, one participant
replied:
“Um, yeah, sex. I was pretty sexually active when I was younger, so I'm sure it
was from sexual partners, and it was probably several sexual partners ... multiple
partners. So I definitely think that was where it was from” (Christina, 24 years
old).
In addition, many of the women’s stories reflected confusion about the actual event—or,
more frequently, person—through which they contracted HPV:
“And as soon as she said [it was HPV], I started thinking back and I'm like
‘which one of those sons-of-bitches gave me HPV? You bastards! Which one of
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you is the reason that I'm in this room right now?’ The thing is that I don't know
... I never had any STD; I've never had anything my whole life -- I could have
gotten if from my high school boyfriend; I could have gotten it from my husband. I
have no idea. I guess I could take my husband down there, but I guess at this
point it doesn't matter. There's no way to know. So, did he get it from me? It's so
hard to know. Because when I think about other boys, I'm like, "All your fault!”
(Kate, 25 years old).
Cervical Cancer: Theories of Causation
Participants’ responses about the potential causes of cervical cancer were almost
identical to their explanations about the potential causes of HPV. For example, many
cited specific behaviors—frequently sexual behaviors—as a potential cause, and almost
seemed to take for granted HPV’s role in cervical cancer, using the two terms almost
interchangeably. For example, one woman replied that:
“If you have multiple sex partners, it increases the chances of having [cervical
cancer], but I guess the HPV […] has now been identified as relating to that. And
so women who are exposed to that, and I guess if they have more partners they
are more likely to be exposed to that – those are the ones who are more likely to
get cervical cancer” (Helen, 61 years old).
On the other hand, personal theories about the cause of that individual woman’s
cervical cancer are on the whole much fuzzier and reflect varying degrees of uncertainty.
In general, women’s explanations about why they themselves became sick tended to fall
into two broad categories: the first, which I refer to as “Individual Behavior,” explains
cervical cancer as resulting from choices on the part of the woman herself. For example,
women spoke about not going to the doctor enough, not getting Pap smears as frequently
as they felt they should have, sleeping with the wrong man, smoking, or just generally not
taking care of oneself properly.
“I have all of the risk factors, you know. I had sex before 17, I have multiple
partners and you know basically the only one I didn’t have was that I didn’t
smoke.” (Joyce, 39 years old)
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“It is my fault that I had cervical cancer, because I have never had a Pap
smear”(Beatrice, 65 years old).
“Well, I guess I had the HPV, because I'd had the abnormality a long time ago,
and I think that my immune system was just really run down. That's my feeling. I
think that my typical self was very different from my self when I got diagnosed,
because I'd lost the pregnancy and that was really really really hard physically
and emotionally, and my body was just really run down” (Amanda, 45 years old).
The second category includes “External Factors”—these explain cervical cancer
as a result of external forces acting upon the individual in such a way as to cause the
disease. For example, some women described their cancer as resulting from the actions
of a philandering husband or from a rape that took place a couple of years prior—in both
of these instances, the man had been the one to pass HPV onto these women. Several
others believed that the fertility treatments they were undergoing had played a central
role. One woman suspected that her tampons had been the primary cause of her disease:
“I think that [my experience with cervical cancer] started when I was 12 years
old and my menstrual cycle began. At first I used sanitary pads, but then before
my 13th birthday, I decided to switch to tampons...I religiously used tampons from
that time on until a year before I was diagnosed with cervical cancer. A little bit
later I started to notice there were publications on findings that there were traces
of asbestos found in certain brands of tampons… Now that’s considered very
dangerous in air filtration systems, and in building structures. So I started
researching that. And I started to discover that it was because the asbestos being
present in the tampon causes more bleeding. When more bleeding is produced,
more tampons are purchased. The market profits. And that’s a risk to women that
are using tampons.” (Kim, 57 years old)
No matter some women’s assurance about the overall cause of their cervical
cancer, its diagnosis seemed to cast a shadow of uncertainty onto everything from their
past behavior to the behavior of others. Many spoke about the difficulty of living without
a clear answer as to how it arose, and whether or not it will return. Still others raised the
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issue of trust in marriage, and how this diagnosis had raised some doubt as to their
partners’ fidelity over the years. For example, one woman confided that:
“Well, that's a weird one, and to me there's kind of like a stigma with cervical
cancer, because you know, the whole HPV thing, which is basically like a sexually
transmitted disease. So, I've been married for 15 years, and I had my last child
about 11 years ago, and I'm not unfaithful. I don't know, I'm thinking it had to
come that way cause it's not the type of cancer that generally ... it's not a breast
cancer. I don't know how long the HPV virus would be there, they never really
said if it was like HPV, from that strand or not” (Candace, 36 years old).
Sexuality
A prominent theme emerging out of the interviews was sexuality. In particular,
participants’ narratives touched upon the idea that there are aspects of female sexuality
and the female body that predispose certain women to developing cervical cancer by
increasing their risk of contracting HPV—whether it be actual physical attributes, or
subjective judgments about female sexual nature. For example, one woman believed that
the relative uncleanliness of female genital anatomy as compared to males’ was a
contributing factor to her condition, stating that:
“It’s definitely because of my sexual history [rather than my husband’s] because I
don’t think that men can carry the virus that long... The male organs…are
definitely cleaner, you know, there are no places for bacteria or germs to hide”
(Meredith).
Another participant commented upon society’s judgments about the type of woman who
gets cervical cancer, noting that:
“We do assume that if you get HPV, you’re a slut. Any kind of sexually
transmitted disease, you’re a whore. Unless you’re a guy, and then it’s some
girl’s fault” (Kate, 25 years old).
Another important idea revolved around the tension between the public and
private aspects of female sexuality. Many women tended to regard the female sexual and
reproductive organs, and further, sexual behavior, as extremely private. At the same
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time, however, a diagnosis of cervical cancer presented a big dilemma because it required
them to become public about a part of the body that they are not used to being public
about. One woman said:
“I think that there is a much smaller percentage of women talking about cervical
cancer than talking about breast cancer...Breasts have a very different feeling
about them. In a way they are considered a sexual part of the body but then at the
same time they’re kinda not. Whereas the cervix, vagina and all that are very
private, very sexual… so a lot of women would tend to keep it to themselves. ‘This
is my personal part of my body, not for anyone else. It’s for me to witness’” (Kim,
57 years old).
“When I was diagnosed, I felt that a lot of my sexual life [was] under
investigation…That has been really, really uncomfortable…And you start
explaining [to your friends and family], but a lot of things are private, so you
have to open your sexual life” (Carmen, 28 years old).
The private nature of this area of the body seemed to influence many women’s
ability to get support during the experience, and the degree to which they thought their
family was responsive to their needs. Speaking about her experience with dysplasia, one
participant explained that:
“My mom has been very supportive; I certainly cannot talk to my dad about any
of it. My dad does not care about what's going on in my lady parts -- he doesn't
want to hear it! As far as he's concerned, they do not exist. Unless I drop dead on
the floor, he doesn't want to hear about it…It is not in his realm of existence”
(Kate, 25 years old).
Less often mentioned were the sexual effects of having had cervical cancer, even
though a large proportion of women had undergone treatment that might permanently
affect the sensation and functioning of organs in that area of the body—such as internal
radiation, external radiation and surgeries that produce scarring. If it was mentioned at
all, it was touched upon very briefly and with some resignation. It is a topic, perhaps,
that might be a little too sensitive or private for a one-time interview.
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Prevention
Two aspects of the concept of prevention were salient in these interviews:
“preventability” as a (newly recognized) quality of cervical cancer itself, and prevention
via the new HPV vaccine. First, women spoke frequently about the idea that cervical
cancer is preventable by “responsible sexual behavior” and how this knowledge can
impact them in adverse ways because people now see them as responsible for their
cervical cancer. Several argued that this recognition of cervical cancer’s preventability is
recent, and due largely to new discoveries about HPV and about the vaccine.
“Because it's preventable, then they feel like [the fault] is kind of on you. That's
the way I think people might see it. No one's ever said it, but that's the way I
think” (Candace, 36 years old).
“It is pretty prevalent, and still preventable -- and that can add to the stigma too,
because if you had gone in to get your Pap, you might not have cervical cancer”
(Christina, 24 years old).
Or, conversely, women noted that this piece of knowledge has contributed to a personal
sense of blame:
“You feel embarrassed about it; you feel guilty thinking that ‘I could have done
something about this.’ Wishing that I would have. It makes you feel a lot of
regret as far as prolonging the visit to the doctor, not getting my Pap smear -- it's
like, God, if only I would have” (Candace, 36 years old).
This concept of preventability also influenced the ways in which women
conceptualized cervical cancer and themselves in relation to the outside world. For
example, in some instances, cervical cancer’s “preventability” was blamed for a lack of
research and medical attention on this issue—one woman reported that a grant-making
agency denied her request because “cervical cancer is preventable” along with the fact
that it only affects a small proportion of women compared to breast cancer. On the other
hand, many women cited this aspect of preventability as a reason behind their own
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involvement in raising awareness of cervical cancer, the need for screening, and
importance of the vaccine.
“I feel like the medical community should reach out, because if it is really
preventable, then why not really teach people? […] If this is preventable, why
isn’t this like breast cancer [in terms of the resources committed to
it]?”(Candace, 36 years old).
“[Cervical cancer] is a disease that you don’t have to get. You don’t have to get
it; they don’t talk about it enough. Cervical cancer is one of the issues that we
need to be talking about […and doing] exactly what I’m doing right now: talking
and running your mouth to anybody that will listen. Talk on TV, talk on the radio,
talk at speaking engagements, talk about motivational events…talk everywhere.
Keep sharing, keep hearing—that’s the way we’re going to get the word out”
(Tanya, 41 years old).
Second, this code also encompassed discussion of the HPV vaccine, and the fact
that cervical cancer has now been made preventable by the vaccine itself. The vast
majority of women were very supportive of the vaccine, and of making it as widely
available as possible. Only one participant took issue with the vaccine, explaining that
she has mixed feelings given the danger that certain vaccine components pose to
developing body tissues. Several women were somewhat whimsical in their discussion
of the vaccine, commenting that “I wish I could have gotten this when I was 18” (Heidi,
41 years old).
Many favored mandatory vaccination for all girls, explaining that if mandatory
vaccination is what it takes to prevent other women from repeating their own experience,
then it is worthwhile. In addition to this support, there was widespread discussion and
denouncement of the current controversy surrounding mandatory vaccination. It is
important to note here that, on the whole, participants’ opinions regarding the effect of
the publicity and media attention surrounding the HPV vaccine were extraordinarily
complex, and will be addressed in-depth later in this section. For our purposes here,
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though, it remains that the majority of participants supported the widespread use of the
vaccine on principle.
Awareness
The code of “awareness” referred to either positive or negative aspects of
awareness about HPV, cervical cancer, or screening. This theme arose either in the
context of its impact on one’s own experience, or in the context of its impact on others’
experiences—either loved ones or wider society.
In relation to the self, awareness about HPV and cervical cancer was often spoken
about in “then and now” terms. Specifically, the majority of women lamented about how
little they knew about HPV before they were diagnosed—a good proportion of women
had never even heard of it before that moment. These comments were often made in
juxtaposition with a description of how much they now know about both HPV and
cervical cancer, and how important it was for them to have that information—either by
getting it from their providers, or, failing that, by seeking it out on their own. “Raising
awareness” was often referred to by survivors as an overall personal goal, something in
which they saw themselves participating on a long-term basis. A common effect of
cervical cancer seemed to be an increased sense of responsibility and activism; women
frequently discussed how they had felt compelled by their own experiences to help others
through awareness-raising, and the large need that they were now responsible for
addressing.
On the other hand, survivors also spoke about awareness in terms of its impact on
others. First, their loved ones’ “increasing awareness” about cervical cancer and the need
for screening was commonly cited as a positive by-product of witnessing their own
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experience with cancer. For example, one woman noted that, after her diagnosis, “a lot
of ladies at work have daughters, [and they will] pay more attention to that when their
daughters get of age. Just being more aware of getting Pap tests like we’re supposed to”
(Mary, 57 years old). Second, increasing awareness was seen as the positive
consequence of the media attention surrounding the HPV vaccine—although this media
attention was often seen as a double-edged sword (to be discussed more in the next
section), the positive side of the equation was consistently and almost predictably stated
to be awareness on the part of the public: as one woman notes, “I think [the media
attention] makes [cervical cancer] more difficult to hide … With any issue brought to the
forefront, it’s harder to pretend that it’s not there anymore. Which is good” (Kate, 25
years old).
Media
Many women also spoke about the impact of the current media campaigns
surrounding the HPV vaccine and how they are publicizing the link between HPV and
cervical cancer. Media attention was frequently discussed as a “double-edged sword.”
The positive side effect was always presented as an increased awareness of cervical
cancer, while the negative side effect surfaced as one of two potential consequences.
First, in many women the current media attention seemed to create an anger or bitterness
that this particular knowledge or awareness had not been around before they were
diagnosed; thus, they could not themselves directly benefit from it. In fact, many had had
the experience of learning about HPV for the first time when they saw the commercials
on television, and were dealing with the anger of feeling misled by their healthcare
providers. For example, one participant responded that:
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“Well the ads, half of me [thinks] it’s like great. I’m glad that it’s getting out
there. ‘Cause the more people that it reaches the more people it can save from
the experience like mine. And the other half, you know I get pissed because if
those ads had been around before, I probably maybe would have looked into this
a bit more. Maybe it would have sparked something. ‘Why don’t you get another
Pap? Why don’t you get that checked out?’ So it’s a good thing…It’s like half
angry and half good” (Samantha, 38 years old).
Second, many women pointed out that the increasing recognition of the link
between an STI and cervical cancer negatively impacted other peoples’ perceptions about
them. For example, one participant explained that:
“I think it can be positive or negative…No one really talks about it. It's making
people aware of the fact that having a simple STD or something like an STD like
HPV can turn into cancer. It could make women more aware of the fact that they
have this. That's the positive…You're hearing women talk about the fact that they
have it, and they'll be more aware of it. But then I also feel that because of the
advertisements, it can be a two-fold thing. That on one hand, they can be alerting
the public that something is going on ... but on the other hand, it does affect us
negatively because people basically do look at it like an STD” (Candace, 36 years
old).
Some women spoke explicitly about their own experiences with the commercials
creating personal feelings of embarrassment or shame. For example, one woman said,
“So I don't like what the commercials have done, because anyone who knows I had it
thinks I'm this like diseased person. What my father thinks! That's what bothers me! I
want to tell him, ‘Dad, I didn't have HPV’ — I hope he doesn't think that I did this to
myself. [There is] this horrible stigma that goes along with it” (Sarah, 34 years old).
Several women had had the uncomfortable experience of being in treatment for cervical
cancer when the commercials for the vaccine were released, which had the effect of
seemingly exposing how they developed cervical cancer in the first place. One woman
described her experience with her father:
“The hardest part was facing my dad when the commercials came out. When I
came home and told him I have cervical cancer, I told him—‘it's not genetic, and
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it's not from smoking, and it's not from this and it's not from that. We don’t know
what it's from’ —and then a week later, all these commercials come out saying
that ‘If you have cervical cancer, then it's from HPV, and it is a sexually
transmitted disease.’ And I was sitting in the living room with him the first time I
saw the commercial, and it was just ... (long pause) ... It was just hard. He has
never brought it up to me, but on my end, I just got the impression that he was
looking at me differently from that” (Holly, 30 years old).
Stigma
Stigma and feelings of stigmatization seemed to be generated through several
mechanisms: first, by survivors’ assessment of the place of cervical cancer in our society;
second, by their perceptions of other people’s beliefs; third, by the actual treatment by
and the reactions of others; and finally, by their own feelings and reactions to these
assumptions and incidents.
Cervical Cancer in Society
In large part, participants believed that cervical cancer is a stigmatized condition
in American society. This stigmatization is due, they felt, to two things: first, its
association with a sexually transmitted infection, and second, to the fact that it is now
recognized as having been caused by an individual’s actions. This aspect of
preventability adds a whole new layer of personal responsibility to their situation that
most were not comfortable with. Indeed, it led many to compare cervical cancer to lung
cancer—a type of cancer that has historically been stigmatized because of its association
with the personal choice to smoke.
“It's interesting; I met this woman this year who’s doing her PhD dissertation on
the stigma of lung cancer. People think you got it because you deserved it because
you smoked. I think there's a stigma with cervical cancer. That you got it because
you, you know...And that's far from the truth” (Amanda, 45 years old).
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“When people say they have lung cancer, the next question is ‘did you smoke?’
That type of mentality, like you have cervical cancer – ‘oh, did you …?’ Whereas
if it were liver, it would be a different reaction” (Holly, 30 years old).
The consequences of this stigmatization are numerous—many pointed out how
cervical cancer is ignored in funding and research circles in comparison to more “socially
acceptable” forms of cancer, such as breast cancer, and how these conceptions result in
the subsequent stigmatization of the HPV vaccine.
“It's almost a bitter-sweet victory because we've done so much research and we
know so much about cervical cancer now, that they know it's coming from
HPV...But because now we know that it's caused by HPV, now we've changed the
way people look at it. So, before, if you could say ‘I'll come up with a cure for
cervical cancer. I could come up with something that would reduce cervical
cancer by 80%’ -- people would jump all over it! But now that we know that it's
caused by a virus, and that it's an STD, and we have a vaccine that could reduce
cancer rates by 80% -- now that we know it's a sexual disease, now we're like,
‘oh’ -- you know what I mean? It's TOTALLY different…It's a HUGE stigma. A
huge stigma. Otherwise, they'd all be vaccinated. Everyone would be vaccinated”
(Kate, 25 years old).
In addition, participants felt that cancer as a whole was stigmatized. The negative
connotations around cancer, they felt, were not so much due to the origins of the disease
as is the case specifically for cervical cancer, but because of its enduring association with
death. This conception of cancer seemed to impact them doubly—it generated fear and
anxiety in themselves related to their own mortality, and also anxiety and discomfort
because they assumed that others were thinking the same thing and believed that they
were going to die.
“I think when people hear the word cancer […] everyone gets really offput…Mostly people, when they hear you have cancer, can't believe that, and they
see it as a death word. ‘Cause like on every TV show, if someone's gonna die of
an illness, it's generally going to be cancer. And that's one reason I didn't want to
tell my kids, because I didn't want them thinking that it was a death issue. For me,
I just didn't want to see it that way. And it was great, because I never saw it in
them when I was with them -- it was like, ‘oh, mom's not feeling well. She hasn't
been feeling well a lot lately.’ And they kind of felt that something may be wrong,
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but not having that word kind of let them feel like it was going to be okay”
(Candace, 36 years old).
“I think [that the general public thinks that cancer] is an equation to death. A
death sentence. And it’s scary” (Joyce, 39 years old).
“[I didn’t think about cancer patients too much before I was diagnosed]. Except
for you pass somebody on the street who’s obviously going through chemotherapy
or something…you know they have a headscarf, they look terrible…except to be
scared shitless when you see people like that…Yeah, just imagining how awful the
treatment must be and how scared they must be and how shitty it must be to feel
how they must feel, which is probably scared for their lives” (Samantha, 38 years
old).
Perceptions of Others’ Beliefs
More prominent a theme than any actual incident or treatment by others was
participants’ belief that others think negatively of them. Many of the women were certain
that negative, judgmental thoughts were constantly running through the minds of people
who found out about their diagnosis, because they had had the same thoughts and
assumed others would have them too. Many assumed that others blamed them for getting
the disease because they were irresponsible or had sex with many people, something that
was particularly relevant now because of the HPV vaccine commercials. This is an
important pattern to note—not so much because of what others are actually thinking—but
because of what it reveals about a survivors’ own conception of self and assessment of
the situation, and the ways in which we internalize society’s judgments about a
stigmatized condition.
“You know, I think they think…that you're promiscuous, which is a little
unnerving. I think that it's kind of a drag that I feel like I'm admitting that I
played around or something. I don't think anybody has said ‘Oh, were you just so
sexually active that you caught this?’ specifically, but they probably think it. I'd
probably think it too, if I was just exposed to what you're exposed to about this
disease now. Especially with this new vaccination, that it can prevent it”
(Amanda, 45 years old).
72

“As soon as you say cervical cancer to people, they automatically ... you get this
response like, it's your fault. Like, ‘you must have been sleeping around’…But
I've met people who haven't had sex, and they have HPV. Or people who have
been with one person, and they have HPV. But people automatically look at you
when you say cervical cancer, and think that you must have been sleeping around
and that must be why you have it -- because it's a sexually transmitted disease,
and that's where their knowledge stops” (Holly, 30 years old).
Another interesting pattern to note was survivors’ reactions to questions from
others. A number of women mentioned that a friend or family member had asked them
about HPV, and this seeming audacity provoked an angry and defensive reaction from
these survivors. They assumed that others were asking these questions in an accusatory
manner based on the new information about HPV’s role in cervical cancer.
“I don't like it. One of my girlfriends asked me if I had HPV, because I had
cervical cancer, and I said no. I understand why they're asking me that, but it's
kind of a stigma. I caught something that gave me cancer--that's the only reason
why someone would ask me that. NO, that was not a good feeling, that somebody
asked me that. I did not like that at all…Disturbing! [This happened] probably
whenever these ads started coming out, somewhere around that time. I remember
one of my friend's sisters asking me, we had a conversation about why I was sick
... I guess, with what was going on in the advertising, maybe they didn't think it
was wrong to ask me—but it was judgmental, and I didn't like it” (Sarah, 34 years
old).
Reactions and Treatment by Others
Although most of the participants spoke hypothetically about other people’s
beliefs and cervical cancer’s and HPV’s reputations in American society, a number of
women actually experienced negative treatment. One woman related a story to me that
when she told her friend about her diagnosis, the friend replied that “well, I guess you
know that you screwed up.” Another woman told me a story about her so-called friend’s
reaction, while another discussed her classmate’s frequent diatribes against women with
HPV:
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“The other women [at my job] when they found out about the cervical cancer,
actually terrorized me, publicly humiliated me about that […] This one woman
who used to be my friend decided that she was not going to be my friend. She went
on public boards and called me ‘warty pants’ and all kinds of things. And said I
had a venereal disease, and was going on and on. So cervical cancer has a stigma
attached to it. People are blaming you for getting it. I don't see with any other
disease, whether it's HIV or anything, you get the sort of blame and some label
attached to you. As if you were bad. And evil. And so now you get this thing, and
you're dirty” (Heidi, 41 years old).
“I'm in the nursing program, and HPV and cancer and things like that come up a
lot, just in the course of your studies. One of the girls in the study group, every
time anyone would mention HPV or cancer, she would say things like ‘oh well
only sluts get that. Basically, if you're not a really big slut, then you won't get
cervical cancer.’ […] She thinks that she's being funny, because she assumed
that no one here would do something like that. No one here is slutty enough to get
HPV […] It’s frustrating, because you have to deal with your diagnosis, and
you're worried that something is going to come back [...] You also deal with the
fact that people who don't know you or your situation will indirectly call you a
whore while they're sitting next to you. But if I had stomach cancer, that wouldn't
happen. Maybe gluttony, but they wouldn't call me a whore” (Kate, 25 years old).
Other women spoke about the ways in which they felt isolated as cancer patients.
One had had an encounter with a friend not long after she was diagnosed; this friend
backed away as if she were contagious, all the while saying that “I would hug you, but I
don’t think I should” (Mary, 57 years old). Another spoke of the cancer experience in
relation to the staff at the hospital, who tended to keep her at arms’ length and subtly treat
her differently now that she was a cancer patient: “all of a sudden you feel like you’re in
a box—the cancer box, and everybody else in the happy healthy box” (Samantha, 38
years old).
Self-Reflections
All of these previously discussed themes—ideas about causation, female
sexuality, preventability, awareness and media influence—surface in the ways in which
the women reflected on their own experiences with cervical cancer. Conflict emerged
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between how these women viewed themselves and their own bodies and how those views
interacted with both the disease as well as society’s explanations for why the disease
occurred in them. Much of the discourse on risk and individual responsibility emerged in
their explanations, and many felt ashamed and embarrassed for having had cervical
cancer—for example, one woman commented that “I personally feel responsible for
having made a decision and blame myself about that” (Lauren, 41 years old). Another
remarked that she felt as if she were “wearing the scarlet letter” (Joyce, 39 years old)
and wondered whether cervical cancer was a punishment for not making the right choices
in her life. Others spoke similarly:
“I know that I say uterine cancer instead of cervical cancer, because uterine
cancer could have started from the inside versus the outside, and that’s my way of
dealing with it. Because I do feel, in myself, embarrassed about that. I don’t
know if anybody else sees it that way because no one’s ever said anything
negative to me about that. But in myself you know I do shy away from saying
cervical cancer—I feel like it’s the preventable cancer, and the only thing I’ve
ever heard about cervical cancer is the HPV commercials” (Candace, 36 years
old).
[Referring to HPV] “Yeah, I do [still feel embarrassed] because it is an STD, so
it is embarrassing. It's like you did it to yourself. If you jumped off a bridge and
broke your leg, nobody would have sympathy for you -- you did that to yourself.
So, even though this is something that gives you cancer -- it is, it is
embarrassing” (Kate, 25 years old).
At the same time, some also challenged these discourses in their explanations for
other people’s reactions to them, offering reasons for why they thought other people
made the assumption that their cervical cancer was related to an STI. To them, it
appeared almost natural that others must concoct stories about people with a scary
disease, because it makes them feel safer, more comfortable, and less worried about
getting it themselves. In the minds of several participants, this phenomenon was
responsible for the parallel stigma of cervical cancer and lung cancer: both cancers are
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seen as preventable because they are caused by “bad behavior” on the part of the
individual—and others need to draw this distinction between “me” and “them” for their
own sanity. For example:
“[Since it’s from sexual activity], I’m sure it’s running across their minds.
Everybody’s mind. And in a way… if people think about it that way, it helps them
feel secure and insulated because they can think, ‘you know this won’t happen to
me because I didn’t have all those boyfriends in my twenties like she did’…
…It helps them. If they can blame the cancer on something the person did
behaviorally it helps them feel safer. Oh, like, ‘that one had lung cancer.’ ‘Oh did
she smoke? ‘Yeah for 20 years.’ ‘Oh, okay.’ And it’s almost like a sigh of relief”
(Samantha, 38 years old).
Participants also expressed a discomfort with cancer in general—not just cervical
cancer—because of its association with death and disability. Women did not necessarily
feel embarrassed or ashamed for being termed a “cancer patient.” Rather, they expressed
a heightened awareness of other peoples’ pity or fear, or an idea of themselves and other
cancer patients as irreversibly altered, and negatively so—or, to use the frequentlymentioned term, “damaged goods.”
“I look normal from the outside as far as, a cancer patient is supposed to look
normal. Yet if you could see me from inside out, you would see all the damage…
all of the stuff they did from the inside of my body. Then maybe you would
understand how the outside of me feels” (Tanya, 41 years old).
“I just felt diseased. Somehow I just felt really ugly and diseased” (Heidi, 41
years old).
Disclosure
The decision of who should be told about their diagnosis, when, and why was a
very delicate one for participants. Topics ranged from the discomfort of revealing it to
others because of negative assumptions about cervical cancer and indeed cancer in
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general, to the distinction between voluntary and involuntary disclosure, to strategic ways
to use disclosure for a purpose.
Often, choosing how and when to reveal their diagnosis to someone was difficult
because of the stigma associated with the disease, and the experience was often
uncomfortable even though participants related that the outcome was frequently positive.
Nevertheless, participants were forced to confront this situation often, especially in the
context of employment. For example, one woman related her experience with informing
her employers when she realized that she would have to take a leave of absence from
work. Though clearly uncomfortable, it ended supportively:
“I did feel embarrassed and ashamed when I had to tell them that I had cervical
cancer. And the questions came that it was HPV. And I do remember being
hunched over at work, huddled all by myself having to tell them and that was
embarrassing, but they were very supportive and nobody said anything. But it did
make me feel…here you are talking to a bunch of nurses, and physicians too. And
they know [about HPV]. I was pretty close with them. But they were all awesome.
They would help in anyway that they could help” (Joyce, 39 years old).
Due to cancer’s frequent association with death, women frequently chose not to
disclose their diagnosis to loved ones—often older parents or younger children—because
they did not want to worry them. Many times, they told them after treatment was over.
“It was hard to talk to my mom about anything, because as soon as I was
diagnosed, she immediately went to ‘oh my god, she is going to die.’ So talking to
her was just very difficult for me” (Holly, 30 years old).
Disclosure was a major issue among a couple of the unmarried women—
decisions about whether to tell a potential partner, and at what point in a relationship,
were difficult and without clear answers.
“Sometimes I say that I had girly cancer […] When I say things like that, they
leave it at that. They don't want to know. I would hate to lie, that's the thing. I
don't want to say ‘I have ovarian cancer’ and then they find out later that I had
cervical cancer. At first I felt like it was something I had to tell somebody, not that
77

I had cervical cancer, but that I was a cancer survivor. As if this was some
significant thing, and that a partner would find you unlovable or not healthy.
Then I realized, that maybe it's just none of their business. I just would hate to tell
the wrong things...I would hate to tell a lie and then accidentally slip up. I don't
think they deserve to know, but since it is such a significant thing...You couldn't
date somebody, and have not told them the story of how you had cancer. Wouldn’t
it come out?”(Heidi, 41 years old)
Many women lamented the annoyance of being forced to disclose their diagnosis
involuntarily—most often, these incidents occurred when they needed to fill out medical
forms, insurance applications, or adoption forms. Although not a major problem, these
occurrences were seen as an unwelcome intrusion and reminder that they had had cancer
and thus were somehow “different.”
Another interesting theme was the strategic use of disclosure for a clear purpose.
Women referred to telling people that they had had cancer only in the context of
advocacy—when they were lobbying or writing letters to their legislators. Here, there
was a clear identification with the term “cancer survivor.” Others frequently related
stories of telling other women in the hopes of motivating them to follow-up on an
abnormal Pap smear, or to comfort someone who was just diagnosed. Still others
mentioned the “silver lining” of cancer—i.e., the gifts, free haircuts, discounted clothes,
and other unexpected perks that come along with a cancer diagnosis. It seemed that some
women had learned to use this strategically as a way to retain something positive out of
an awful situation.
Support
Overall, participants spoke very highly of the support that they had experienced
during their cancer treatment and beyond. Frequently, while undergoing treatment,
participants were unable to talk about their experiences in-depth with others because it
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was too mentally fatiguing, and they sought support mainly from those in their closest
circle—parents, siblings, spouses, and a best friend or two. The strength and perspective
offered by one’s faith and religious establishment was an enduring theme (discussed later
in its own section).
Many participants’ stories reflected a sense of inevitable re-assessment and reprioritization of their relationships with loved ones. For example, one woman reflected
that “I found out who my real friends were. Who stuck around and all the ones who
didn’t…Kind of like an involuntary weeding-out in a way. So those few friends who stuck
around are still there. They’re the ones who are real close to my heart” (Kim, 57 years
old). Several women related incidents where family members either did not believe
them, or could not accept that they had cancer or HPV:
“It was scary at the time because I didn’t have a lot of support family-wise. My
mother was really strange. We were never really that close, but when I told her
she was like, ‘well, you don’t have cancer.’ I was like, ‘yeah, I do.’ And when I
went into the hospital she didn’t even come and see me. I could never figure it out.
I don’t know if it scared her. I don’t know what it really was. She never really
explained that. My dad came” (Linda, 61 years old).
“It's embarrassing. It's embarrassing because ... I feel like if I had pre-cancerous
cells in my bladder, my family would care. But because [HPV] is an STD, it's just
looked at totally different, totally different” (Kate, 25 years old).
Many women felt compelled to seek support from online message boards or
support groups because there was no adequate in-person group available. Since many felt
that other survivors have a unique capacity to provide support and understanding, they
bemoaned the fact that there are an extremely limited number of in-person cervical
cancer support groups. Meanwhile, breast cancer support groups flourish. To them, this
is just another indication of how cervical cancer is ignored in the wider medical
community because it is not a “socially acceptable” type of cancer. This is an interesting
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contrast with how survivors felt about the effect of stigma on the level of personal
support—when questioned directly about how it may have impacted the support they
received, the vast majority replied that it had no effect. Their loved ones, they felt, knew
them better than to be influenced by those ideas.
Resources
The theme of cervical cancer-specific resources has already emerged numerous
times in this discussion; indeed, an apparent gap in resources is a topic that is interwoven
throughout many of these subject areas because so many of the survivors see it as a direct
result of how cervical cancer is viewed in American society. This perception of cervical
cancer is not coming wholly from a negative place—there are both positive and negative
dimensions to it.
First, the lack of resources centered around three main areas: first, information
related to HPV, and in particular the connection between HPV and cervical cancer;
second, the lack of cervical cancer-specific support groups and/or resources that are not
online; and finally, the scanty research dollars that are devoted to investigating both the
medical underpinnings of cervical cancer as well as the psychosocial and cultural
dimensions of the disease. Throughout all of these interviews, women made a consistent
and repetitive comparison to breast cancer and the resources that are available to patients
stricken with that disease. Surprisingly, this was one of the most predictable patterns to
emerge out of the data, and spoke to the survivors’ feelings of marginalization in the
cancer community because theirs—for varying reasons—is not a socially acceptable
disease. This comparison between breast and cervical cancer is particularly significant
because federal and state funding streams for these two diseases are usually merged
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(usually in the context of grants for screening programs and community organization
projects), and the participants viewed breast cancer as getting a disproportionate amount
of these combined research dollars. They are competing for the same dollars, so to speak,
and since cervical cancer is much rarer than breast cancer and is saddled with the stigma
of a sexually transmitted infection, it usually ends up short-changed.
“With breast cancer, you can get a lot of support if you don't have health
insurance. But with cervical cancer that is not the case. There was not a lot of
financial aid out there for me” (Heidi, 41 years old).
“I was actually surprised initially that you were doing a study because there
doesn't seem to be a lot of funding for that. Now I know that it's something that
you're doing as a thesis, so you're doing it out of your own pocket. But there
really isn't a lot of attention in that, only the pharmaceutical companies are
putting it out there because that's how they make a lot of money, but as far as like
going to the American Cancer Society, and getting grants or things to help with
people who get cervical cancer, everything is geared towards breast cancer.
Cause the rates are so much higher and the death rates are so much higher and
everything. I guess it got me, you know, it hit 100% of me” (Candace, 36 years
old).
Several participants acknowledged the fact that cervical cancer has become much
less common than it used to be, due to the success of the U.S.’s screening system. They
argue that, along with the release of the HPV vaccine and the recognition that it is now
preventable, these decreasing rates are the reason why researchers and funders do not
regard cervical cancer as important enough to invest in—in other words, it is no longer a
big enough problem to merit their attention. One woman was in the midst of starting a
non-profit organization that would provide resources for women going through cervical
cancer, and has had trouble securing funding for it because of this:
“This one lady [at the funding agency] was like ‘you know, cervical cancer is
preventable’—she made it seem like it was such a small population of women that
it was basically not worth it” (Candace, 36 years old).
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The lack of available cervical cancer-specific resources was an issue that greatly
impacted the course of the research project itself. The single biggest issue throughout the
entire study was the difficulty in locating a “community” of cervical cancer patients and
survivors. Breast cancer support groups, programs, and community organizations were
abundant, as well as groups targeted at much less common cancers. However, nowhere
could I find a single cervical cancer-specific resource in all of Tampa Bay, Orlando,
Naples, Sarasota, or indeed, the entire state of Florida (and I looked). The closest was a
gynecologic cancer support group in Sarasota, but they could count no cervical cancer
survivors as members. None of the participants that I interviewed knew of any other
women with cervical cancer in the area, even through the clinics that they visited. I
finally was forced to rely upon locating participants through online groups, listservs, and
the sporadic referral from a clinic.
“KD: Did you meet anybody who had cervical cancer where you were being
treated?
R: That was another sucky part of it. Where I would go for chemo, most of the
women who came in were there for ovarian cancer. Most of them were older.
Most of them had grandkids my age—I would get in there, and I couldn't relate to
any of them. I remember sitting down one morning waiting for the doctor to get
there for chemo, and another patient looks at me and was like ‘you are too young
to be here. You can't be here.’ And I wanted to look at her and say ‘no shit!!’ No,
I'm here because I think this is enjoyable!’ I met some people online, but in
person, you know they offered different things through the hospital, but most of
the people that I was running into are all older. And I was like—‘why am I going
to take more time and energy that I don't have, and go talk to people who are
looking at me like I'm a freak, you know?’” (Holly, 30 years old).
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Healthcare Providers
Care Experiences
The central role that healthcare providers played in the participants’ cancer
experience was a theme threaded throughout the interviews, and occurred mainly in the
form of general satisfaction or dissatisfaction with the care that was provided. Many
participants spoke positively of their providers, relating stories of caring, attentive
physicians and immediate appointments. Many expressed a deep loyalty and bond with
their oncologists.
“Her name is Dr. _____, she's amazing. She's fabulous. Even the doctors and the
nurses, when you go into the hospital, they swear by her. Just being her patient
you just get better treatment, you get your own room” (Candace, 36 years old).
“My oncologist was awesome; every time I called her, she called me right back. I
know she answered the same question like 5 times, but I just had to keep asking
her the same question, I guess for reassurance. But she never complained. And
she never looked at me and was like ‘uh, you already asked me this!’” (Holly, 30
years old).
One woman related how supportive and flexible her oncologists were, despite her limited
ability to pay her medical bills:
“It works out that I owe $50,000 in medical bills, which I can't pay. But my
doctors in _____ were very supportive. They even said to me, ‘Don’t worry about
the bills.’ I didn't have to pay anything, not even one time…They said that they
don't refuse treatment; they don't turn away cancer patients. And from what I
hear that's not always the case. They take every cancer patient; they don't turn
away anybody. Now I owe an arm and a leg, but that's life. That's not their fault,
because we don't have social healthcare. I think that's a big problem, but at least
they treated me. They were really positive and supportive” (Heidi, 41 years old).
Other women’s experiences were more problematic, and many shared troubling
stories about missed diagnoses, lack of information, insensitive treatment and poor
communication between providers on the healthcare team. Six out of the nineteen
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women had had diagnoses that were either missed or prolonged because of
misinformation that they had received from a particular provider. Interestingly, three of
the four women who had been under the regular care of a fertility specialist for months,
or even years, experienced a late diagnosis. Another had been required to see her
gynecologist every three months because she was on Depo Provera birth control,
although she had already been experiencing symptoms that the doctor had not
investigated by the time the cancer was diagnosed. Several had had experiences that
were so questionable that they had looked into malpractice suits.
Most of the participants had at least one “bad doctor” story where one of their
physicians was insensitive, arrogant, incommunicative, or, in some cases, bordering on
unethical. These experiences motivated many to seek care elsewhere or to get second
and third opinions.
“I hate the fact that doctors and caretakers do not inform you of everything that is
going to happen. I really resent that. For instance, they had sit on the edge of a
table and open my gown. He pulls out a Polaroid camera and takes a picture of
my breasts. I’m like, ‘okay…what in the world is that for?’ ‘Oh it goes in your
file… nobody sees it.’ I’m like, ‘yeah, did you maybe want to get my consent
first?’” (Linda, 61 years old).
One of the most common complaints from women about their care was that their
providers had given them an extremely limited amount of information, especially on
HPV. Many of the participants had not even heard of HPV until months or years after
they had completed treatment, and complained about being unable to get straight answers
out of their doctors when they questioned them directly.
“It made me mad that I never heard of [HPV] before, that when I was young,
when I was in my 20’s and I was in my teens that I never heard about it. Why
didn’t somebody feel responsible enough to let us know? What—it’s got to be a
secret? Doctors seem to feel like the more ignorant you are, the smarter they
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seem. I don’t know. I don’t like that. I want to know at least as much as my doctor
knows about my condition.”
“It just made me feel angry. I never heard of it before…that it was an issue. I
always considered myself well-educated so why didn’t I know about this? Why
hadn’t I heard about this? Why haven’t the doctors [said anything]? What logical
reason could they have for not informing the patient? ‘By the way you know this
is HPV. Hey, watch out for this!’” (Linda, 61 years old).
System Breakdown
Participants perceived this inadequate information and education as stemming
from reluctance on the part of their doctors to be open with them about their diagnoses,
and concluded that the medical system was not fulfilling its obligation to educate
patients. Thus, patients were forced to take matters into their own hands, and to seek out
information on their own. Many talked about the need to be “your own advocate,” to
“own” your own healthcare, and to be proactive. These necessary actions protected the
individual from being lost in the large void that had opened up in the system—they
provided the things (or knowledge) for themselves that the system, for varying reasons,
was unable to.
“No matter what, no matter how many doctors you see, you really have to own
your own healthcare. And I mean that was true all throughout the
experience…Even though we rely on our doctors to tell us what to do and to give
us the test that we need, we really need to take more ownership. I regret that I let
the fertility issue—which was so uppermost in my mind at the time—I let it cloud
the more basic care of that area. And I consider that my fault” (Samantha, 38
years old).
“It’s our bodies and if we don’t know to take care of it we’re going to die.
Whatever tests you can do, however many doctors you can see, even if it’s a pain
in the neck—go. Ask a bunch of questions. The best thing you can do is take a
notepad with a bunch of questions on it so the doctor’s not sneaking out of the
room while you’re trying to ask…Cause that’s the whole thing with most
doctors—they want to get in and get out, see as many patients that they can. But
if they see you’ve got a list—okay!” (Linda, 61 years old).
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A recurring theme was how little participants understood both HPV and cervical
cancer when they were first diagnosed, and how it was only later that they were able to
go out and research it on their own. It seems that a lack of knowledge—or confusion
about—HPV and cervical cancer at once made them feel both vulnerable and
disempowered. Respondents often look back upon their “early days” of diagnosis as
being cloudy and confusing, and compare it to the present day when they know all they
can and therefore are positioned to make the best decisions for themselves.
Recommendations
Women had a variety of suggestions for things that would have eased their
experience during and after cervical cancer, including what they believe might reduce
stigmatization of the disease. Recommendations centered around three common themes:
vaccination, information, and support.
As mentioned previously, several women observed that the stigma associated with
cervical cancer had extended to the HPV vaccine. These women believed that
normalizing the vaccine would have a direct effect on reducing stigmatization, and thus
decreasing the incidence of cervical cancer. Mandating the vaccine was a frequent
suggestion. A number complained about the slant of the commercials—for example, that
they were obviously motivated by the desire to make money from a drug rather than out
of a concern for women’s lives. Others observed that targeting the commercials at
mothers of girls was a natural way to raise everyone’s suspicions about the vaccine
because of our society’s preoccupation with protecting the virginity of young females—it
was necessary, they believed, to advertise directly to young women themselves. Another
woman believed that extending the public discussion of HPV to men, and offering them
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the vaccine, would remove some of the stigma associated with women and sexually
transmitted infections.
“I'd like to see them come up with a way to test guys. Because I think that we put
a lot on women. We have to bear the burden of things, and I think that just as
many guys have it as girls, and I think that just because they're not getting cancer
from it…If we could test guys, if we could mandate vaccinations for the HPV
virus, I think that would help. Because it wouldn't be like, ‘well, you got the
vaccine because your parents think you're going to have sex too early.’ If
everybody going into 7th grade would have to get it, then it's just one more shot.
And then I think some of the stigma about it would be lessened, because we'd be
thinking about it just as a virus that you can catch” (Kate, 25 years old).
Numerous other suggestions revolved around information and awareness. In
order to prepare women who have just been diagnosed with cervical cancer, one
participant believed that an honest and candid conversation about stigma with one’s
healthcare providers was a necessary first step:
“Because there's such a stigma attached to cervical cancer, they need to prepare
and help the women out in that way. I don't mean that they have to see a
therapist; I don't think that the person becomes mentally ill because of it, or has
to weep constantly. But it's something that you have to be prepared for and deal
with. And if nobody tells you about it, you're really alone with that. But I think
that that is more of a female discussion. I think it would be real hard for a doctor
to just go through that. So I see a nurse maybe approaching that. Or just
something written up about it. They could give you little information packets:
‘Talking About This With Your Partner’ or ‘Talking About This With Future
Partners’...‘Some women find that there's a stigma attached when discussing
cervical cancer. Understanding the statistics of cervical cancer may make you
feel a little better. 50% of the population of active Americans have HPV in their
systems; it's really not something to feel ashamed about.’ So, if you know that
statistics, and you hear that, it does make you feel better. It makes you not feel
alone. It is feeling isolated about that, and feeling ashamed about that, which is
not okay. And also this big association of warts being the same as cervical
cancer, and it's not the same. It's sort of wart-like, but it's not a vaginal wart. But
that doesn't mean that you should hate yourself because you have a vaginal wart,
so they need a pamphlet. Or maybe someone should start something online,
because you don't need a big group for this. If women could tap into something
like that, and express themselves, and not feel alone. And know how to handle it
socially for dating and future stuff” (Heidi, 41 years old).
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Others preached the value of raising awareness, especially about the prevalence of
cervical cancer—if people know how common it is, they argue, than it would not be
stigmatized.
Women recommended a number of other strategies that would have made their
lives easier. As discussed in the previous sections, information from doctors was a
frequent suggestion, especially around the topic of HPV and causation. Many women
had complained that their doctor had never even discussed HPV with them or had
avoided the topic when broached, and consequently most of the women had been
compelled to look elsewhere for information. This assertion is supported by several
informal conversations that I had with gynecologic oncologists during the recruitment
stage. One oncologist expressed a fear that I would create the actual problem that I was
trying to alleviate—stigmatization. This doctor did not tell his patients about HPV
because he did not want to make them feel any worse than they already did by adding the
knowledge of an STI’s role in cervical cancer. He worried that if I asked an interview
question about HPV, they would get curious, look it up, and then find out that it is a
sexually transmitted infection. Another rather prominent oncologist reflected that “we
have not done a good job of this”—that is, informing patients about HPV, because
oncologists have been uncomfortable as to how to handle this issue sensitively. Given
this, it is perhaps not all that surprising that many of these women had learned of HPV for
the first time months or years after they had finished treatment, and this created
resentment among some. Indeed, if physicians hope to normalize HPV anytime soon, it
seems evident that they must discuss it openly with their patients—avoiding the
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conversation only reinforces the impression that it is something uncomfortable and
shameful.
It is important to briefly touch upon the participants’ other suggestions for
improving their general experience that do not directly relate to the de-stigmatization of
cervical cancer: they included universal health insurance; additional cervical cancerspecific support groups and resources; more research, funding and financial assistance for
cervical cancer (or, at the very least, research, funding and financial assistance that is
proportionate to the disease’s burden); better communication between members of the
healthcare team; and more information about what side effects to expect during treatment
and beyond.
Survivorship
The following three codes emerged very strongly from the data. Some of these
themes may not necessarily relate directly to stigma, but they are included because I
believe they are important in painting a picture of the ways in which these women have
experienced the disease and its repercussions.
One of these strong themes to emerge centered on the definitions of survivor and
survivorship. Although I have frequently used the word ‘survivor’ unproblematically
throughout this paper, I do want to acknowledge the diversity of perspectives and selfidentification that people who have had cancer use to understand and communicate about
their experience. My usage of the term has been utilitarian, meant only to identify those
who have been diagnosed with cervical cancer at some point in the past, but who are still
alive. While many of the participants use it in a similar fashion, a great many others
employ it in such a way as to reveal meanings behind who is worthy to be identified with
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this term, and more broadly, what having a cancer diagnosis means to them. Often in
these instances, it is used to identify not the participant, but others whom the participant
considers truly a “real survivor.”
Several of the women used the term unilaterally—meaning, anyone who has ever
been diagnosed with cancer is a survivor, starting from the day of diagnosis onward.
This usage established equality among survivors, no matter their stage or type of cancer,
or the method of treatment employed. Strength, fight, self-assurance, and faith were
qualities highly associated with all cancer survivors. One woman summed it up by
saying,
“So that will always be in my life, from now on. And I think that yes, I will be a
cancer survivor, not with the same experience that other people have, because I
think that everyone's experience is really different. But yes, I think that every
person that deals with cancer is a cancer survivor, emotionally, physically. All
families trying, praying—families, friends, yourself, treatment, dealing with the
doctors, dealing with emotions. You learn to survive. You are a cancer survivor”
(Carmen, 28 years old).
A conception of cancer survivorship that was more common than the above
attached conditions to whether or not one was a survivor—often, the types of treatment
one experienced, or the number of years since diagnosis. Many women commented that
they would be a survivor when they hit the 5-year disease-free mark, a highly significant
cancer milestone before which most recurrences will happen, and after which many
doctors consider you “cured.” Many reflected that it was still too early to consider
themselves a survivor, and they needed time to process the experience and to re-adjust
their identities. One woman commented that:
“I think it took time. I think it took feeling better physically after the surgery. I
think it's almost like if you have a divorce. It takes a while to think of yourself as a
single person again. A little of it is just the natural time involved in that kind of a
life change, and I think it took a little bit of getting through that first anniversary.
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Because you get those check-ups all the time—they’re always scanning this or
scanning that. You have to get a few of those under your belt. For me, it wasn't
necessarily fear. [It was] that sense of ‘I don’t belong here’ when I go to the
oncology office. I still have that sense, ‘I don't belong here.’ But I think that all of
a sudden, I do belong here, but as a survivor—not as a patient. For me it took
time, it took emotional work, thinking it through, writing about it, talking about it.
It took some clear results” (Amanda, 45 years old).
Others did not want to classify themselves at all as a survivor, because it meant that they
were part of something that they had feared for so long:
“I do I feel almost strange putting that term on me. Like when I think of that term
I think of…I mean even though my situation was horrible, the cancer was at an
early stage and we just surgically removed it—presto! It’s gone. When I think of
cancer survivor, I think of somebody who’s dealt with it for years. You know had
chemo and all that. In a way it’s like even using that term is a little scary to me—I
like to rationalize to myself that I just had a little bit of cancer…I didn’t want to
like put myself into that category. The only time I even use that phrase, is if I’m
like writing an email to a senator. I get these emails that are like ‘write to your
senator to tell them to fight global warming, or tell them to fight for organic
food.’ Sometimes I’ll just stick that in at the beginning of the sentence just to get
their attention. But personally I don’t use that when I’m referring to
myself…because it’s too scary of a term for me” (Samantha, 38 years old).
Religious and Spiritual Faith
Religious and spiritual faith emerged as a major way in which these participants
conceptualized, explained, and endured their trials with cervical cancer. It was
mentioned often as an extremely important means through which participants coped with
their illness, usually referred to early in the interview without prompting. For example,
one woman summarized the meaning of spirituality for her by saying:
“Well, I think people that are spiritual -- and I don't mean religious, it doesn't
matter if they have religion or not, whatever that is -- however it manifests in their
lives -- if they are spiritual to begin with, than any experiences they have would
be more positive. They'll deal with life better because they see meaning in it. They
have meaning and purpose in their lives, in a way that with people that don't have
that, things just happen to them [for no reason at all]” (Heidi, 41 years old).
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Several participants made a brief reference to questioning God or their faith when
they were diagnosed, or wondering even if it was some sort of punishment by God for
improper behavior. One participant commented that:
“It was upsetting at first…and I asked my mom, why would God do this to me?
Do you think it could be that I had premarital sex? And she goes, ‘God doesn’t
punish that way.’ And thinking about it, you know she’s right…That is something
I won’t know until I die—why I had to go through this. And that’s ok” (Joyce, 39
years old).
Several times, participants mentioned their religious affiliation in conjunction
with their opinion on the vaccine—usually citing a disagreement with that
denomination’s stated position. For example, one woman stated that:
“I think that every young woman should get [the vaccine]. If it can prevent what I
had to go through, then definitely. I know being a Catholic I’m supposed to say
abstinence, and absolutely not and it’s a bad thing. But you know from a realitybased [perspective]—I just think that every young woman should get it. And if I
hear any of my friends or family that are that age, I’m saying ‘you need to get that
vaccine’” (Joyce, 39 years old).
Fertility and Reproduction
A frequently-discussed side effect that caused participants an extraordinary
amount of distress and mourning was the loss of fertility. Treatment for cervical cancer
involves three modalities that can and do cause infertility—surgery removes the
reproductive organs, chemotherapy and radiation can shut down ovarian function, and
radiation can create so much scarring or alter the elasticity of the tissue so much that it is
impossible to carry a pregnancy to term. Many of the women who participated in the
interviews were of childbearing age, and in a cruel twist of fate, four out of nineteen of
the participants had been undergoing fertility treatments at the time they were diagnosed.
After years of unsuccessful fertility treatments, one woman had finally been four months
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pregnant with twins when the cancer was discovered. Because of its advanced stage, she
and her husband were forced to make the decision to have an emergency abortion and
radical hysterectomy in the same day. Others had planned for children in the future, but
their treatments left them prematurely menopausal.
Though neither a central focus of the study nor a direct question in the interview
guide, the loss of fertility was one of the most distressing themes to emerge in many of
these interviews. Above and beyond anything else, several of these women mentioned it
as the single hardest aspect of their entire experience with cervical cancer—whether they
were in the middle of treatment or years down the road.
“My friends are getting married, having children, and I just feel like I did
everything right—go to school and try to make something of myself, while other
people are going out, having babies, getting married in their early 20s. I didn't do
that, and now I can't. At this point, I can't have a child. That means I have to get
married first. [It was] taken away from me, and it's tough to deal with” (Sarah,
34 years old).
“I definitely have to say [that the hardest aspect of having cervical cancer] is the
fertility-related stuff. Both losing the twins that we had, and then the permanent
ending of my fertility thereafter” (Samantha, 38 years old).
Although this recurring theme of distress is not such a surprise given that some of
these participants found out about the study from Fertile Hope, an organization focusing
exclusively on cancer and fertility issues, many of the women discussing fertility had
been recruited elsewhere. Given also that cervical cancer tends to strike most often
within a woman’s reproductive years, it is clearly an important issue to address given our
society’s emphasis on genetic constructions of parenthood and childbearing—and how
these two often co-occurring issues can force some young women to redefine their lives
and roles way beyond just dealing with a cancer diagnosis.
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ONLINE SURVEYS
Participant Demographics
A total of 70 women participated in the survey portion of this study. They were
drawn from a variety of sources, mostly non-profit advocacy organizations. Three groups
sent listserv emails to their membership: Tamika & Friends, the National Cervical
Cancer Coalition, and the National Council of Women’s Organizations. Another group,
Women in Government, posted a link to the survey on their website. Finally, other
women who had contacted me about participating in the in-depth interviews after these
had been completed were directed to the online survey instead.
The average age of the survey respondent was 39 years old, while the median age
was 36 and a half. Participants hailed from 29 states and the District of Columbia. They
were asked to self-identify their ethnicity—Table 4.1 below illustrates the breakdown. In
terms of level of education, 2.9 percent (2) reported that they had received some high
school education; 18.8 percent (13) had graduated from high school; 39.1 percent (27)
held a Bachelors degree and 23.2 percent (16) had received a Masters degree; 4.3 percent
(3) held a Doctorate or other professional degree; and 11.6 percent (8) reported that they
had received some other type of education.
12.9 percent (9) of participants responded that they were single; 15.7 percent (11)
had a boyfriend or girlfriend they did not live with, and an additional 8.6 percent (6) had
a boyfriend/girlfriend with whom they resided; 48.6 percent (34) were married or
engaged; 12.9 percent (9) were divorced; none were widowed; and one woman declined
to answer that question. Roughly half of the women had children—25.4 percent (17) of
the respondents had one child, 14.9 percent (10) had two children, 7.5 percent (5) had 3,
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4.5 percent (3) of the women had 4 children, 1.5 percent (1) had five children, and the
remaining 46.3 percent (31) of the women had no children.
Table 4.1. Self-Identified Ethnicity of Online Survey Respondents (N=70)
SELF-IDENTIFIED
ETHNICITY
Caucasian/White

51

Greek

1

African American/Black

9

Hispanic

1

Asian

2

Jewish

1

Caucasian & Asian American

1

Vietnamese

1

Chinese-American

1

Missing

1

Cuban & African American

1

TOTAL

70

Two questions about health insurance status yielded surprising results. Only 5.7
percent (4) responded that they currently do not have any type of health insurance, while
82.9 percent (58) of women had private insurance. Only 5.7 percent (4) responded that
they were on Medicaid, 2.9 percent (2) reported “Other” and one declined to answer.
These numbers were not all that different to those reported about past health insurance
during their cancer diagnoses. 12.9 percent (9) did not have any type of health insurance
while 77.1 percent (54) reported private health insurance at the time they were diagnosed;
2.9 percent (2) had Medicaid; 1.4 percent (1) had student insurance, 2.9 percent (2)
reported “Other” type of insurance; and 2 declined to answer the question.
Subset 1: Invasive Cervical Cancer Participants
While current biomedical knowledge regards cervical cancer as developing along
a spectrum, ranging from the presence of abnormal cells (dysplasia), to carcinoma-in-situ
(CIS), to invasive cancer, there is a somewhat firm delineation between these types of
pre-cancerous lesions and invasive cancer. This delineation determines the intensity and
length of a woman’s treatment and her supposed prognosis; thus, I made the decision to
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analyze separately the sub-sample of women who responded that they had either
dysplasia or CIS. These women totaled 24 and will be discussed in a later section, while
the total number of participants with invasive cervical cancer was 46.
Illness History
These women had, on average, first been diagnosed with cervical cancer a little
over five years ago (63 months), although that number ranged from one month to nearly
24 years. The majority of these women—69.6 percent (32)—had been diagnosed with
Stage I cervical cancer, in which the cancer has not spread outside the cervix. Eleven
percent (5) had Stage II cervical cancer, indicating that the cancer has spread beyond the
cervix but not yet to the pelvic wall or bottom third of the vagina. An additional 11
percent (5) had been diagnosed with Stage III cervical cancer, where the cancer has
spread either to the pelvic wall or to the lower third of the vagina. None of the women
had been diagnosed with Stage IV cancer, the most advanced stage in which the cancer
has spread to a close organ, such as the bladder or rectum, or a distant part of the body,
such as the lungs, liver or brain (NCI 2008b). Three of the participants either did not
remember their stage or did not receive one from their provider, and one woman declined
to answer this question. Most—76.1 percent (35)—had received this diagnosis from their
gynecologist, while 8.7 percent (4) had been diagnosed from their primary care
physician, an additional 8.7 percent (4) by an oncologist, and 4.3 percent (2) by another
type of provider, such as Planned Parenthood. About half had known there was a
problem through a routine Pap smear, while an additional 30.4 percent (14) had been
experiencing symptoms, such as bleeding, painful intercourse, unusual discharge,
abdominal pain, and severe anemia. Two of the women had received incorrect Pap
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Table 4.2. Types of Treatment: Women with Invasive Cervical Cancer (n=46)3
TREATMENT TYPE

No treatment

2.2%

Conization (or Cone
Biopsy):
A surgical procedure in
which a cone-shaped piece of
tissue from the cervix is
removed.

32.6%

Cryotherapy/Cryosurgery:
A surgical procedure in
which abnormal tissue (such
as carcinoma-in-situ) is
frozen in order to destroy it.

10.9%

LEEP:
An electrical current is
passed through a thin wire
loop that cuts out the
abnormal cervical tissue.
Laser Surgery:
A surgical procedure in
which a laser beam is used to
cut out abnormal tissue.
Radical Hysterectomy:
The uterus, cervix, and part
of the vagina are removed
surgically; sometimes the
ovaries and fallopian tubes
are removed as well.
Total Hysterectomy:
The uterus and cervix are
removed surgically through
the vagina or abdomen, or
laparoscopically through the
abdomen.

3

TREATMENT TYPE
Pelvic Exenteration:
A radical surgical procedure
that removes the lower
colon, rectum, and bladder,
along with the cervix,
vagina, ovaries, and nearby
lymph nodes. Used to treat
advanced/recurrent cancers.
Trachelectomy:
An experimental surgery in
which the cervix, lower
uterus, and upper vagina are
removed but the rest of the
uterus is left intact.
Because a stitch is used to
close the uterus after the
surgery, it is used as a
fertility-sparing option for
early-stage cancer.
Internal Radiation:
Radioactive needles, seeds,
wires or catheters are
inserted internally next to
the cancer to deliver
radiation directly to the site.

0%

10.9%

30.4%

28.3%

External Radiation:
External beams deliver
radiation toward the cancer
through other tissues.

41.3%

4.3%

Chemotherapy:
A therapy in which drugs
are used to either kill the
cancer cells or stop their
growth—can be orally or
intravenously delivered.

32.6%

50%

Other (such as cervical
stenosis)

6.5%

Decline to Answer

2.2%

10.9%

Descriptions of treatment modalities were obtained from the NCI (2008c).
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results from their doctors’ office that later turned out to be cancer. Two women noted
that they had had recurrences, and another had been diagnosed with breast cancer several
years after her initial cervical cancer diagnosis.
Treatment varied considerably among participants. A variety of biomedical
treatment modalities were employed; Table 4.2 below details these. Physical side effects,
both from the cancer and from the treatment, were considerable. The most significant of
these was general pain (54.3 percent: 25), and also included fatigue (50 percent: 23);
painful intercourse and/or difficulty having sex (43.5 percent: 20); difficulty urinating or
having a bowel movement (each 43.5 percent: 20); nausea/vomiting (39.1 percent: 18);
diarrhea (39.1 percent: 18); cramping (37 percent: 17); dry, itchy or irritated skin (34.8
percent: 16); loss of appetite (32.6 percent: 15); vaginal discharge (23.9 percent: 11); hair
loss (21.7 percent: 10); vaginal bleeding (15.2 percent: 7); frequent sickness/infection
(15.2 percent: 7); and mouth sores (2.2 percent: 1). Thirteen percent (6) had no side
effects at all, and several participants listed other side effects such as lymphedema,
neuropathies, kidney and bladder problems (such as a ruptured bladder, cystitis, and loss
of bladder control), weight gain, and difficulties coping emotionally, psychologically, and
socially with the disease and treatment.
One survey item detailed several potential short-term and long-term repercussions
of cervical cancer and its treatment, and the degree to which participants found these
troubling in their own lives. The most frequently reported response to “physical
symptoms before treatment” was not at all troubling (40 percent: 18); “physical side
effects of treatment” were somewhat troubling (35.6 percent: 16); “loss of fertility or
compromised fertility” was extremely troubling (37.8 percent: 17); “other long-term side
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effects of treatment” were extremely troubling (27.3 percent: 12); “fear of recurrence”
was extremely troubling (59.1 percent: 26); “effect on ability to perform job” was not at
all troubling (37.8 percent: 17); “financial effects” were extremely troubling (37.8
percent: 17); “problems with health insurance” were not at all troubling (28.9 percent:
13); “difficulties in marriage or relationship with significant other” were tied for both not
at all troubling and extremely troubling (both 33.3 percent: 15); and “difficulties in
relationship with friends or family members” was not at all troubling (48.9 percent: 22).
Five women added that they have had great difficulties with sexual intercourse and
intimacy, due to both physical and psychological reasons. One woman related that “I
still bleed, have pain and sex has never been the same again,” while another wrote, “I
haven’t been sexual with my husband for fear that any action could trigger HPV to
become active again. All [doctors] say that couldn’t happen but they don’t have any
proof that would encourage me to risk my life for sex.” Several wrote that stigma was
their biggest issue, one noting that this had created problems with her employer when she
returned to work. Still others noted a loss of a sense of self and place in the world—for
example, one woman wrote that “the most profound effect has been the loss of emotional
connectedness and inability to continue writing poetry,” her livelihood.
Perceptions about Disease and Self
When asked about the cause of their cervical cancer, 25 out of the 45 who
answered the question said HPV. Others suggested a variety of other potential causes or
were unsure, such as a weakened immune system, family history, smoking, birth control,
sexual abuse, and in one case, a “doctor’s stupidity and not seeing the signs that were
right there on the Paps and colpos.” More than the actual causes mentioned, what was
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most notable about these lists was how specific they were and how targeted to each
person’s individual life and behavior. For example:
“I have no idea! 1. Maybe a sexual partner (I had four relationships/partners)
before my husband. I had one abnormal Pap smear about 6 years before my
diagnosis...but was told all was fine and never informed of HPV or worries of
cancer or dysplasia. 2. Maybe hormonal issues combined with lack of
sleep/eating well. I had my son two years before my diagnosis. During birth I
hemorrhaged because of retained placenta which left me sad/scared and required
a few procedures during the first six months of my son’s life (D&C and
Hysteroscopy). 3. Maybe the puncture during my hysteroscopy. When I woke from
the hysteroscopy the OB/GYN told me they were keeping me at the hospital
overnight to monitor for bleeding because she had perforated my uterus on the
way in. THANKFULLY I was not bleeding and from the pictures they found that
she most likely perforated the upper/back part of my cervix (just before entering
the uterus). This is the same area my cervical cancer was found. 4. Some days I
will never know...I blame myself maybe it's because I drink coffee once a day,
maybe it's because I wasn't sleeping enough with a new baby, I think the guessing
might never end. :-)”
Thus, in the absence of a scientific explanation—or a scientific explanation that
women did not feel “fit” their own situation, or that was unclear and not well-articulated
by biomedicine—women had created personally meaningful hypotheses. Another quote
illustrates this well:
“My physician said that my cancer was an adenocarcinoma, and that I tested
negative for HPV. As far as a scientific cause of my cancer, I can’t say. I’ve
always felt, though, that getting cancer was sort of the universe’s (God’s,
whomever’s) way of saying ‘You waited too late to have kids. Your options are
now limited. You’ll have to work a lot harder to make it happen now.’”
When queried about who they believe is at risk for cervical cancer, most women
responded either “all females” or “all sexually active females” are the ones at risk. Some,
however, qualified their responses further—most commonly, either people of color, the
poor, the uneducated, or the uninsured were seen as at higher risk. These factors were
thought to influence one’s access to medical care and/or screening—whether it is because
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one cannot afford it or because they are unaware of the risks and do not seek out
screening measures.
Responses to the question “What are the first three words or things that come to
mind when you hear the word cancer?” were illuminating and almost uniformly negative
in their presentation. Death or some aspect of facing one’s mortality was mentioned 30
times, the treatments themselves as well as side effects such as vomiting and hair loss
were mentioned 23 times, fear was used 21 times, and sadness and loss eight times. But,
in the midst of these responses were nine that touched upon some aspect of
“overcoming”—battle, fight, survival, life.
Seventy percent (35) of women identified themselves as cancer survivors. Many
of these women offered the reason that they had made it through treatment, past their
five-year mark, or were survivors simply because they were still alive after their
diagnosis: “Cancer is cancer, no matter where you got it or how you got it. I am a
survivor!” The same “conditional” concept of survivorship that appeared in the in-depth
interviews is applied frequently in the responses to this question—that one is only a
survivor if you had aggressive treatments or if you made it to the five-year mark, which
implies cure. Responses from the remaining 24 percent (11) that did not identify
themselves as cancer survivors are illuminating. One replied that she was “not sure,
actually. I feel a little presumptuous identifying myself that way, because I got off
REALLY easy. So many friends went through so much more in terms of pain and
treatment.” Another woman recounted her feelings of ambivalence about the term:
“I vacillate on this one. On the one hand, in its most literal sense, a cancer
survivor is someone who has been diagnosed with cancer, has been treated, and
has survived. However, I sometimes think that "survivor" implies more of a battle
with the disease than I experienced. I never felt any pain, nor did I experience any
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symptoms. I feel like less of a survivor because I didn't have to undergo radiation,
chemotherapy, or other non-surgical forms of treatment. Then, I decide that the
radical hysterectomy, as major surgery, along with the inability to bear a child,
was more than enough to make me a survivor. I survived the physical and mental
effects of a life-threatening illness.”
Experiences of Stigma
The biggest proportion of women (26.7 percent: 12) felt that people looked at
them differently sometimes because they had cancer; others felt that this happened all the
time (11.1 percent: 5); frequently (24.4 percent: 11); rarely (22.2 percent: 10); or never
(8.9 percent: 4). Four percent (2) did not know, and 2.2 percent (1) declined to answer.
Women mentioned several ways in which they feel others look at them differently. Some
wrote about their dislike of the pity that they feel from people—“I hate the pity look”—
while others discussed how difficult it is for people to figure out how to relate to them.
“People [make] a strong association between cancer and death,” and so women also
experience their loved ones’ fear and anxiety about their diagnosis; for example, one
participant noted that “for quite a while [after my diagnosis], people would see me and
the first question they would ask me was, ‘how’s your health?’”
These answers contrasted slightly to responses to the more specific question,
“How often do you feel people look at you differently because you had cervical cancer?”
13.3 percent (6) of women felt that this happened always; 20 percent (9) responded that it
frequently occurred; 20 percent (9) that it sometimes occurred; 17.8 percent (8) that it
rarely occurred; 13.3 (6) percent that it never occurred; and another 13.3 (6) percent did
not know. 2.2 percent (1) declined to answer. Additional comments for this question
tended to center around cervical cancers’ connection to a sexually transmitted infection:
one woman wrote that “when they found out what type of cancer I had, they look at me as
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though I’m a whore or dirty,” while another noted that “they either see you as this great
inspiration or the slut that got HPV…either way it affects how others see you.”

One

woman recounted that stigma has impacted who she tells: “Part of the reason I am still
‘in the closet’ is because I fear that people will judge me. Cervical cancer is now
associated with HPV and is considered to be a sexually transmitted disease. Because of
the availability of the vaccine, people are now more aware of cervical cancer than they
were 20 years ago. If they have read about it recently, they are probably also aware that
it can be sexually transmitted.” Similarly, many women connected the presence of the
“HPV ads” to others’ awareness and subsequently to a fear of judgment.
Table 4.3. Responses to Stigma Items: Women with Invasive Cervical Cancer (n=46)
Never

Rarely

Sometimes

Frequently

Always

Don’t
Know

How often do you feel that
people look at you
differently because you
have/had cancer?

8.9%

22.2%

26.7%

24.4%

11.1%

4.4%

How often do you feel that
people look at you
differently because you
had/have cervical cancer?

13.3%

17.8%

20%

20%

13.3%

13.3%

A follow-up item posed the question, “How often do you feel that people treat
you differently because you had/have cancer?” Here, the most common response was
that this rarely happens (31.1 percent: 14). Others felt that it always occurred (8.9
percent: 4); frequently (13.3: 6); sometimes (28.9 percent: 13); or never (11.1 percent: 5).
Two did not know, and 2.2 percent (1) declined to answer. More specifically, when
questioned whether people treat them differently because of their cervical cancer, 28.9
percent (13) thought that this sometimes happened. A little over 13.3 percent (6) thought
that it happened always; 11.1 percent (5) frequently; 13.3 percent (6) rarely; and 17.8
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percent (8) never. An additional 11.1 percent (5) did not know, and 4.4 percent (2)
declined to answer.
Table 4.4. Responses to Stigma Items: Women with Invasive Cervical Cancer (n=46)
Never

Rarely

Sometimes

Frequently

Always

Don’t
Know

How often do you feel that
people treat you
differently because you
have/had cancer?

11.1%

31.1%

28.9%

13.3%

8.9%

4.4%

How often do you feel that
people treat you
differently because you
had/have cervical cancer?

17.8%

13.3%

28.9%

11.1%

13.3%

11.1%

The majority of women (64.4 percent: 29) were not afraid that others would have
less respect for them if they knew about their diagnosis, whereas 33.3 percent (15) did.
One woman agreed that “because of the prevalence of information about cervical cancer
and the connection to the HPV virus, which is sexually transmitted, I definitely think that
some people would have less respect for someone who is diagnosed with cervical
cancer.” A number strongly resisted that idea; for example, one woman wrote that “I
could care less if they respect me less. I am a respectable woman and if they want to be
ignorant or look at me different, they can carry that around with them,” while another
noted that “if they do, that is their own ignorance.”
Interestingly, these numbers were inverted for the question, “In your experience,
do you feel that women with cervical cancer are stigmatized (in others words, looked
down upon and negatively stereotyped because of their diagnosis)?” In this case, 64.4
percent (29) of the women responded that cervical cancer is indeed stigmatized, while
28.9 percent (13) did not feel that way. One woman explained her answer by saying “I’m
afraid they would think I was promiscuous or in some way ‘deserved’ what I got.”
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Others described how their feelings on this question have changed for the better: “at first
[I was afraid]. I didn’t tell my 3 best friends because I was ashamed and embarrassed
because it came from HPV. However, my friends have all experienced this in the past so
I felt good about that.”
The elaborating comments for this question are powerful, almost more so than
similar questions asking about stigma in the semi-structured interviews. Many comments
reflected themes that arose during the interviews of cervical cancer being tied to
promiscuity: “People make assumptions about you and say derogatory things, like you
were being a slut, whore, or that you have no shame.” People who stigmatized were
often labeled as ignorant or uneducated, and who did not know about the true prevalence
of HPV and thus had an incorrect judgment of their own risk. A number of women
explained that fear of stigmatization keeps many silent:
“Because cervical cancer is associated with an STI, people seem to think it is our
own fault for getting it, like we asked for it. Not to mention, the statistics and info
in the media tends to paint us all as poor, uneducated whores that will sleep with
anyone and that we have no respect for ourselves. They are so misinformed and
have no idea who the face of cervical cancer is because so many of us suffer in
silence out of shame.”
“[Women with cervical cancer are stigmatized] especially if they come from a
certain background, and now because of the HPV virus some women may never
come forward to tell their experience for fear of being looked down on.”
Several others noted that they had personally not experienced it, but they knew of
others who had. Those women that did not agree that cervical cancer is stigmatized
explained that, because it is not visible to outsiders, no one knows that one has cervical
cancer specifically—although they might think about the effects of treatment. Still others
replied that they simply didn’t know.
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Table 4.5 illustrates responses to several stigma items posed in the survey where
participants were asked to rate how often they agreed with a specific statement. Women
most frequently never agreed that “I blame myself for my condition” (28.9 percent: 13);
sometimes agreed that “I think that others blame me for my condition” (31.1 percent: 14);
and always agreed that “I think that this condition could have been prevented” (33.3
percent: 15). Most frequently women never agreed that “I am angry at myself” (31.1
percent: 14), “I feel embarrassed or ashamed” (31.1 percent: 14), “I am too embarrassed
Table 4.5. Responses to Stigma Items: Women with Invasive Cervical Cancer (n=46)
Never

Rarely

Sometimes

Frequently

Always

N/A

I blame myself for my
condition.

28.9%

15.6%

22.2%

15.6%

15.6%

2.2%

I think that others blame me
for my condition.

17.8%

22.2%

31.1%

17.8%

4.4%

6.7%

I think that this condition
could have been prevented.

8.9%

15.6%

22.2%

15.6%

33.3%

4.4%

31.1%

11.1%

20%

22.2%

13.3%

2.2%

31.1%

15.6%

24.4%

17.8%

8.9%

2.2%

42.2%

22.2%

15.6%

11.1%

6.7%

2.2%

42.2%

15.6%

22.2%

11.1%

6.7%

2.2%

My family thinks less of me
because of my condition.

51.1%

17.8%

6.7%

8.9%

2.2%

13.3%

I think that others pity me.

24.4%

20%

31.1%

11.1%

6.7%

6.7%

I think that others judge me
negatively because of my
condition.

26.7%

24.4%

31.1%

6.7%

6.7%

4.4%

I am angry at myself.
I feel embarrassed or
ashamed.
I am too embarrassed or
ashamed to tell someone
about it.
I think less of myself because
of my condition.

or ashamed to tell someone about it” (42.2 percent: 19), “I think less of myself because of
my condition” (42.2 percent: 19), or that “My family thinks less of me because of my
condition” (51.1 percent: 23). Respondents sometimes agreed that “I think others pity
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me” (31.1 percent: 14) and that “I think that others judge me negatively because of my
condition” (31.1 percent: 14).
Support and Disclosure
On the whole, the vast majority of women had told others about their diagnosis.
91.1 percent (41) had told their spouse/partner/significant other, 82.2 percent (37) had
told their parents, 86.7 percent (39) had told their siblings, 82.2 percent (37) had told
other members of their family, 93.3 percent (42) had told their friends, 84.4 percent (38)
had told their co-workers, 48.9 percent (22) had told members of their religious groups,
48.9 percent (22) had told neighbors or community members, and an additional 22.2
percent (10) had confided in other people not listed. None of the respondents hadn't told
anyone. Many of the additional comments revolved around the need to speak out about
cervical cancer in order to raise awareness; for example, one woman wrote that “I have
two published articles and will speak to anyone about this issue. We have to bring about
change.” There were a number of reasons why some women chose not to tell their
family and friends, the most central one being fear of their reactions—whether it be
concern, pity, or outright disapproval. One woman wrote that “I do not want them to
know what type of cancer I have. I have heard the jokes already.” Another confided that
“I didn’t tell my parents and family right away because they are so conservative and
religious. Even when I did tell them, they still looked at me different, like I was a slut or
something. I could see it in their eyes…the contempt they had for me getting this
affliction.” Others felt differently: “I am certainly not ashamed though. I would feel
more self-blame if, say, I was a big smoker and got lung cancer, or a heavy drinker and
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got liver cancer. But to be ashamed that at my age of 57 that I had sex—my word! I’d be
ashamed if I hadn’t had sex!”
In line with these responses, the majority felt that they would not prefer to keep
others from knowing about their diagnosis (48.9 percent: 22), although 20 percent (9)
responded that they would, and an additional 28.9 percent (13) that they sometimes prefer
to keep others from knowing. For those that did not prefer to keep others from knowing,
it gave them a chance to, for example, “remind others to keep up on their annual
examinations” and to be aware of their own health. Others felt that this was important to
reduce the stigma associated with the disease: “It is important for us to share our
experiences. This will help people learn the truth about who gets this disease and how
common it is. Understanding will help remove the stigma.” Other women, who
preferred that people did not know, were uncomfortable with the visibility of the disease:
“some people think that since they know, any question about yourself, your history, your
feelings are free game,” or “I would rather keep it to myself rather than risk being
judged in personal relationships or possibly discriminated against in the workplace.”
Some were torn about this issue: “Sometimes I think it’d be empowering to educate
people because I was not educated about this, but I do not want to subject myself to
public criticism.”
In terms of the quality of support provided from the above parties, the most
frequent response was that it “exceeded my expectations.” 53.3 percent (24) felt this way
about their significant other/spouse/partner; 40 percent (18) about their parents; 37.8
percent (17) about their siblings; 31.1 percent (14) about their other family members;
35.6 percent (16) about their friends; 28.9 percent (13) about their co-workers; 22.2
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percent (10) about members of their religious groups; and 26.7 (12) percent about
neighbors or community members. The remaining responses were spread rather evenly
across the rest of the response categories: good enough support, some support, not
enough support, and no support at all. Additional qualitative comments concerned the
importance of support groups and the central role they have played for those participants.
Information-Seeking
The majority of women received information about cervical cancer either from
their doctor or from the internet. Sources of information about the causes of cervical
cancer were split evenly between the two (63.6 percent: 28 each). Information about
treatment and side effects was obtained mostly from their doctor (81.8 percent: 36) with
internet as a close second (50 percent: 22), and likewise for information on long-term
side effects of treatment (60.5 percent: 26 and 39.5 percent: 17, respectively).
Information on support groups and advocacy groups was obtained primarily through the
internet (50 percent: 22 and 45.5 percent: 20, respectively). Other healthcare workers,
organizations such as the American Cancer Society, and media sources such as
magazines (other than television) were additional primary sources of information; less so
were family, friends, or television. Disturbingly, a fair number of women did not receive
information on any of these topics—13.6 percent (6) did not receive any information on
causes, 9.1 percent (4) on treatment and its side effects, 25.6 percent (11) on long-term
side effects of treatment; 20.5 percent (9) on support groups; and 36.4 percent (16) on
advocacy organizations.
Although they were still primary sources of information about HPV, doctors did
not play as much of a role as they did for information about cervical cancer. In terms of
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information about causes, most women sought that through the internet (48.8 percent:
21), while doctors were second (39.5 percent: 17). Information about treatment and side
effects were evenly split between the two (40.5 percent each: 17 each), while most
women did not receive any information either about the HPV vaccine (42.9 percent: 18)
or about support modalities (46.3 percent: 19).
Additional Comments
About half of the women offered additional comments at the end of the survey,
some thanking us for doing it, and others offering suggestions for future research—such
as more detailed research about long-term side effects of treatment. Many of the other
comments tied into themes that were identified in the interviews: specifically, care
experiences and resources. A good deal of women expressed frustration with the way
that they were treated—whether it be missed diagnoses, misinformation, or just complete
lack of information about HPV and what to expect. Others noted the lack of research and
attention on cervical cancer, again comparing it to the wealth of resources available for
those with breast cancer.
Subset 2: Dysplasia and CIS Participants
A total of 24 additional women responded that they had either Stage 0 cancer
(known as carcinoma-in-situ or CIS), or some grade of cervical dysplasia (abnormal
cervical cells). This was an interesting occurrence because the survey was clearly
tailored to those with diagnosed invasive cervical cancer, and was titled “Women’s
Experiences with Cervical Cancer.” Although many professed that their diagnosis was
not cervical cancer—that there is, in fact, a firm delineation in some of their minds
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between what they have and what “real” cervical cancer is—these women decided to
complete the survey anyway. This sample has been included in the analysis because,
first, their responses to the stigma items differed and in many cases were stronger, and
also because their simultaneous rejection and acceptance of a cervical cancer designation
in their lives blurs the biomedical distinction between these two diagnoses. It speaks to a
larger societal conception about what it means to have cancer, and the motivation behind
why people might identify with it in certain instances and not in others. In many
instances, women marked that they were diagnosed at Stage 0, or left the question blank
and wrote a response in the comment box. It is important to note that some of the
questions that were more clearly suited to women with invasive cancer were not included
here in this discussion.
In general, these women tended to be younger and were less likely to be married.
While the average age of a woman with invasive cervical cancer was 41.5 years old,
women with dysplasia or CIS were 34.6, on average. Only 20.8 percent (5) of these
women were married, compared with 63 percent (29) of women with invasive cervical
cancer. 62.5 percent (15) were either single or had a boyfriend/girlfriend, compared with
23.8 percent (11) of the other group. These women were also less likely to have private
health insurance when they were diagnosed—66.7 percent (16) compared to 82.6 percent
(38) of women with invasive cervical cancer. More of them tended to be on Medicaid,
student health insurance, or to have no health insurance at all.
Illness History
These women had, on average, first been diagnosed with dysplasia or CIS
approximately five years prior to the survey (57 months), with a range of one week
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through 16 years. Most of the women in this group had been diagnosed by their
gynecologist (83.3 percent: 20) through a routine Pap smear (87.5 percent: 21). Only one
had been experiencing symptoms. These women had had much different treatment
regimens, detailed in Table 4.6 below.
Table 4.6. Types of Treatment: Women with Dysplasia or CIS (n=24)4
TREATMENT TYPE

TREATMENT TYPE

No treatment

8.7%

Pelvic Exenteration

0%

Conization (or Cone Biopsy)

21.7%

Trachelectomy

4.3%

Cryotherapy/Cryosurgery

4.3%

Internal Radiation

0%

LEEP

69.9%

External Radiation

0%

Laser Surgery

13%

Chemotherapy

0%

Radical Hysterectomy

4.3%

Other (such as cervical
stenosis)

4.3%

Total Hysterectomy

8.7%

Decline to Answer

0%

Because treatment modalities differed between the two groups, side effects did as
well: vaginal bleeding (39.1 percent: 9) and vaginal discharge (30.4 percent: 7) were the
most common. Others mentioned weight gain, bloating, difficulties with sexual
intercourse and sex drive, and menopausal symptoms. Several referred to psychological,
social and emotional repercussions such as “emotional trauma, loss of relationship,”
anxiety, and depression. Of several potential short-term and long-term repercussions of
cervical cancer and its treatment, participants reported the following effects as extremely
troubling: loss of fertility/compromised fertility (31.8 percent: 7), fear of recurrence (54.5
percent: 12), and financial effects (31.8 percent: 7). They noted that their diagnosis had
caused difficulties in a marriage or relationship with a significant other that were
somewhat troubling (36.4 percent: 8). A number of women commented that sexual side

4

See Table 4.2 for a full description of treatment modalities.
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effects such as “reduction in the strength of orgasm” were the worst consequences of
their experience, and still others were frustrated with the healthcare that they had received
and the personal confusion they felt about their diagnosis: “Frustrations with getting
information from doctors and having things explained—EXTREMELY TROUBLING.”
Perceptions about Disease and Self
The majority of women—19 out of the 23 who answered the question—believed
that HPV had been the cause of their dysplasia or carcinoma-in-situ, and another two
suggested that sexual contact had been the cause: in one case, “sex with an idiot.”
Interestingly, many of the answers reflected a frustration with medicine’s lack of
knowledge about HPV and its role in dysplasia and cervical cancer, and—similar to the
findings in the interviews—women suggested a host of other causal factors they believed
played a role in their condition. For example, women mentioned birth control pills,
trauma to the cervix, second-hand smoke, weakened immune system, stress, and lack of
knowledge. Three complained that their doctor did not follow the standard screening
guidelines, either failing to inform them that they needed a Pap smear as frequently as
they did, or not performing an HPV test.
Responses to a query about who is at risk for the disease were similar to the
previous group with invasive cervical cancer. A majority answered that females, or more
specifically, sexually active females, were at greater risk. Others qualified this response
by saying that people of color, the poor, the uneducated, or the uninsured were at higher
risk.
When asked about the first three words or things that come to mind when they
hear the word cancer, the responses were quite similar to the other group. Death was
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mentioned the most frequently—15 times—followed by fear (7), treatment and side
effects (7), and impact on family (5). References to “overcoming” popped up
occasionally (7)—for example, survival, fight, challenge, life-changing, strong, and
“I.am.fine.”
Not surprisingly, fewer participants in this sample identified themselves as cancer
survivors. 65.2 percent (15) did not think so. Most of these women reasoned that since
they did not have invasive cancer, and as such their lives were not threatened, then they
were not cancer survivors. Interestingly, however, a significant proportion did identify
themselves as such—34.8 percent (8): “So far I am. I’m still alive despite having a Stage
0 diagnosis. I’m hoping it doesn’t come back.” Another woman commented that “My
doctor said that the piece from the cervix they removed was starting to form cancer so I
do consider myself a lucky and fortunate cancer survivor!!!”
Experiences of Stigma
There were four questions on this survey that inquired about whether or not
participants felt as though other people looked at or treated them differently because they
had/have cancer, and more specifically cervical cancer. These questions don’t directly
relate to this sample, but some of the qualitative comments were illuminating. Instead of
feeling as though people are looking at them differently because of their cancer diagnosis,
a number of women felt this way because of their HPV diagnosis: “I would say that they
don’t look differently at me because I had pre-cancer, but rather that I have HPV.” Two
women mentioned this in the context of their healthcare: “Sometimes I feel like the nurses
and doctors may look at me differently because my cancer is caused by the HPV virus
which is sexually transmitted.” It may even affect the quality of their care. “To clarify
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my situation, I asked them if they know what strain(s) of HPV I have. Instead of
answering my question, the nurse asked me in a condescending tone if I know how HPV
is transmitted. She went on to tell me that people with many partners are more likely to
develop cervical cancer.”
While the majority of women with invasive cervical cancer had not feared that
other people would have less respect for them if they knew about their diagnosis (64.4
percent: 29), this figure was inverted in this sample—57.1 percent (12) were afraid that
this would be the case, while 33.3 percent (7) did not. Proportionately more women in
this sample believed that those with cervical cancer are stigmatized—76.2 percent (16)
compared to 64.4 percent (29). Respondents noted that this stigma tended to arise (or
continue) because it is tied to an STI, that people think you brought it on yourself, and
that educational and media messages created a “face” of cervical cancer that was
stigmatizing—multiple sex partners, sex at a young age, and those that do not seek out
screening.
“I'm not sure how much of the stigma comes from us and how much comes from
outside of us. But I do believe that we feel a huge amount of stigma and shame.
I'm not sure where this comes from. I think it's reinforced by constant messages
that list risk factors as "multiple sexual partners", "smoking" and "compromised
immune systems." It makes people feel like somehow it's their fault for not being
able to clear the virus like 90% of other people -- like we somehow brought it on
ourselves -- either by being promiscuous or having a bad lifestyle.”
Interestingly, there was much more mention about the HPV vaccine in this
question—women linked the stigma of cervical cancer as directly impacting the way that
people think about getting the vaccine. One woman noted that:
“This is one reason why the Gardasil vaccine has received so much negative
media/government attention. Cervical cancer is a very misunderstood disease. On
many websites about cervical cancer it states risk factors for the disease as
having a high number of sexual partners, sex at a very early age, being minority
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and other risk factors. While these are statistics, not all women with cervical
cancer/precancer fit in these neat little categories. HPV is extremely common.
Most people do not understand this and the stigma is just continually promoted.”
Table 4.7 below displays the detailed responses to specific stigma questions—on
the whole, women with dysplasia or CIS agreed more frequently with certain items than
women with invasive cervical cancer: specifically, “I blame myself for this condition,” “I
think that others blame me for this condition,” “I am angry at myself,” and “I feel
embarrassed or ashamed.” Some of the additional comments to this table centered on the
Table 4.7. Responses to Stigma Items: Women with Dysplasia or CIS (n=24)
Never

Rarely

Sometimes

Frequently

Always

N/A

I blame myself for my
condition.

9.5%

9.5%

33.3%

42.9%

4.8%

0%

I think that others blame me
for my condition.

14.3%

23.8%

19%

33.3%

4.8%

4.8%

I think that this condition
could have been prevented.

19%

4.8%

19%

28.6%

28.6%

0%

23.8%

9.5%

33.3%

23.8%

9.5%

0%

I am angry at myself.
I feel embarrassed or
ashamed.
I am too embarrassed or
ashamed to tell someone
about it.
I think less of myself because
of my condition.

14.3%

19%

28.6%

33.3%

4.8%

0%

33.3%

23.8%

19%

23.8%

0%

0%

33.3%

19%

19%

23.8%

4.8%

0%

My family thinks less of me
because of my condition.

57.1%

14.3%

14.3%

4.8%

4.8%

4.8%

I think that others pity me.

47.6%

19%

19%

4.8%

4.8%

4.8%

I think that others judge me
negatively because of my
condition.

33.3%

23.8%

28.6%

4.8%

4.8%

4.8%

effects of increasing knowledge and research: “If more people knew how cervical cancer
can be started, I think I would be more embarrassed or ashamed. Not many people know
that I have the HPV virus.” One woman implied that the current research is stigmatizing
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in itself: “My parents judge me and I judge myself. Close friends and co-workers don’t,
but the general messages in research studies and people I don’t know always seem to
imply this resulted from promiscuity.”
Support and Disclosure
Fewer women had disclosed their diagnosis to others: 85.7 percent (18) had told
their spouse/partner/significant other, 81 percent (17) had told their parents, 76.2 percent
(16) had told their siblings, 42.9 percent (9) had told other members of their family, 90.5
percent (19) had told their friends, 57.1 percent (12) had told their co-workers, 14.3
percent (3) had told members of their religious groups, 33.3 percent (7) had told
neighbors or community members, and an additional 38.1 percent (8) had confided in
other people not listed. In response to a question about why they may not have told
family or close friends, women responded equally that they were embarrassed, ashamed,
and afraid of being judged, and also that the uncertainty of their diagnosis and prognosis
held them back. A few women reported negative experiences when they confided in
others: “I tell some and not others about my HPV. It’s also come back to haunt me—and
a large group of people have found out and judged. At the end of the day, it seems to
come down to an STD, not the fact that I had basically had pre-cancer.”
A greater percentage of this sample would prefer to keep others from knowing
about their diagnosis: the biggest proportion responded that they sometimes (47.6 percent:
10) or always prefer it (9.5 percent: 2). Many of these women argued that privacy was
the motivation for this, feeling that it was not anybody else’s business. Others were
frightened about being judged or stigmatized: “I would be reluctant to tell my extended
family because they are conservative Christians and would blame this on ‘promiscuity’
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because I’m 46, not married, and have had various relationships over the years.” On the
other hand, 42.9 percent (9) of this sample do not prefer to keep others from knowing.
The underlying rationale behind this is that by being open about their diagnosis, they help
others and raise awareness about HPV and cervical cancer: “I am an open book and
believe knowledge is key. I would tell anyone in the same situation of my experience to
try to enlighten them and let them know it can be treated if caught early enough.”
In terms of support, many women responded positively, although less so than the
women with invasive cervical cancer: 38.1 percent (8) felt that the support of their
significant other/spouse/partner exceeded my expectations, as well as 28.6 percent (6) for
siblings and 33.3 percent (7) for co-workers. Parents offered some support to 28.6
percent (6) of participants, and friends offered good enough support (38.1 percent: 8).
One woman offered an enlightening comment about the support available to her: “There
is not enough understanding about HPV in the general community to provide the support
you really need in these cases. I feel I am educating others more about it, and it's hard
for them to really understand. It's hard to find sex-positive doctors that will help you
through it as well.”
Information-Seeking
Similar to the other sample, women’s primary source of information on cervical
cancer—causes, treatment, side effects, long-term side effects, support groups, and
advocacy organizations—were both doctors and the internet. A good many had not
received any information on long-term side effects (30 percent: 6), support groups (45
percent: 9), or advocacy organizations (50 percent: 10). Information on HPV came
mainly from the internet—73.7 percent (14) had accessed information about its causes
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there, 57.9 percent (11) about the vaccine, and 47.1 percent (8) about support groups. A
significant difference between the two groups was the central role television played in
gaining access to information—52.6 percent (10) of this group, compared with 7 percent
(3) of the other group, used television as a main source for information about the cause of
HPV, while 52.6 percent (10) of this group versus 23.8 percent (10) of the other had
received information about the HPV vaccine from television.
Additional Comments
Nine women volunteered additional comments at the end of the survey. It is
interesting that many of these comments addressed HPV and dyplasia’s relative
“invisibility” among researchers, where these conditions are not seen as worthy of
investigating (unless they turn into cervical cancer, that is) because they are preventable.
There is not that much information available and the outcome is uncertain, and so these
women are left in limbo for an indefinite period of time. This is clearly an area of
necessary future research. One woman articulated her situation quite eloquently:
“I wish that we had better statistics on the cost of "preventing" cancer. Doctors
downplay the morbidity involved in treatment of "pre-cancer" and people don't
understand that "pre-cancer" is difficult, if not impossible, to fully prevent. We
aren't counting the hundreds of thousands of women impacted by pre-cancer, so
we don't even know the true cost of our screening programs. We are only
counting elimination of cancer as the goal, and I wish we would focus on
elimination of pre-cancers. I don't think the vaccine is enough, and we need an
infection control strategy. The current messages do women a disservice because
they state that almost everyone has HPV and almost everyone clears it on their
own (if they have a normal immune system). This downplays the risk, so that no
one takes HPV seriously until they have a bad outcome. Messages say to reduce
sexual partners, but that's not really true prevention because you can't control
how many partners your partner has had. It's very frustrating, and I just feel very
angry and have not yet come to terms with my experience even though I'm more
than a year post LEEP. I wonder if people with cervical cancer are doing better
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emotionally than people with dysplasia, because maybe they have come to terms
with life and death and feel grateful to be alive, but we don't feel that sense of
relief, just more a sense of what we've lost.”
SUMMARY
This chapter delved in detail into each of the themes emerging from the key
informant interviews, content analysis, semi-structured interviews, and online survey.
The content analysis of the websites contributed a number of insights that were then
incorporated into both the interview and survey questions, such as causation, destigmatization, a focus on women, and perceptions of the HPV vaccine. Because the
overall goal of this research was to investigate the dynamics and subtleties of women’s
experiences with cervical cancer and stigma attached to the disease, the analysis put its
primary emphasis on qualitative methods, that is, the interviews. Major interdependent
themes emerged from the analysis of this data that served to illuminate the complexities
of each participant’s experience with cervical cancer and stigma, such as their ideas about
causation, sexuality, prevention, the role of the media, the HPV vaccine, and their
perceptions about resources. Aspects of a number of these themes were then tested
through the use of an online survey. Importantly, many participants from both the
interview and survey phases offered suggestions to minimize stigma that will be
incorporated into the next chapter’s discussion and recommendations.
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Chapter Five:
Discussion and Recommendations
Chapter Five will present a detailed synthesis and discussion of the key informant
interview, content analysis, in-depth interview and survey results, focusing on concrete
areas for action and potential contributions to applied anthropology. Although this study
brought forth many issues and difficulties surfacing in participants’ experiences with
cervical cancer, its primary research questions concern the nature, origin, and
consequences of stigma attached to the disease. Thus, for the purposes of space, this
summary of results will be limited to a discussion stemming from this perspective.
Indeed, many of the seemingly disparate themes surfacing throughout the results of these
methods are, on closer inspection, not so disparate at all—and thus, many of them find
their reflection in a discussion of these research questions. Others expose current gaps in
our understanding while posing important future avenues for anthropological and public
health research. This chapter will conclude by offering recommendations gleaned from
the insights of both the participants as well as myself, the researcher.
SUMMARY OF RESULTS
The Nature of Cervical Cancer-Related Stigma
Erving Goffman—the sociologist famed for his examination of stigma in the
1960s, followed by successive waves of scholars in various social science disciplines
building upon his theories—have differentiated between enacted stigma and felt stigma.
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According to these scholars, enacted stigma refers to the active discrimination of people
who are perceived to have a trait that is stereotyped negatively by society. Felt stigma,
on the other hand, is a more internal-level phenomenon that reflects the individual’s
actual experience with this discrimination, or their anxiety and fear of its occurrence.
This kind of dual outward-inward experience of stigma is clearly reflected in
these interviews and surveys. Indeed, in many instances there seems to be a disconnect
between what the participants have actually experienced in terms of treatment by others,
and what they perceive others to be thinking about them—or indeed what they think
about themselves. Although there are some very notable exceptions, many of the women
did not feel as though they had been treated poorly or that others had made negative or
insinuating remarks to them about their cervical cancer. More frequently, they were
certain that others were thinking about them differently and judging them—because,
some argued, they might do the same given the information now circulating about HPV
and cervical cancer. These assessments resulted in fear, increased stress, anxiety, and
reluctance to share experiences with others not directly involved.
One of the most important points of Goffman’s and successors’ work, I believe, is
that stigma is not just limited to actual negative and stereotyping behavior enacted
against the individual with the unacceptable trait. Rather, participants are also looking
outward to society’s conceptions about cervical cancer and measuring themselves against
it, creating a process of internalization that can have tangible repercussions on their
physical, emotional, and social health. Although they might not all be actively
experiencing discriminating behaviors from others, by reflecting on others’ changed
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beliefs and judgments about them, they are certainly perceiving cervical cancer’s
negative connotation in wider society and the existence of stigma attached to the disease.
Origins
Given that participants feel that, on the whole, cervical cancer is a stigmatized
condition in the United States, what then are the origins of this stigmatization? The
answer to that is multi-layered, and appears as though women’s experiences of stigma are
often tied to interacting and interdependent belief systems regarding causation, female
sexuality, and prevention.
In her work on the moral reasoning of cancer, Hunt (1998) argued that individuals
must create meanings behind why they themselves become sick, given that biomedicine
has failed to articulate with certainty the fundamental cause of cancer. Considering this
continuing ambiguity surrounding the scientific knowledge about HPV and its possible
role in an individual’s cervical cancer, participants in our study have likewise developed
personally meaningful hypotheses that make sense in their own lives and situations.
First, their theories of causation regarding HPV and cervical cancer in a general, abstract
sense tended to reflect the current biomedical discourse and were almost identical to one
another—for example, they frequently cited specific behaviors (mostly sexual behaviors)
as potential causes of both conditions, and seemed to take for granted HPV’s causative
role in the development of cervical cancer. Second, these discourses were in many ways
incorporated into their own individual theory of disease development, although not
entirely. These personal explanations reflect varying degrees of uncertainty and tend to
fall into broad categories of causation—individual behavior and external factors. Many
felt that they were responsible in some sense for their cervical cancer by a certain
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behavior, lifestyle, or choice—such as sleeping with the wrong person, smoking, not
going to the doctor enough, or not taking care of oneself properly. This sense of guilt and
personal responsibility frequently contributed to great deal of shame and embarrassment
on the part of that individual woman.
The sexual nature of this causal relationship between HPV and cervical cancer
frequently heightened this sense of shame and embarrassment for women, especially
given that many women’s narratives touched upon the idea that there are aspects of
female sexuality and the female body that predispose certain women to developing
cervical cancer by increasing their risk of contracting HPV. Here one can see the
moralistic overtones of biomedical discourse about HPV transmission and cervical cancer
development reflected in a clear way. It is important to note here that these assumptions
were not without critical reflection by the women themselves. A majority argued that the
reason that cervical cancer is stigmatized in society is its association with sexual
behavior, and because HPV is a sexually transmitted infection. Many acknowledged
Americans’ discomfort with sexuality, or more specifically, female sexuality,
simultaneously critiquing the reason behind the stigmatization while being forced to deal
with its structural and individual-level consequences.
The concept of prevention was one that cropped up repeatedly throughout the
interviews, and was itself seen as a large underlying factor in the generation of cervical
cancer-related stigma. With continuing scientific discovery relating to HPV,
“preventability” is now widely seen as a quality of cervical cancer in two ways. First, it
is seen as preventable by “responsible” sexual behavior—participants spoke frequently
about how this concept impacts them adversely because now others believe that they are
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responsible for their own condition. Or, importantly, they believe that about themselves.
Secondly, it is now recognized as being preventable by the existence of the new HPV
vaccine. These beliefs combine to seemingly decrease others’ sympathy towards the
cervical cancer patient or survivor, and increase blame-finding. An interesting parallel
was drawn between cervical cancer and lung cancer—a type of cancer that has long been
recognized as stigmatized because of its causal association with a behavior that is socially
unacceptable in contemporary American culture.
This increasing recognition of cervical cancer’s preventability is recent and seen
as due largely to new discoveries about HPV and the vaccine. These new developments
are leading to a significant increase in the publicity surrounding the association between
HPV and cervical cancer, which in turn is leading to a situation that many referred to as a
“double-edged sword.” In other words, this increasing awareness of HPV’s role, and
strategies that an individual can use to protect him/herself, is simultaneously creating
both positive and negative change. Awareness is being raised, hopefully leading to a
decreased incidence of both diseases and sparing many women from a cervical cancer
diagnosis. At the same time, it is serving as fodder for further stigmatization—creating a
scientifically proven link between sex and cervical cancer that leads to negative
assumptions and stereotypes about those who are dealing with the disease.
It is critical to note that survivors’ experiences with the disease are affected not
only by society’s assumptions about cervical cancer’s cause, its association with sexual
behavior, and its newly-recognized quality of preventability. They too are impacted by
the wider negative connotations about cancer itself, and indeed, it is often impossible to
conceptually separate the effects of the two. Participants argued that cancer on the whole
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is stigmatized, not so much because of its origins, but because of its enduring association
with death, disability, and suffering. The impact of this is two-fold: it creates fear and a
sense of vulnerability in the survivors themselves because it challenges their own
mortality, and also anxiety and discomfort because it is assumed that others must think
the same thing—that is, they must believe that the patient was going to die, and pitied her
because of it.
Consequences
The reported consequences of cervical cancer-related stigma are numerous and
multi-faceted, ranging from individual-level effects to societal structures and policies that
both respond to the stigma and perpetuate its existence. For example, individual-level
consequences that have been threaded throughout this discussion include a heightened
sense of fear, guilt, stress, anxiety, and personal vulnerability. Socially, many
participants reported a reluctance to share their experiences with others not directly
involved in their care, something which may impact their ability to access adequate social
support.
Ironically, one of the consequences of cervical cancer-related stigma was seen as
a positive rather than a negative—self-advocacy. In other words, the stigma that some
women witness and experience is a powerful catalyst for their own involvement in the
awareness-raising movement. Their personal experience created the realization that only
by raising awareness of the devastation of cervical cancer and the true prevalence of HPV
(i.e., the fact that it is so common) will the situation change for the better. Perceptions
will improve once HPV and cervical cancer are normalized, and the only way to achieve
this is by speaking out and being public.
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Interestingly, the most frequently discussed consequences of cervical cancer’s
stigmatization were not strict individual-level effects such as discriminating treatment by
others, but rather structural-level impact. Of course, these structural consequences have
powerful trickle-down implications for an individual, and so these issues must be seen as
multi-faceted. For example, a recurrent theme was the lack of clear information and
candid conversations with participants’ healthcare providers about the connection of HPV
and cervical cancer and implications for their future. Many women learned about HPV
for the first time months or years after their treatment had been completed, and attributed
this omission to providers’ discomfort with the topic. Furthermore, this assertion is
supported by several informal conversations with gynecologic oncologists and
gynecologists during the recruitment stage who stated that they did not want to create a
feeling of stigmatization by informing their patients about HPV. In the end, these
scenarios seem to both reflect and reinforce the idea that cervical cancer is something
uncomfortable, secret and perhaps shameful, even though this is most likely the opposite
of the providers’ beliefs and intentions.
One of the most consistent themes to emerge from these data was the lack of
resources available to cervical cancer patients and survivors. More often than not, these
observations were juxtaposed with a comparison to the vast resources available for breast
cancer, and many of the survivors see it as a direct result of how cervical cancer is
viewed in American society. It is not a “culturally acceptable” form of cancer because of
its apparent and increasingly recognized link to a sexually transmitted infection, and thus
does not engender as much sympathy and goodwill among funders, researchers and the
advocacy community as breast cancer, a seemingly “blameless” disease.
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The implications of the above statement are numerous, and thus, the umbrella
term of “resources” took many forms throughout the interviews and surveys. Lack of
attention to cervical cancer in research of any persuasion—biomedical, psychosocial, or
cultural—was a major grievance. According to participants, this disinterest appears to
spring from the same sources as stigma itself: the recognition that it is preventable means
that it no longer necessitates cutting-edge research, and its tie to a sexually transmitted
infection makes it an “un-glamorous” topic to investigate.
Furthermore, survivors referenced the lack of financial assistance available to
patients and survivors, and the dearth of cervical cancer-specific support resources.
Indeed, one of the underlying challenges to this entire research project was an inability to
locate any cervical cancer-specific resources in the entire state of Florida—a situation
that has major implications for the ways in which survivors access support. There
appears to be no organized community, and few of the participants knew even a single
other person who had experienced cervical cancer. Thus, the majority used internetbased support groups to fill this need. Although most interview participants noted that
they personally had not experienced trouble getting support from their loved ones, this
need arose among survey respondents, and both groups cited the lack of specific support
resources available to them.
Not only does the stigmatization of cervical cancer impact the resources available
to those suffering from it, it extends to preventative measures such as the HPV vaccine.
The current controversy over mandatory vaccination for school-age girls was attributed to
Americans’ inability to accept the occurrence of pre-marital sex among women—
something that is, according to many respondents, besides the point. In other words, does
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it really matter where a disease might come from, as long as a vaccine for it can spare
suffering for so many? It is not hard to imagine the vast policy implications that exist
when laws based on moralistic expectations about female sexuality are passed and
enforced.
FURTHER CONNECTIONS TO THE LITERATURE
Major findings from previous work on stigma, cancer, and sexually transmitted
infections surface throughout the results of this study. One of the most predominant
connections is that of the “immoral” underpinnings of disease. For example, many
participants viewed cervical cancer as arising from a “moral” transgression that took
place at an often unspecified time in their lives, many questioning whether or not it was a
punishment for past behavior—a strong theme in much of the literature reviewed (Brandt
1987; Erwin 2007; Gregg 2003; Chavez et al. 1995; Hunt 1998; McMullin 2007;
McMullin et al. 1996; and Patterson 1987). In the majority of instances, this
transgression was presumed to be sexual, although others believed that not utilizing
screening healthcare as expected and recommended was the primary reason for the
development of their cervical cancer. Either case, though, portrayed an element of
personal irresponsibility.
Extending this further, many stigma scholars have argued that the existence of
stigma is highly tied to a perception that one has violated a moral—often sexual—taboo
(Das 2001; Gilmore and Somerville 1994; Goffman 1963; Newton and McCabe 2005).
Indeed, whether or not participants themselves viewed their cervical cancer as arising
from their own sexual transgression, a more frightening idea was that others believed that
this was the case. It often appeared that the negative assumptions of others was a more
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disturbing and anxiety-producing scenario than the prospect that a participant’s own
behavior had created her predicament (whether or not that this was actually the case in a
purely biomedical sense). Thus, a sexual taboo violation took place which then created
an illness, setting the stage for stigmatization of that individual to occur.
As touched upon in an earlier paragraph, a theme woven throughout many of
these explanatory models is that of personal (ir)responsibility. This is perhaps not
surprising at all, given the lifestyle risk paradigm that has been centralized in much recent
public health work—and which has often been the subject of critique and concern by
public health scholars, anthropologists, and others (Lupton 1993). It is, perhaps, much
more salient in this discussion now that cervical cancer has been increasingly positioned
as a preventable disease—first, by responsible sexual behavior, second, by “proper”
screening according to determined guidelines, and third, by the HPV vaccine. This
recognition by participants spurred a comparison by several to lung cancer and its public
perception as a disease arising from bad behavior. Not coincidentally, this is a subject
that has been the target of recent interest by those linking the current lack of biomedical
research and funding attention on lung cancer to its stigmatization and association with a
culturally unacceptable type of behavior.
A further link to previous research concerns the role of media in generating
unfavorable cultural perceptions of disease. A recurring grievance within both the
interviews and surveys, media-generated stigma has also been the subject of
anthropological research (Inhorn 1986; Pliskin 1997). Media involvement was a pivotal
but complicated experience for many of the participants, something which does not
necessarily arise in past literature. Often ill-defined and conveyed as a shape-shifting,
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borderless goliath, “the media” was seen to be simultaneously positive and negative: it
raised awareness, therefore saving lives, but it created a bad reputation for cervical cancer
and thus complicated the lives of the participants.
This brings to the fore the related ideas of advocacy and resistance, a subject of
recent stigma research (Gilmore and Somerville 1994; Parker and Aggleton 2003;
Whittaker 1992). Advocacy—both individual-level and collective—was unilaterally
conceived of as a positive thing. Simply put, it saved lives by raising awareness of
cervical cancer and the need for screening—the lives of women who had not yet been
diagnosed, but also, in an indirect way, those of the participants’ themselves. It was a
way to resist the stereotypes of cervical cancer and its negative associations, and
decreasing these stereotypes was presumed to have an inverse effect on the interest of
scientists using their research dollars on cervical cancer—thus positively impacting the
lives of the participants.
CONTRIBUTIONS TO ANTHROPOLOGY AND PUBLIC HEALTH
Viewing the subject of cervical cancer and stigma from within an anthropological
framework poses many more questions than answers, and therein lies the value of this
study. Cervical cancer can serve as a case study of those “diseases of disparity” (illnesses
that are distinguished by great socioeconomic disparities among those affected) as well as
those seen as resulting from failures of individual responsibility. It can help to explain
why, on a cultural level, we are motivated to find explanations for disease that rest on the
immoral—or, at the very least, culturally unacceptable—behavior of its victims. Of
course, it is not a new idea in anthropology that certain illnesses spring from immoral
sources—as a century of writing can attest. But, clearly, new forms of medical
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interventions such as the HPV vaccine can have significant cultural impact, and so call
for new research and new ways of understanding how we define health, illness and
disease. These questions lie at the heart of medical anthropology, and this study
contributes one example that has broader relevance to any number of biomedicallydefined diseases that are seen as resulting from lifestyle choices.
This study further contributes to the anthropological literature in a number of
ways. First, it has been thoroughly informed by the voices of people most affected by
cervical cancer, a perspective that has often been neglected in previous stigma research
and is something that has been the subject of recent anthropological critique (Castro and
Farmer 2005; Kleinman et al. 1995; Link and Phelan 2001a, 2001b; Parker and Aggleton
2003; Whittaker 1992). Second, it adds to the volume of work currently ongoing on
disease-related stigma as a case example of the nature, origins and effects of it on a
specific population—women living with and beyond cervical cancer in a new era of
vaccines. Finally, it helps to fill the large gap in the anthropological literature focusing
on sexually transmitted infections outside of HIV/AIDS.
Simply stated, applied anthropology concerns itself with the application of
anthropological theory and methods to real-world problems, with the overall goal of
affecting some kind of positive change or solution. In this study, qualitative methods
were used to develop a deep and holistic understanding of an emerging problem—the
stigmatization of cervical cancer patients and survivors. Women who are impacted
personally by this issue were involved in the research development process as key
informants, and helped shape the research questions and instruments. Given the evolving
nature of this issue and cervical cancers’ changing “reputation,” applied anthropology is
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particularly suited to clarifying its dimensions and complexities through the application
of its theory and methods. Perhaps most importantly, this research will be put back into
the hands of those who might be able to utilize it more widely through an executive
report.
It would be beneficial for further anthropological research into cervical cancerrelated stigma to focus on the structural and economic forces that give it shape and in
which the condition is embedded. This type of approach is exemplified by McMullin’s
(in press) recent analysis of social inequalities and cervical cancer disparities among
Latinas: in it, she examines how their “status in society and epidemiological risk factors
[sex at a young age, multiple sexual partners] are used to stigmatize them” (McMullin in
press:115) in the context of the current political discourse surrounding Latinos in the U.S.
This task would benefit greatly from the expertise of anthropologists, who are uniquely
situated to examine both large-scale forces and local experiences of a particular issue—in
this case, the ways in which cultural beliefs about cancer and political, economic and
social policies are actualized in an individual’s everyday life. Combining this particular
research project (which focuses strongly on individual-level experiences with stigma)
with a broad cultural and social analysis will provide rich data with which to
contextualize cervical cancer survivors’ experiences with stigma.
Not only is this topic highly relevant for anthropologists. The field of public
health has a critical interest, first, because of stigma’s role in disease development and
perpetuation, and second, because of the field’s major focus on the elimination of health
disparities. Numerous public health scholars have written about the significant role that
stigma plays in shaping and exacerbating rates of disease in the population because it
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mediates access to healthcare—both preventive and treatment (Bayer 2008). On an
individual level, for example, stigmatization can hinder an individual’s willingness to
seek out screening services because she is embarrassed or because she experiences
degrading treatment from healthcare professionals when she does. Or, on a structural
level, stigma may decrease policy-makers empathy for certain diseases and make them
less likely to commit dollars for outreach programs. Accordingly, the argument that
disease incidence, prevalence, and mortality are directly linked to stigmatization places
the issue squarely in the domain of public health. Attention to stigma in the design and
implementation of population-wide health programs may help to mitigate stigma’s effects
on care-seeking and provision among certain populations.
As addressed in Chapter Two, a number of stigma scholars have argued that the
same structural and economic forces that create social inequalities and give rise to health
disparities also influence who and what is stigmatized within a given culture (Castro and
Farmer 2005; Jones et al. 2004; McMulllin in press). The relationship between
disparities and stigma is thus bi-directional in that stigma both contributes to creating
disparities within a particular disease and is perpetuated by existing disparities.
According to this argument, public health—because of its attention to health disparities—
would have a large stake in further research on the subject if there is ever hope of
creating a just healthcare system. Public health’s expertise in program development,
evaluation and social marketing could greatly benefit from an increased focus on stigma
and its role in mediating access to healthcare.
In sum, the combined understandings of micro- and macro-level causes and
consequences of stigma will have great value for both applied anthropology and public
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health. The information and recommendations generated by this study can be put to
several uses, ideally in a collaborative setting. First, this study is premised on the idea
that a fuller understanding of the dimensions of patients’ and survivors’ experiences with
cervical cancer and disease-related stigma will help to inform future educational
messages tailored to reduce its impact. Second, the finding that differential application of
the HPV vaccine has generated and fostered negative stereotypes and incorrect
perceptions about women and sexually transmitted infections can be taken into
consideration in the design of vaccine programs and educational materials. These
findings, along with a more detailed understanding of the consequential stigmatization of
the HPV vaccine, could help to inform future vaccine policy and prevention messages.
Third, participants’ grievances regarding current breast and cervical cancer funding
patterns exposes a major need to analyze the utility of agency and governmental policies
that have historically combined these funding streams. Fourth, a great gap has been
exposed related to cervical cancer-specific support and financial resources, and this report
serves as a call for more action and attention to these issues. A more thorough
understanding of stigma related to this disease is a first step in designing more effective
and relevant cervical cancer-specific support programs. And finally, healthcare providers
who deal with survivors on a day-to-day basis can use this information to generate more
positive and candid interactions with their clients regarding the social impact of cervical
cancer.
RECOMMENDATIONS
As “stigma occurs as a result of social processes that can be potentially
challenged by social action” (Newton and McCabe 2005:68), I would like to offer several
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recommendations based upon the insights of this analysis and those coming directly from
the participants’ themselves. These fall into the general categories of de-stigmatization,
interactions with healthcare providers, funding policy, and future research directions.
De-Stigmatization
A consistent point to emerge from all phases of research concerns the prevalence
of HPV. It is the most common sexually transmitted infection, such that between 70 to
80 percent of sexually active adults will contract HPV at some point in their lifetime
(Burk et al. 1996; Koutsky 1997; Lorincz 1996). In a recent report, the National
Institutes of Health discovered that 26.8 percent of sexually active females between the
ages of 14 and 59 tested positive for one or more strains of HPV in a point prevalence
(one-time) study (National Institutes of Health 2008). It was found through the website
content analysis that non-profit advocacy organizations emphasized these statistics above
many others, which could be interpreted as an attempt to normalize, and thus destigmatize, the infection. Further, participants in the interview and survey phases
consistently argued that if the public knew how common the infection is, then it would
cease to carry such a heavy moral weight. Women with cervical cancer who later learned
about the high prevalence of the infection felt comforted by this knowledge, and reported
that they felt less embarrassed and guilty. These findings closely parallel those of other
studies and reports on STIs (IOM 1997), and the idea of “normalizing” HPV infection
because of its high prevalence has precedent in the literature (Perrin, Daley, Naoom,
Packing-Ebuen, Rayko, McFarlane, and McDermott 2006; Waller 2004).
Another frequently-mentioned idea was a dual emphasis on men and HPV. The
website content analysis revealed a disproportionate emphasis on women, creating an
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appearance that HPV is chiefly a woman’s disease. Developing and marketing the
vaccine exclusively to girls and women bolsters this perception. Aside from the fact that
most websites failed to report the fact that men too can contract HPV and that it can have
serious health consequences for them, it also leaves the burden of vaccination, prevention
and stigma on women’s shoulders. Giving equal focus to men in educational messages
and eventually offering the HPV vaccine to them will remove some of the stigma
associated with women as the “carriers” of sexually transmitted infection, an enduring
stereotype.
Interactions with Healthcare Providers
The ability to have an honest and candid conversation with their doctor was a
prized asset among study participants. Many reported the frustration, bitterness, and
ensuing resentment created when they felt that they did not receive timely information
about the connection between HPV and cervical cancer by their healthcare providers.
This was a serious omission in many respondents’ eyes, no matter what the underlying
intention of the provider. It appears as though a number of providers do not like to raise
the issue, either because they feel it is a moot point (given that the participants had
already developed cervical cancer), or because they assume the information will make the
patients feel badly about themselves. Nevertheless, participants seemed to highly value
information about HPV when it was received, and longed for a candid conversation with
their physician about its role in their own cervical cancer as well as future implications
for their lives—including an acknowledgement and open discussion of the issue of
stigmatization.
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Funding Policy
A comparison to breast cancer and its disproportionate funding levels was a topic
raised so often that I believe it is important to include a recommendation to address it. It
is not clear why funding streams for breast cancer and cervical cancer are combined—
this is especially confusing in the case of low-cost breast and cervical cancer screening
programs where eligibility guidelines for both are based on the ages where breast cancer
incidence is the highest, between ages 50 and 64 (Daley 2008, personal communication).
In contrast, cervical cancer incidence is highest in a woman’s reproductive years, and
peaks in her 30s. Thus, these programs are inherently missing a large portion of the
women at highest risk for cervical cancer. In addition, socioeconomically these cancers
tend to affect, on the whole, completely different populations: breast cancer incidence is
highest among those in the upper income brackets, while cervical cancer incidence peaks
among lower-income populations. A policy evaluation that assesses the effectiveness of
combining these funding streams, and its relative benefits and drawbacks, would be
extremely useful in addressing some of the disparities in resources for the two cancers
(Daley 2008, personal communication).
Future Research Directions
Based on the fact that the survey’s stigma items and qualitative comments were
frequently stronger amongst the dysplasia and carcinoma-in-situ participants than in the
invasive cancer sample, this remains a critical area for future research. I have found little
in the way of research on this population and the uncertainties of living with a possible
cancer diagnosis at any time. Additionally, numerous comments in the survey revolved
around HPV and dysplasia’s “invisibility” among researchers, and how these conditions
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are not seen as worthy of research dollars because they are considered preventable by
sexual behavior, screening, and now the vaccine. An important discussion ensued on a
non-profit’s discussion board about this very topic, and one woman’s comment
summarizes this point succinctly:
“We need some visibility for women with cancer ‘precursors’ since this is a huge
group of women that are completely missing from any statistics and any usual
discussion of cervical cancer. It is said that cervical cancer is almost 100%
preventable through routine screening, and that it only impacts about 10,000
women per year. Yet no one talks about the hundreds of thousands of women who
are diagnosed with cancer precursors (that are not preventable, short of
abstinence) and how these women’s fertility, sexuality, relationships, finances and
emotional health are impacted…I don’t mean to diminish the experience of those
with cancer, I just want to say that we can’t have a realistic and meaningful
discussion of the impact of HPV without addressing the women (often very young
women) who risk losing their fertility and other things to HPV even though they
aren’t counted in the numbers because they don’t have cancer.”
Additionally, an investigation of what we consider the boundaries of “cancer,”
“pre-cancer”, and healthy cells—or what Martinez (2005) might term the ambiguous
“borderlands of health, disease and illness”—would shed much light on our cultural
beliefs about this illness. Future study would speak to what it means to have cancer, and
the motivation behind why some people might identify with it in certain instances and not
in others.
This relates somewhat to another potential research direction: survivor identity
and survivorship. An interesting finding of this study revealed that survivors often pick
and choose the most appropriate and strategic occasions to use this terminology, and the
point at which they begin to identify at all with the label is highly individualized.
Additional explorations into survivor identity would shed light on the complexities of
living with a stigmatized and life-threatening condition that is not admittedly wellunderstood or explained by the biomedical community.
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A final important theme emerged in the interview data whose importance was
reinforced by findings from the survey. The potential loss of fertility was one of the most
distressing aspects of the whole experience for many of these women, and on that very
basis it merits in-depth further study. Cervical cancer incidence peaks in a woman’s
reproductive years, and thus these two life-changing medical diagnoses—cancer and
infertility—tend to frequently co-exist. Post-treatment quality of life is also a relatively
new concern for cancer research and treatment, usually undertaken by researchers in the
psychosocial realm. An anthropological perspective on this issue, incorporating our
society’s genetic and biological constructions of parenthood and a differentially applied
“right to reproduce,” would lend considerable, important and innovative insight.
On the whole, anthropology has much to contribute in the future research needs
identified above. Holistic ethnographic accounts are few and far between in both the
cancer and sexually transmitted infection realm, and would add considerable depth and
breadth to our understanding of what it means to have these afflictions in an era of
rapidly-evolving medical technologies and advancing scientific discovery. Research on
the cultural and social impact must keep pace with these modern developments;
meanwhile, many of the seminal anthropological works in these areas are decades old.
STUDY LIMITATIONS
This study was limited by several factors. First, as discussed in detail in Chapter
Three, I experienced difficulties with recruitment that resulted in an inability to establish
a long-term rapport and relationship with a community of women. There was no inperson “community” to be found. Although I am not sure that this is a clear-cut
“limitation” as it revealed much about the local context of cervical cancer resources and
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support services, in an anthropological study many might consider it a limitation given
the fact that I am researching a topic with sensitive roots—sexual behavior. Second, this
scenario perhaps resulted in a skewed inclusion of women who are particularly outspoken
and who have involved themselves in advocacy circles, and thus would be the people
with whom I was able to make contact. This certainly creates the possibility that the
issues here might be under-reported, and overall merits consideration in terms of any
future studies undertaken on this topic. This reflects the difficulties involved in
researching any stigmatized condition, and it is clearly possible that the women who are
feeling the impact of stigmatization most acutely are the ones least likely to volunteer for
a research project of this nature.
Methodologically, the use of telephone interviews in an anthropological study is
certainly less-than-ideal and may have resulted in interviews that were not as candid or
in-depth as they might have been if conducted in-person; however, this was a last-resort
option that was necessitated by recruitment difficulties. Further, because of financial
constraints and the self-funded nature of the study, women participated strictly on a
volunteer basis and were offered no compensation, which arguably might have had an
impact on the participation rate.
Finally, women varied greatly with regards to when they were diagnosed, ranging
from just one week to 33 years prior to the interview or survey. While this approach
allowed for a great range of experiences along the continuum of cancer diagnosis,
treatment, and long-term “survivorship,” it would be helpful—perhaps in future studies—
to investigate how a person’s location in the process of coping or managing a cancer
diagnosis might interplay with their experiences of stigma and perceptions about the
141

disease. Certainly, a woman diagnosed one week ago is dealing with greatly different
issues than one who has had 33 years to reflect on and process the experience.
CONCLUSION
This study has detailed numerous underlying factors and intricacies regarding the
nature and source of cervical cancer-related stigma—its connection to sexual behavior, its
perception as a disease that is caused by individual lifestyle choices and behaviors, and
its new recognition as a preventable condition. Beliefs about all of these characteristics
have combined to generate untold consequences from the perspective of the survivors—
guilt, shame, and embarrassment, fear of others’ beliefs and perceptions, lack of services
and cutting-edge treatment, and structural discrimination in funding and research policy.
All of these find reflection in the ways in which survivors live their daily lives, from the
healthcare that they receive, from the types of treatment that are available to them, to the
financial assistance and support resources that they are able to locate and access, and to
the people they choose (or not choose) to confide in. These are the ways in which
stigma, in both micro- and macro-level expressions, come to affect and shape the lives of
those who must confront cervical cancer even as a possibility—individuals in the
screening system, women who have been diagnosed, loved ones, and those who have
chosen to resist, either individually or collectively, the labels that this disease begets.
The more that we can explain the ways in which stigma operates on both of these levels,
and its role in cervical cancer’s demographic label as a disease of disparity, the better
able we will be to design programs and health messages aimed at mitigating stigma and
its vast consequences. This holds true not only for cervical cancer but for any disease
that is tied in the public consciousness to poverty and individual responsibility.
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INTERVIEW GUIDE: Cervical Cancer and Stigma

1.

How would you describe yourself?

2.

What are the three most important things in your life? Why?

3.

There are many problems that we face every day. What are the biggest
problems facing you now?

4.

When you think about cancer, what are the first three things that come to
your mind?

5.

Could you tell me a little bit about your experience with cervical cancer?

6.

What are some of your ideas about how you may have gotten cancer?

7.

Who have you told about your cancer experience?

8.

Where have you been able to get support during this experience?

9.

Have there been any situations where you had to tell someone about it, even
if you did not want to?

10. How do you feel about having had cervical cancer?
11. A lot of people talk about the words ‘cancer survivor,’ and it has many
different meanings. What do the words ‘cancer survivor’ mean to you?
12. Are there positive aspects of having cervical cancer? Tell me about them …
13. What have the hardest aspects of having had cervical cancer been?
14. What kinds of things could have made it easier?
15. Who do you think gets cervical cancer?
16. What did you think about people with cancer before you were diagnosed?
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17. How do you think the general public views cervical cancer?
18. Do you think that people treat you or look at you differently because you
have had cervical cancer?
19. Have you heard anything recently in the media on cervical cancer? (If yes)
What have you heard about the new HPV vaccine that came out?
20. What kind of effect, if any, do you think the media attention on HPV and
the vaccine is having on cervical cancer patients and survivors?
21.

Do you seek out information about HPV? (If yes) Where do you get your
information from?

22. Do you seek out information about cervical cancer? (If yes) Where do you
get your information from?
23.

Is there anything else you would like to add to this that we have not already
covered today?

Demographics:
Age:
How would you identify yourself in relation to ethnicity or race?
Place of residence:
What do you do for a living?
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ONLINE SURVEY: Women’s Experiences with Cervical Cancer
Thank you for taking the time to complete this online survey! This is part of a study at
the University of South Florida that explores women’s experiences with cervical cancer.
We are interested in your personal opinions, feelings, and beliefs, and we will use this
information to help women like you in similar situations. Please answer these questions
to the best of your ability.
This survey will take about 15 minutes to complete. It is completely confidential and
anonymous, and you are not required to use your name. You do not have to answer any
questions that make you feel uncomfortable and you can stop taking this survey at any
time. If you have any questions or concerns, please contact Karen Dyer, the study’s
Principal Investigator, at (813) 974-8379 or kdyer@health.usf.edu.
Consent to Participate in Survey: Please read the following statement and check the box
below if you would like to fill out the survey.

You have been invited to participate in a study through the University of South Florida’s College of
Public Health and Department of Anthropology. The study is entitled “Women’s Experiences with
Cervical Cancer” and is being conducted by Karen Dyer, a graduate student, and Dr. Roberta Baer
in the Department of Anthropology. The purpose of this research project is to explore the
experiences of women who have been diagnosed with cervical cancer. If you agree to voluntarily
participate in this research, your participation will include the completion of a short online survey
that asks questions about your experiences with cervical cancer. If you choose to volunteer, you
will not be compensated for your time. There are no known risks to participants taking part in this
research project. If you do decide to participate, you may withdraw at any time without
consequences and there is no need to offer an explanation. Everything that you answer in this
survey will be kept completely confidential. For the purposes of analysis and to ensure
confidentiality, you will be assigned a numerical code that will be used in place of your first and
last name. The only people allowed to see the study records are the Principal Investigator Karen
Dyer, Faculty Advisor Dr. Roberta Baer, the University of South Florida Institutional Review
Board, and the Florida Department of Health. We may publish what we learn from this study, but
no personally identifying information about you will be used. If you have any questions, concerns
or complaints about this study, please call Karen Dyer at (813) 974-8379, or the USF Division of
Research Integrity and Compliance at (813) 974-9343.

 Checking this box indicates that you have read the above consent form and
are giving your consent to participate in our survey.
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I. DEMOGRAPHICS
1.

What is your current age?

2.

What is your state of residence?

3.

What is your ethnicity? (for example, Caucasian, African American, etc.)

4.

What is your occupation?

5.

What is the highest degree that you received in school?
Some high school
High school diploma
Bachelor’s degree
Master’s degree
Doctorate or professional degree
Other
Decline to answer

6.

How many children do you have, if any?

7.

What type of health insurance do you currently have?
I do not have health insurance
Private
Medicaid
Medicare
Student
Military
Other
Decline to answer

8.

What type of health insurance did you have when you learned you had
cervical cancer?
I did not have health insurance
Private
Medicaid
Medicare
Student
Military
Other
Decline to answer

9.

What is your current relationship status?
Single
Boyfriend/girlfriend, not living together
Boyfriend/girlfriend, living together
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Married/engaged
Divorced
Widowed
Decline to answer

II. ILLNESS HISTORY
10.

When were you first diagnosed with cervical cancer? Please give the
approximate month and year, if possible.

11.

What was the stage of your cancer when you were diagnosed?
Stage 0
Stage 1
Stage 2
Stage 3
Stage 4
I don’t know
Decline to answer
Please add any comments ____________________________

12.

Who diagnosed you?
Primary care physician
Gynecologist
Oncologist
Other __________ (please list)
Decline to answer

13.

How did you first know that there was a problem?
Experiencing symptoms (please list below)
Routine Pap smear
Other __________ (please list)
Decline to answer
Please add any comments ____________________________

14.

If you were treated for cervical cancer, how long did (or will) your
treatment last?

15.

What type(s) of treatment have you had, or will you have? Please check
all that apply.
No Treatment
Pelvic Exenteration
Conization
Trachelectomy
Cryotherapy
Internal Radiation
LEEP
External Radiation
Laser Surgery
Chemotherapy
Radical Hysterectomy
Other
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Total Hysterectomy
Decline to answer
Please list any other treatments: __________________________
16.

What side effects have you experienced during your treatment? Please
check all that apply.
Diarrhea
No side effects
Fatigue
Nausea/vomiting
Dry, itchy or irritated skin
Loss of appetite
Painful intercourse/difficulty having
Hair loss
sex
Pain
Cramping
Frequent sickness or infection
Vaginal bleeding
Mouth sores
Vaginal discharge
I don’t remember
Difficulty urinating or
Others (please list) ______________
having a bowel
Decline to answer_______________
movement

17.

Do you identify yourself as a cancer survivor? Why or why not?
Yes
No
Please explain your answer: _______________________

18.

Please list any OTHER cancer diagnoses that you have had, including
recurrences. Please include the approximate dates that you received
them.

19.

What are the first three words or things that come to mind when you
hear the word “cancer”? __________, ___________ , ____________

20.

What do you think caused your cervical cancer? Please explain.

21.

Who do you think is more at risk of getting cervical cancer?

III. EXPERIENCES
22.

Since your first diagnosis, please rate how troubling the following have
been for you:
Not at all
troubling

A little bit
troubling

Physical symptoms before
diagnosis (for ex., bleeding,
painful intercourse)
Physical side effects of treatment
(for ex., pain, nausea/vomiting,
hair loss)
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Somewhat
troubling

Extremely
troubling

N/A

Loss of fertility or compromised
fertility
Other long-term side effects of
treatment
Fear of recurrence
Effect on ability to perform job
Financial effects
Problems with health insurance
Difficulties in marriage or
relationship with significant other
Difficulties in relationships with
friends or family members

Please list any other effects you may have had:___________________________
23.

How often do you feel that people look at you differently because you
had/have cancer?
Always
Frequently
Sometimes
Rarely
Never
I don’t know
Decline to answer
Please add any comments: ________________

24.

How often do you feel that people treat you differently because you
had/have cancer?
Always
Frequently
Sometimes
Rarely
Never
I don’t know
Decline to answer
Please add any comments: ________________
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25.

Specifically, how often do you feel that people look at you differently
because you had/have CERVICAL cancer?
Always
Frequently
Sometimes
Rarely
Never
I don’t know
Decline to answer
Please add any comments: ________________

26.

Specifically, how often do you feel that people treat you differently
because you had/have CERVICAL cancer?
Always
Frequently
Sometimes
Rarely
Never
I don’t know
Decline to answer
Please add any comments: ________________

27.

Are you afraid that other people would have less respect for you if they
knew about your diagnosis?
Yes
No
Decline to answer
Please add any comments: ________________

28.

Since your first diagnosis, please rate how often you agree with the
following:
Never

Rarely

Sometimes

I blame myself for my
condition.
I think that others blame
me for my condition.
I think that this
condition could have
been prevented.
I am angry at myself.
I feel embarrassed or
ashamed.
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Frequently

Always

N/A

I am too embarrassed or
ashamed to tell someone
about it.
I think less of myself
because of my
condition.
My family thinks less of
me because of my
condition.
I think that others pity
me.
I think that others judge
me negatively because
of my condition.

Please add any comments _________________________________________________
29.

In your experience, do you feel that women with cervical cancer are
stigmatized (in other words, looked down upon and negatively
stereotyped because of their diagnosis)?
Yes
No
Decline to answer
Please explain your answer _____________________

IV. RELATIONSHIPS
30.

Whom have you told about your diagnosis? Please check all that apply.
Significant other/spouse/partner
Parent(s)
Sibling(s)
Other family
Friends
Co-workers
Members of my religious group (ex., church, temple, etc.)
Neighbors/community members
Others ______ (please list)
No one
Decline to answer

31.

If you did not tell your family members and friends, why not?

32.

If possible, would you prefer to keep people from knowing about your
diagnosis?
Yes
Sometimes
No
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Decline to answer
Please explain your answer _____________________
33.

How would you characterize the support of these people during your
experience?
No support
at all

Not enough
support

Some
support

Good
enough
support

Exceeded
my
expectations

N/A

Significant other/
spouse/partner
Parent(s)
Sibling(s)
Other family
members
Friends
Co-workers
Members of my
religious group
(ex., church,
temple, etc.)
Neighbors/community members
Others (please
list)

V. INFORMATION & RESOURCES
34.

For each type of information, please select where you received that
information. Check all that apply.

Information on CERVICAL CANCER:
Didn’t
receive
info on
this topic

Doctors

Other
healthcare
workers

Family
and
friends

Causes
Treatment and
side effects
Long-term side
effects of
treatment
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Internet

T.V.

Other
media
(ex.,
radio)

Organizations
(ex.,
ACS)

Support groups
Advocacy
organizations

Information on HPV (HUMAN PAPILLOMAVIRUS):
Didn’t
receive
info on
this topic

Doctors

Other
healthcare
workers

Family
and
friends

Internet

T.V.

Other
media
(ex.,
radio)

Organizations
(ex.,
ACS)

Causes
Treatment and
side effects
HPV vaccine
Support groups

VI. THANK YOU!
Thank you very much for taking the time to participate in this survey! Your efforts
have made this study possible, and have helped us to learn as much as we can about
women’s experiences with cervical cancer.
Please add any additional comments about your experiences with cervical cancer:
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
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